id	sid	tid	token	lemma	pos
ajlm-1578	1	1	abstract	abstract	ADJ
ajlm-1578	1	2	introduction	introduction	NOUN
ajlm-1578	1	3	methods	method	NOUN
ajlm-1578	1	4	results	result	VERB
ajlm-1578	1	5	discussion	discussion	NOUN
ajlm-1578	1	6	acknowledgements	acknowledgement	NOUN
ajlm-1578	1	7	references	reference	NOUN
ajlm-1578	1	8	about	about	ADP
ajlm-1578	1	9	the	the	DET
ajlm-1578	1	10	author(s	author(s	NOUN
ajlm-1578	1	11	)	)	PUNCT
ajlm-1578	1	12	katherine	katherine	PROPN
ajlm-1578	1	13	e.	e.	PROPN
ajlm-1578	1	14	hodkinson	hodkinson	PROPN
ajlm-1578	1	15	department	department	PROPN
ajlm-1578	1	16	of	of	ADP
ajlm-1578	1	17	molecular	molecular	ADJ
ajlm-1578	1	18	medicine	medicine	NOUN
ajlm-1578	1	19	and	and	CCONJ
ajlm-1578	1	20	haematology	haematology	NOUN
ajlm-1578	1	21	,	,	PUNCT
ajlm-1578	1	22	faculty	faculty	NOUN
ajlm-1578	1	23	of	of	ADP
ajlm-1578	1	24	health	health	NOUN
ajlm-1578	1	25	sciences	sciences	PROPN
ajlm-1578	1	26	,	,	PUNCT
ajlm-1578	1	27	university	university	NOUN
ajlm-1578	1	28	of	of	ADP
ajlm-1578	1	29	the	the	DET
ajlm-1578	1	30	witwatersrand	witwatersrand	NOUN
ajlm-1578	1	31	,	,	PUNCT
ajlm-1578	1	32	johannesburg	johannesburg	PROPN
ajlm-1578	1	33	,	,	PUNCT
ajlm-1578	1	34	south	south	PROPN
ajlm-1578	1	35	africa	africa	PROPN
ajlm-1578	1	36	institution	institution	NOUN
ajlm-1578	1	37	of	of	ADP
ajlm-1578	1	38	national	national	PROPN
ajlm-1578	1	39	health	health	PROPN
ajlm-1578	1	40	laboratory	laboratory	PROPN
ajlm-1578	1	41	service	service	PROPN
ajlm-1578	1	42	,	,	PUNCT
ajlm-1578	1	43	johannesburg	johannesburg	PROPN
ajlm-1578	1	44	,	,	PUNCT
ajlm-1578	1	45	south	south	PROPN
ajlm-1578	1	46	africa	africa	PROPN
ajlm-1578	1	47	nikki	nikki	PROPN
ajlm-1578	1	48	bouwer	bouwer	PROPN
ajlm-1578	1	49	department	department	PROPN
ajlm-1578	1	50	of	of	ADP
ajlm-1578	1	51	molecular	molecular	ADJ
ajlm-1578	1	52	medicine	medicine	NOUN
ajlm-1578	1	53	and	and	CCONJ
ajlm-1578	1	54	haematology	haematology	NOUN
ajlm-1578	1	55	,	,	PUNCT
ajlm-1578	1	56	faculty	faculty	NOUN
ajlm-1578	1	57	of	of	ADP
ajlm-1578	1	58	health	health	NOUN
ajlm-1578	1	59	sciences	sciences	PROPN
ajlm-1578	1	60	,	,	PUNCT
ajlm-1578	1	61	university	university	NOUN
ajlm-1578	1	62	of	of	ADP
ajlm-1578	1	63	the	the	DET
ajlm-1578	1	64	witwatersrand	witwatersrand	NOUN
ajlm-1578	1	65	,	,	PUNCT
ajlm-1578	1	66	johannesburg	johannesburg	PROPN
ajlm-1578	1	67	,	,	PUNCT
ajlm-1578	1	68	south	south	PROPN
ajlm-1578	1	69	africa	africa	PROPN
ajlm-1578	1	70	institution	institution	NOUN
ajlm-1578	1	71	of	of	ADP
ajlm-1578	1	72	national	national	PROPN
ajlm-1578	1	73	health	health	PROPN
ajlm-1578	1	74	laboratory	laboratory	PROPN
ajlm-1578	1	75	service	service	PROPN
ajlm-1578	1	76	,	,	PUNCT
ajlm-1578	1	77	johannesburg	johannesburg	PROPN
ajlm-1578	1	78	,	,	PUNCT
ajlm-1578	1	79	south	south	PROPN
ajlm-1578	1	80	africa	africa	PROPN
ajlm-1578	1	81	jenifer	jenifer	PROPN
ajlm-1578	1	82	vaughan	vaughan	PROPN
ajlm-1578	1	83	department	department	PROPN
ajlm-1578	1	84	of	of	ADP
ajlm-1578	1	85	molecular	molecular	ADJ
ajlm-1578	1	86	medicine	medicine	NOUN
ajlm-1578	1	87	and	and	CCONJ
ajlm-1578	1	88	haematology	haematology	NOUN
ajlm-1578	1	89	,	,	PUNCT
ajlm-1578	1	90	faculty	faculty	NOUN
ajlm-1578	1	91	of	of	ADP
ajlm-1578	1	92	health	health	NOUN
ajlm-1578	1	93	sciences	sciences	PROPN
ajlm-1578	1	94	,	,	PUNCT
ajlm-1578	1	95	university	university	NOUN
ajlm-1578	1	96	of	of	ADP
ajlm-1578	1	97	the	the	DET
ajlm-1578	1	98	witwatersrand	witwatersrand	NOUN
ajlm-1578	1	99	,	,	PUNCT
ajlm-1578	1	100	johannesburg	johannesburg	PROPN
ajlm-1578	1	101	,	,	PUNCT
ajlm-1578	1	102	south	south	PROPN
ajlm-1578	1	103	africa	africa	PROPN
ajlm-1578	1	104	institution	institution	NOUN
ajlm-1578	1	105	of	of	ADP
ajlm-1578	1	106	national	national	PROPN
ajlm-1578	1	107	health	health	PROPN
ajlm-1578	1	108	laboratory	laboratory	PROPN
ajlm-1578	1	109	service	service	PROPN
ajlm-1578	1	110	,	,	PUNCT
ajlm-1578	1	111	johannesburg	johannesburg	PROPN
ajlm-1578	1	112	,	,	PUNCT
ajlm-1578	1	113	south	south	PROPN
ajlm-1578	1	114	africa	africa	PROPN
ajlm-1578	1	115	citation	citation	PROPN
ajlm-1578	1	116	hodkinson	hodkinson	PROPN
ajlm-1578	1	117	ke	ke	PROPN
ajlm-1578	1	118	,	,	PUNCT
ajlm-1578	1	119	bouwer	bouwer	PROPN
ajlm-1578	1	120	n	n	CCONJ
ajlm-1578	1	121	,	,	PUNCT
ajlm-1578	1	122	vaughan	vaughan	PROPN
ajlm-1578	1	123	j.	j.	PROPN
ajlm-1578	1	124	south	south	PROPN
ajlm-1578	1	125	african	african	PROPN
ajlm-1578	1	126	study	study	NOUN
ajlm-1578	1	127	of	of	ADP
ajlm-1578	1	128	blast	blast	NOUN
ajlm-1578	1	129	phase	phase	NOUN
ajlm-1578	1	130	chronic	chronic	ADJ
ajlm-1578	1	131	myeloid	myeloid	NOUN
ajlm-1578	1	132	leukaemia	leukaemia	NOUN
ajlm-1578	1	133	:	:	PUNCT
ajlm-1578	1	134	a	a	DET
ajlm-1578	1	135	poor	poor	ADJ
ajlm-1578	1	136	prognostic	prognostic	ADJ
ajlm-1578	1	137	outlook	outlook	NOUN
ajlm-1578	1	138	.	.	PUNCT
ajlm-1578	2	1	afr	afr	PROPN
ajlm-1578	2	2	j	j	PROPN
ajlm-1578	2	3	lab	lab	PROPN
ajlm-1578	2	4	med	med	PROPN
ajlm-1578	2	5	.	.	PUNCT
ajlm-1578	3	1	2022;11(1	2022;11(1	NUM
ajlm-1578	3	2	)	)	PUNCT
ajlm-1578	3	3	,	,	PUNCT
ajlm-1578	3	4	1578	1578	NUM
ajlm-1578	3	5	.	.	PUNCT
ajlm-1578	4	1	https://doi.org/10.4102/ajlm.v11i1.1578	https://doi.org/10.4102/ajlm.v11i1.1578	X
ajlm-1578	4	2	original	original	ADJ
ajlm-1578	4	3	research	research	NOUN
ajlm-1578	4	4	south	south	ADJ
ajlm-1578	4	5	african	african	ADJ
ajlm-1578	4	6	study	study	NOUN
ajlm-1578	4	7	of	of	ADP
ajlm-1578	4	8	blast	blast	NOUN
ajlm-1578	4	9	phase	phase	NOUN
ajlm-1578	4	10	chronic	chronic	ADJ
ajlm-1578	4	11	myeloid	myeloid	NOUN
ajlm-1578	4	12	leukaemia	leukaemia	NOUN
ajlm-1578	4	13	:	:	PUNCT
ajlm-1578	4	14	a	a	DET
ajlm-1578	4	15	poor	poor	ADJ
ajlm-1578	4	16	prognostic	prognostic	ADJ
ajlm-1578	4	17	outlook	outlook	NOUN
ajlm-1578	4	18	katherine	katherine	PROPN
ajlm-1578	4	19	e.	e.	PROPN
ajlm-1578	4	20	hodkinson	hodkinson	PROPN
ajlm-1578	4	21	,	,	PUNCT
ajlm-1578	4	22	nikki	nikki	PROPN
ajlm-1578	4	23	bouwer	bouwer	PROPN
ajlm-1578	4	24	,	,	PUNCT
ajlm-1578	4	25	jenifer	jenifer	PROPN
ajlm-1578	4	26	vaughan	vaughan	PROPN
ajlm-1578	4	27	received	receive	VERB
ajlm-1578	4	28	:	:	PUNCT
ajlm-1578	4	29	11	11	NUM
ajlm-1578	4	30	mar	mar	PROPN
ajlm-1578	4	31	.	.	PROPN
ajlm-1578	4	32	2021	2021	NUM
ajlm-1578	4	33	;	;	PUNCT
ajlm-1578	4	34	accepted	accept	VERB
ajlm-1578	4	35	:	:	PUNCT
ajlm-1578	4	36	22	22	NUM
ajlm-1578	4	37	feb	feb	NOUN
ajlm-1578	4	38	.	.	PROPN
ajlm-1578	4	39	2022	2022	NUM
ajlm-1578	4	40	;	;	PUNCT
ajlm-1578	4	41	published	publish	VERB
ajlm-1578	4	42	:	:	PUNCT
ajlm-1578	4	43	31	31	NUM
ajlm-1578	4	44	may	may	AUX
ajlm-1578	4	45	2022	2022	NUM
ajlm-1578	4	46	copyright	copyright	NOUN
ajlm-1578	4	47	:	:	PUNCT
ajlm-1578	4	48	©	©	PROPN
ajlm-1578	4	49	2022	2022	NUM
ajlm-1578	4	50	.	.	PUNCT
ajlm-1578	5	1	the	the	DET
ajlm-1578	5	2	author(s	author(s	PROPN
ajlm-1578	5	3	)	)	PUNCT
ajlm-1578	5	4	.	.	PUNCT
ajlm-1578	6	1	licensee	licensee	NOUN
ajlm-1578	6	2	:	:	PUNCT
ajlm-1578	6	3	aosis	aosis	NOUN
ajlm-1578	6	4	.	.	PUNCT
ajlm-1578	7	1	this	this	PRON
ajlm-1578	7	2	is	be	AUX
ajlm-1578	7	3	an	an	DET
ajlm-1578	7	4	open	open	ADJ
ajlm-1578	7	5	access	access	NOUN
ajlm-1578	7	6	article	article	NOUN
ajlm-1578	7	7	distributed	distribute	VERB
ajlm-1578	7	8	under	under	ADP
ajlm-1578	7	9	the	the	DET
ajlm-1578	7	10	terms	term	NOUN
ajlm-1578	7	11	of	of	ADP
ajlm-1578	7	12	the	the	DET
ajlm-1578	7	13	creative	creative	ADJ
ajlm-1578	7	14	commons	common	NOUN
ajlm-1578	7	15	attribution	attribution	NOUN
ajlm-1578	7	16	license	license	NOUN
ajlm-1578	7	17	,	,	PUNCT
ajlm-1578	7	18	which	which	PRON
ajlm-1578	7	19	permits	permit	VERB
ajlm-1578	7	20	unrestricted	unrestricted	ADJ
ajlm-1578	7	21	use	use	NOUN
ajlm-1578	7	22	,	,	PUNCT
ajlm-1578	7	23	distribution	distribution	NOUN
ajlm-1578	7	24	,	,	PUNCT
ajlm-1578	7	25	and	and	CCONJ
ajlm-1578	7	26	reproduction	reproduction	NOUN
ajlm-1578	7	27	in	in	ADP
ajlm-1578	7	28	any	any	DET
ajlm-1578	7	29	medium	medium	NOUN
ajlm-1578	7	30	,	,	PUNCT
ajlm-1578	7	31	provided	provide	VERB
ajlm-1578	7	32	the	the	DET
ajlm-1578	7	33	original	original	ADJ
ajlm-1578	7	34	work	work	NOUN
ajlm-1578	7	35	is	be	AUX
ajlm-1578	7	36	properly	properly	ADV
ajlm-1578	7	37	cited	cite	VERB
ajlm-1578	7	38	.	.	PUNCT
ajlm-1578	8	1	abstract	abstract	ADJ
ajlm-1578	8	2	background	background	NOUN
ajlm-1578	8	3	:	:	PUNCT
ajlm-1578	8	4	chronic	chronic	ADJ
ajlm-1578	8	5	myeloid	myeloid	NOUN
ajlm-1578	8	6	leukaemia	leukaemia	NOUN
ajlm-1578	8	7	(	(	PUNCT
ajlm-1578	8	8	cml	cml	PROPN
ajlm-1578	8	9	)	)	PUNCT
ajlm-1578	8	10	is	be	AUX
ajlm-1578	8	11	a	a	DET
ajlm-1578	8	12	haematological	haematological	ADJ
ajlm-1578	8	13	malignancy	malignancy	NOUN
ajlm-1578	8	14	characterised	characterise	VERB
ajlm-1578	8	15	by	by	ADP
ajlm-1578	8	16	the	the	DET
ajlm-1578	8	17	translocation	translocation	NOUN
ajlm-1578	8	18	t(9;22)(q34;q11.2	t(9;22)(q34;q11.2	NOUN
ajlm-1578	8	19	)	)	PUNCT
ajlm-1578	8	20	,	,	PUNCT
ajlm-1578	8	21	resulting	result	VERB
ajlm-1578	8	22	in	in	ADP
ajlm-1578	8	23	a	a	DET
ajlm-1578	8	24	constitutively	constitutively	ADV
ajlm-1578	8	25	active	active	ADJ
ajlm-1578	8	26	tyrosine	tyrosine	NOUN
ajlm-1578	8	27	kinase	kinase	PROPN
ajlm-1578	8	28	.	.	PUNCT
ajlm-1578	9	1	globally	globally	ADV
ajlm-1578	9	2	,	,	PUNCT
ajlm-1578	9	3	overall	overall	ADJ
ajlm-1578	9	4	survival	survival	NOUN
ajlm-1578	9	5	of	of	ADP
ajlm-1578	9	6	blast	blast	NOUN
ajlm-1578	9	7	crisis	crisis	NOUN
ajlm-1578	9	8	phase	phase	NOUN
ajlm-1578	9	9	(	(	PUNCT
ajlm-1578	9	10	bc	bc	PROPN
ajlm-1578	9	11	)	)	PUNCT
ajlm-1578	9	12	cml	cml	PROPN
ajlm-1578	9	13	is	be	AUX
ajlm-1578	9	14	one	one	NUM
ajlm-1578	9	15	year	year	NOUN
ajlm-1578	9	16	.	.	PUNCT
ajlm-1578	10	1	newer	new	ADJ
ajlm-1578	10	2	tyrosine	tyrosine	PROPN
ajlm-1578	10	3	kinase	kinase	PROPN
ajlm-1578	10	4	inhibitors	inhibitor	NOUN
ajlm-1578	10	5	and	and	CCONJ
ajlm-1578	10	6	allogeneic	allogeneic	ADJ
ajlm-1578	10	7	stem	stem	NOUN
ajlm-1578	10	8	cell	cell	NOUN
ajlm-1578	10	9	transplantation	transplantation	NOUN
ajlm-1578	10	10	offer	offer	NOUN
ajlm-1578	10	11	remission	remission	NOUN
ajlm-1578	10	12	;	;	PUNCT
ajlm-1578	10	13	however	however	ADV
ajlm-1578	10	14	,	,	PUNCT
ajlm-1578	10	15	refractory	refractory	NOUN
ajlm-1578	10	16	and	and	CCONJ
ajlm-1578	10	17	relapsed	relapse	VERB
ajlm-1578	10	18	disease	disease	NOUN
ajlm-1578	10	19	remain	remain	VERB
ajlm-1578	10	20	the	the	DET
ajlm-1578	10	21	biggest	big	ADJ
ajlm-1578	10	22	challenges	challenge	NOUN
ajlm-1578	10	23	.	.	PUNCT
ajlm-1578	11	1	objective	objective	NOUN
ajlm-1578	11	2	:	:	PUNCT
ajlm-1578	11	3	in	in	ADP
ajlm-1578	11	4	south	south	PROPN
ajlm-1578	11	5	africa	africa	PROPN
ajlm-1578	11	6	,	,	PUNCT
ajlm-1578	11	7	literature	literature	PROPN
ajlm-1578	11	8	is	be	AUX
ajlm-1578	11	9	lacking	lack	VERB
ajlm-1578	11	10	on	on	ADP
ajlm-1578	11	11	bc	bc	PROPN
ajlm-1578	11	12	-	-	PUNCT
ajlm-1578	11	13	cml	cml	PROPN
ajlm-1578	11	14	.	.	PUNCT
ajlm-1578	12	1	this	this	DET
ajlm-1578	12	2	study	study	NOUN
ajlm-1578	12	3	aimed	aim	VERB
ajlm-1578	12	4	to	to	PART
ajlm-1578	12	5	determine	determine	VERB
ajlm-1578	12	6	the	the	DET
ajlm-1578	12	7	disease	disease	NOUN
ajlm-1578	12	8	characteristics	characteristic	NOUN
ajlm-1578	12	9	and	and	CCONJ
ajlm-1578	12	10	overall	overall	ADJ
ajlm-1578	12	11	survival	survival	NOUN
ajlm-1578	12	12	in	in	ADP
ajlm-1578	12	13	south	south	PROPN
ajlm-1578	12	14	africa	africa	PROPN
ajlm-1578	12	15	.	.	PUNCT
ajlm-1578	13	1	methods	method	NOUN
ajlm-1578	13	2	:	:	PUNCT
ajlm-1578	13	3	this	this	DET
ajlm-1578	13	4	retrospective	retrospective	ADJ
ajlm-1578	13	5	,	,	PUNCT
ajlm-1578	13	6	laboratory	laboratory	NOUN
ajlm-1578	13	7	-	-	PUNCT
ajlm-1578	13	8	based	base	VERB
ajlm-1578	13	9	study	study	NOUN
ajlm-1578	13	10	reviewed	review	VERB
ajlm-1578	13	11	all	all	DET
ajlm-1578	13	12	new	new	ADJ
ajlm-1578	13	13	bc	bc	PROPN
ajlm-1578	13	14	-	-	PUNCT
ajlm-1578	13	15	cml	cml	PROPN
ajlm-1578	13	16	diagnoses	diagnosis	NOUN
ajlm-1578	13	17	via	via	ADP
ajlm-1578	13	18	flow	flow	NOUN
ajlm-1578	13	19	cytometry	cytometry	NOUN
ajlm-1578	13	20	at	at	ADP
ajlm-1578	13	21	charlotte	charlotte	PROPN
ajlm-1578	13	22	maxeke	maxeke	PROPN
ajlm-1578	13	23	johannesburg	johannesburg	PROPN
ajlm-1578	13	24	academic	academic	ADJ
ajlm-1578	13	25	hospital	hospital	PROPN
ajlm-1578	13	26	in	in	ADP
ajlm-1578	13	27	johannesburg	johannesburg	PROPN
ajlm-1578	13	28	,	,	PUNCT
ajlm-1578	13	29	south	south	PROPN
ajlm-1578	13	30	africa	africa	PROPN
ajlm-1578	13	31	,	,	PUNCT
ajlm-1578	13	32	between	between	ADP
ajlm-1578	13	33	april	april	PROPN
ajlm-1578	13	34	2016	2016	NUM
ajlm-1578	13	35	and	and	CCONJ
ajlm-1578	13	36	october	october	PROPN
ajlm-1578	13	37	2019	2019	NUM
ajlm-1578	13	38	.	.	PUNCT
ajlm-1578	14	1	bc	bc	PROPN
ajlm-1578	14	2	-	-	PUNCT
ajlm-1578	14	3	cml	cml	PROPN
ajlm-1578	14	4	was	be	AUX
ajlm-1578	14	5	defined	define	VERB
ajlm-1578	14	6	as	as	ADP
ajlm-1578	14	7	the	the	DET
ajlm-1578	14	8	presence	presence	NOUN
ajlm-1578	14	9	of	of	ADP
ajlm-1578	14	10	>	>	SYM
ajlm-1578	14	11	20	20	NUM
ajlm-1578	14	12	%	%	NOUN
ajlm-1578	14	13	blasts	blast	VERB
ajlm-1578	14	14	with	with	ADP
ajlm-1578	14	15	a	a	DET
ajlm-1578	14	16	cml	cml	PROPN
ajlm-1578	14	17	history	history	NOUN
ajlm-1578	14	18	or	or	CCONJ
ajlm-1578	14	19	the	the	DET
ajlm-1578	14	20	bcr	bcr	ADJ
ajlm-1578	14	21	-	-	PUNCT
ajlm-1578	14	22	abl1	abl1	ADJ
ajlm-1578	14	23	fusion	fusion	NOUN
ajlm-1578	14	24	gene	gene	NOUN
ajlm-1578	14	25	(	(	PUNCT
ajlm-1578	14	26	p210	p210	PROPN
ajlm-1578	14	27	/	/	SYM
ajlm-1578	14	28	p190	p190	PROPN
ajlm-1578	14	29	)	)	PUNCT
ajlm-1578	14	30	in	in	ADP
ajlm-1578	14	31	the	the	DET
ajlm-1578	14	32	appropriate	appropriate	ADJ
ajlm-1578	14	33	clinical	clinical	ADJ
ajlm-1578	14	34	or	or	CCONJ
ajlm-1578	14	35	pathological	pathological	ADJ
ajlm-1578	14	36	context	context	NOUN
ajlm-1578	14	37	.	.	PUNCT
ajlm-1578	15	1	survival	survival	NOUN
ajlm-1578	15	2	outcomes	outcome	NOUN
ajlm-1578	15	3	were	be	AUX
ajlm-1578	15	4	inferred	infer	VERB
ajlm-1578	15	5	from	from	ADP
ajlm-1578	15	6	clinical	clinical	ADJ
ajlm-1578	15	7	and	and	CCONJ
ajlm-1578	15	8	laboratory	laboratory	NOUN
ajlm-1578	15	9	data	datum	NOUN
ajlm-1578	15	10	.	.	PUNCT
ajlm-1578	16	1	results	result	NOUN
ajlm-1578	16	2	:	:	PUNCT
ajlm-1578	16	3	twenty	twenty	NUM
ajlm-1578	16	4	-	-	PUNCT
ajlm-1578	16	5	two	two	NUM
ajlm-1578	16	6	new	new	ADJ
ajlm-1578	16	7	cases	case	NOUN
ajlm-1578	16	8	of	of	ADP
ajlm-1578	16	9	bc	bc	PROPN
ajlm-1578	16	10	-	-	PUNCT
ajlm-1578	16	11	cml	cml	PROPN
ajlm-1578	16	12	were	be	AUX
ajlm-1578	16	13	diagnosed	diagnose	VERB
ajlm-1578	16	14	(	(	PUNCT
ajlm-1578	16	15	median	median	ADJ
ajlm-1578	16	16	age	age	NOUN
ajlm-1578	16	17	:	:	PUNCT
ajlm-1578	16	18	34	34	NUM
ajlm-1578	16	19	years	year	NOUN
ajlm-1578	16	20	)	)	PUNCT
ajlm-1578	16	21	.	.	PUNCT
ajlm-1578	17	1	there	there	PRON
ajlm-1578	17	2	were	be	VERB
ajlm-1578	17	3	20	20	NUM
ajlm-1578	17	4	(	(	PUNCT
ajlm-1578	17	5	91	91	NUM
ajlm-1578	17	6	%	%	NOUN
ajlm-1578	17	7	)	)	PUNCT
ajlm-1578	17	8	cases	case	NOUN
ajlm-1578	17	9	with	with	ADP
ajlm-1578	17	10	the	the	DET
ajlm-1578	17	11	fusion	fusion	NOUN
ajlm-1578	17	12	transcripts	transcript	NOUN
ajlm-1578	17	13	p210	p210	PROPN
ajlm-1578	17	14	and	and	CCONJ
ajlm-1578	17	15	two	two	NUM
ajlm-1578	17	16	(	(	PUNCT
ajlm-1578	17	17	9	9	NUM
ajlm-1578	17	18	%	%	NOUN
ajlm-1578	17	19	)	)	PUNCT
ajlm-1578	17	20	cases	case	NOUN
ajlm-1578	17	21	with	with	ADP
ajlm-1578	17	22	p190	p190	PROPN
ajlm-1578	17	23	bcrabl1	bcrabl1	PROPN
ajlm-1578	17	24	.	.	PUNCT
ajlm-1578	18	1	for	for	ADP
ajlm-1578	18	2	blast	blast	NOUN
ajlm-1578	18	3	lineage	lineage	NOUN
ajlm-1578	18	4	,	,	PUNCT
ajlm-1578	18	5	14	14	NUM
ajlm-1578	18	6	cases	case	NOUN
ajlm-1578	18	7	were	be	AUX
ajlm-1578	18	8	myeloid	myeloid	ADJ
ajlm-1578	18	9	(	(	PUNCT
ajlm-1578	18	10	63.6	63.6	NUM
ajlm-1578	18	11	%	%	NOUN
ajlm-1578	18	12	)	)	PUNCT
ajlm-1578	18	13	,	,	PUNCT
ajlm-1578	18	14	six	six	NUM
ajlm-1578	18	15	were	be	AUX
ajlm-1578	18	16	lymphoid	lymphoid	ADJ
ajlm-1578	18	17	(	(	PUNCT
ajlm-1578	18	18	27.3	27.3	NUM
ajlm-1578	18	19	%	%	NOUN
ajlm-1578	18	20	)	)	PUNCT
ajlm-1578	18	21	,	,	PUNCT
ajlm-1578	18	22	and	and	CCONJ
ajlm-1578	18	23	two	two	NUM
ajlm-1578	18	24	were	be	AUX
ajlm-1578	18	25	ambiguous	ambiguous	ADJ
ajlm-1578	18	26	(	(	PUNCT
ajlm-1578	18	27	9.1	9.1	NUM
ajlm-1578	18	28	%	%	NOUN
ajlm-1578	18	29	)	)	PUNCT
ajlm-1578	18	30	.	.	PUNCT
ajlm-1578	19	1	there	there	PRON
ajlm-1578	19	2	was	be	VERB
ajlm-1578	19	3	a	a	DET
ajlm-1578	19	4	72.7	72.7	NUM
ajlm-1578	19	5	%	%	NOUN
ajlm-1578	19	6	mortality	mortality	NOUN
ajlm-1578	19	7	(	(	PUNCT
ajlm-1578	19	8	16	16	NUM
ajlm-1578	19	9	cases	case	NOUN
ajlm-1578	19	10	)	)	PUNCT
ajlm-1578	19	11	;	;	PUNCT
ajlm-1578	19	12	sepsis	sepsis	NOUN
ajlm-1578	19	13	,	,	PUNCT
ajlm-1578	19	14	refractory	refractory	NOUN
ajlm-1578	19	15	and	and	CCONJ
ajlm-1578	19	16	relapsed	relapse	VERB
ajlm-1578	19	17	disease	disease	NOUN
ajlm-1578	19	18	were	be	AUX
ajlm-1578	19	19	the	the	DET
ajlm-1578	19	20	major	major	ADJ
ajlm-1578	19	21	causes	cause	NOUN
ajlm-1578	19	22	.	.	PUNCT
ajlm-1578	20	1	patients	patient	NOUN
ajlm-1578	20	2	who	who	PRON
ajlm-1578	20	3	achieved	achieve	VERB
ajlm-1578	20	4	remission	remission	NOUN
ajlm-1578	20	5	had	have	VERB
ajlm-1578	20	6	lower	low	ADJ
ajlm-1578	20	7	blast	blast	NOUN
ajlm-1578	20	8	percentages	percentage	NOUN
ajlm-1578	20	9	,	,	PUNCT
ajlm-1578	20	10	simple	simple	ADJ
ajlm-1578	20	11	karyotypes	karyotype	NOUN
ajlm-1578	20	12	,	,	PUNCT
ajlm-1578	20	13	and	and	CCONJ
ajlm-1578	20	14	a	a	DET
ajlm-1578	20	15	trend	trend	NOUN
ajlm-1578	20	16	towards	towards	ADP
ajlm-1578	20	17	higher	high	ADJ
ajlm-1578	20	18	white	white	ADJ
ajlm-1578	20	19	cell	cell	NOUN
ajlm-1578	20	20	and	and	CCONJ
ajlm-1578	20	21	platelet	platelet	NOUN
ajlm-1578	20	22	counts	count	NOUN
ajlm-1578	20	23	at	at	ADP
ajlm-1578	20	24	presentation	presentation	NOUN
ajlm-1578	20	25	.	.	PUNCT
ajlm-1578	21	1	conclusion	conclusion	NOUN
ajlm-1578	21	2	:	:	PUNCT
ajlm-1578	21	3	optimised	optimise	VERB
ajlm-1578	21	4	management	management	NOUN
ajlm-1578	21	5	of	of	ADP
ajlm-1578	21	6	early	early	ADJ
ajlm-1578	21	7	-	-	PUNCT
ajlm-1578	21	8	stage	stage	NOUN
ajlm-1578	21	9	cml	cml	PROPN
ajlm-1578	21	10	,	,	PUNCT
ajlm-1578	21	11	prevention	prevention	NOUN
ajlm-1578	21	12	and	and	CCONJ
ajlm-1578	21	13	aggressive	aggressive	ADJ
ajlm-1578	21	14	management	management	NOUN
ajlm-1578	21	15	of	of	ADP
ajlm-1578	21	16	sepsis	sepsis	NOUN
ajlm-1578	21	17	,	,	PUNCT
ajlm-1578	21	18	with	with	ADP
ajlm-1578	21	19	advocation	advocation	NOUN
ajlm-1578	21	20	for	for	ADP
ajlm-1578	21	21	newer	new	ADJ
ajlm-1578	21	22	therapies	therapy	NOUN
ajlm-1578	21	23	are	be	AUX
ajlm-1578	21	24	needed	need	VERB
ajlm-1578	21	25	to	to	PART
ajlm-1578	21	26	improve	improve	VERB
ajlm-1578	21	27	the	the	DET
ajlm-1578	21	28	overall	overall	ADJ
ajlm-1578	21	29	survival	survival	NOUN
ajlm-1578	21	30	of	of	ADP
ajlm-1578	21	31	bc	bc	PROPN
ajlm-1578	21	32	-	-	PUNCT
ajlm-1578	21	33	cml	cml	PROPN
ajlm-1578	21	34	in	in	ADP
ajlm-1578	21	35	south	south	PROPN
ajlm-1578	21	36	africa	africa	PROPN
ajlm-1578	21	37	.	.	PUNCT
ajlm-1578	22	1	keywords	keyword	NOUN
ajlm-1578	22	2	:	:	PUNCT
ajlm-1578	22	3	chronic	chronic	ADJ
ajlm-1578	22	4	myeloid	myeloid	NOUN
ajlm-1578	22	5	leukaemia	leukaemia	NOUN
ajlm-1578	22	6	;	;	PUNCT
ajlm-1578	22	7	blast	blast	NOUN
ajlm-1578	22	8	phase	phase	NOUN
ajlm-1578	22	9	;	;	PUNCT
ajlm-1578	22	10	major	major	ADJ
ajlm-1578	22	11	molecular	molecular	ADJ
ajlm-1578	22	12	route	route	NOUN
ajlm-1578	22	13	abnormalities	abnormality	NOUN
ajlm-1578	22	14	;	;	PUNCT
ajlm-1578	22	15	south	south	PROPN
ajlm-1578	22	16	africa	africa	PROPN
ajlm-1578	22	17	;	;	PUNCT
ajlm-1578	22	18	p210	p210	PROPN
ajlm-1578	22	19	bcrabl1	bcrabl1	ADJ
ajlm-1578	22	20	fusion	fusion	NOUN
ajlm-1578	22	21	transcript	transcript	NOUN
ajlm-1578	22	22	;	;	PUNCT
ajlm-1578	22	23	p190	p190	NUM
ajlm-1578	22	24	bcrabl1	bcrabl1	VERB
ajlm-1578	22	25	fusion	fusion	NOUN
ajlm-1578	22	26	transcript	transcript	NOUN
ajlm-1578	22	27	;	;	PUNCT
ajlm-1578	22	28	responses	response	NOUN
ajlm-1578	22	29	by	by	ADP
ajlm-1578	22	30	quantitative	quantitative	ADJ
ajlm-1578	22	31	reverse	reverse	ADJ
ajlm-1578	22	32	transcriptase	transcriptase	NOUN
ajlm-1578	22	33	-	-	PUNCT
ajlm-1578	22	34	polymerase	polymerase	NOUN
ajlm-1578	22	35	chain	chain	NOUN
ajlm-1578	22	36	reaction	reaction	NOUN
ajlm-1578	22	37	;	;	PUNCT
ajlm-1578	22	38	karyotype	karyotype	NOUN
ajlm-1578	22	39	.	.	PUNCT
ajlm-1578	23	1	introduction	introduction	NOUN
ajlm-1578	23	2	chronic	chronic	ADJ
ajlm-1578	23	3	myeloid	myeloid	NOUN
ajlm-1578	23	4	leukaemia	leukaemia	NOUN
ajlm-1578	23	5	(	(	PUNCT
ajlm-1578	23	6	cml	cml	PROPN
ajlm-1578	23	7	)	)	PUNCT
ajlm-1578	23	8	is	be	AUX
ajlm-1578	23	9	a	a	DET
ajlm-1578	23	10	haematological	haematological	ADJ
ajlm-1578	23	11	malignancy	malignancy	NOUN
ajlm-1578	23	12	that	that	PRON
ajlm-1578	23	13	arises	arise	VERB
ajlm-1578	23	14	within	within	ADP
ajlm-1578	23	15	a	a	DET
ajlm-1578	23	16	pluripotent	pluripotent	ADJ
ajlm-1578	23	17	haemopoietic	haemopoietic	ADJ
ajlm-1578	23	18	stem	stem	NOUN
ajlm-1578	23	19	cell.1,2,3	cell.1,2,3	X
ajlm-1578	24	1	the	the	DET
ajlm-1578	24	2	defining	define	VERB
ajlm-1578	24	3	molecular	molecular	ADJ
ajlm-1578	24	4	aberration	aberration	NOUN
ajlm-1578	24	5	is	be	AUX
ajlm-1578	24	6	a	a	DET
ajlm-1578	24	7	translocation	translocation	NOUN
ajlm-1578	24	8	involving	involve	VERB
ajlm-1578	24	9	the	the	DET
ajlm-1578	24	10	long	long	ADJ
ajlm-1578	24	11	arms	arm	NOUN
ajlm-1578	24	12	of	of	ADP
ajlm-1578	24	13	chromosome	chromosome	NOUN
ajlm-1578	24	14	9	9	NUM
ajlm-1578	24	15	and	and	CCONJ
ajlm-1578	24	16	22	22	NUM
ajlm-1578	24	17	(	(	PUNCT
ajlm-1578	24	18	t[9;22][q34;q11.2	t[9;22][q34;q11.2	NOUN
ajlm-1578	24	19	]	]	PUNCT
ajlm-1578	24	20	)	)	PUNCT
ajlm-1578	24	21	which	which	PRON
ajlm-1578	24	22	results	result	VERB
ajlm-1578	24	23	in	in	ADP
ajlm-1578	24	24	a	a	DET
ajlm-1578	24	25	chimeric	chimeric	ADJ
ajlm-1578	24	26	breakpoint	breakpoint	NOUN
ajlm-1578	24	27	cluster	cluster	NOUN
ajlm-1578	24	28	region	region	NOUN
ajlm-1578	24	29	-	-	PUNCT
ajlm-1578	24	30	abelson	abelson	NOUN
ajlm-1578	24	31	murine	murine	PROPN
ajlm-1578	24	32	leukaemia	leukaemia	VERB
ajlm-1578	24	33	viral	viral	ADJ
ajlm-1578	24	34	oncogene	oncogene	NOUN
ajlm-1578	24	35	homolog	homolog	NOUN
ajlm-1578	24	36	1	1	NUM
ajlm-1578	24	37	(	(	PUNCT
ajlm-1578	24	38	bcr	bcr	PROPN
ajlm-1578	24	39	-	-	PUNCT
ajlm-1578	24	40	abl1	abl1	ADJ
ajlm-1578	24	41	)	)	PUNCT
ajlm-1578	24	42	fusion	fusion	NOUN
ajlm-1578	24	43	gene	gene	NOUN
ajlm-1578	24	44	encoding	encoding	NOUN
ajlm-1578	24	45	for	for	ADP
ajlm-1578	24	46	a	a	DET
ajlm-1578	24	47	constitutively	constitutively	ADV
ajlm-1578	24	48	active	active	ADJ
ajlm-1578	24	49	tyrosine	tyrosine	NOUN
ajlm-1578	24	50	kinase.4,5,6,7	kinase.4,5,6,7	NOUN
ajlm-1578	24	51	this	this	DET
ajlm-1578	24	52	protein	protein	NOUN
ajlm-1578	24	53	drives	drive	VERB
ajlm-1578	24	54	the	the	DET
ajlm-1578	24	55	expansion	expansion	NOUN
ajlm-1578	24	56	and	and	CCONJ
ajlm-1578	24	57	survival	survival	NOUN
ajlm-1578	24	58	of	of	ADP
ajlm-1578	24	59	the	the	DET
ajlm-1578	24	60	clone	clone	NOUN
ajlm-1578	24	61	through	through	ADP
ajlm-1578	24	62	the	the	DET
ajlm-1578	24	63	proliferation	proliferation	NOUN
ajlm-1578	24	64	of	of	ADP
ajlm-1578	24	65	the	the	DET
ajlm-1578	24	66	myeloid	myeloid	NOUN
ajlm-1578	24	67	compartment	compartment	NOUN
ajlm-1578	24	68	,	,	PUNCT
ajlm-1578	24	69	anti	anti	ADJ
ajlm-1578	24	70	-	-	ADJ
ajlm-1578	24	71	apoptotic	apoptotic	ADJ
ajlm-1578	24	72	properties	property	NOUN
ajlm-1578	24	73	and	and	CCONJ
ajlm-1578	24	74	reduced	reduce	VERB
ajlm-1578	24	75	adherence	adherence	NOUN
ajlm-1578	24	76	to	to	ADP
ajlm-1578	24	77	the	the	DET
ajlm-1578	24	78	bone	bone	NOUN
ajlm-1578	24	79	marrow	marrow	NOUN
ajlm-1578	24	80	niche.8,9,10	niche.8,9,10	PROPN
ajlm-1578	24	81	chronic	chronic	ADJ
ajlm-1578	24	82	myeloid	myeloid	NOUN
ajlm-1578	24	83	leukaemia	leukaemia	NOUN
ajlm-1578	24	84	is	be	AUX
ajlm-1578	24	85	a	a	DET
ajlm-1578	24	86	bior	bior	ADJ
ajlm-1578	24	87	tri	tri	ADJ
ajlm-1578	24	88	-	-	ADJ
ajlm-1578	24	89	phasic	phasic	ADJ
ajlm-1578	24	90	disease	disease	NOUN
ajlm-1578	24	91	that	that	PRON
ajlm-1578	24	92	classically	classically	ADV
ajlm-1578	24	93	progresses	progress	VERB
ajlm-1578	24	94	through	through	ADP
ajlm-1578	24	95	chronic	chronic	NOUN
ajlm-1578	24	96	,	,	PUNCT
ajlm-1578	24	97	accelerated	accelerate	VERB
ajlm-1578	24	98	,	,	PUNCT
ajlm-1578	24	99	and	and	CCONJ
ajlm-1578	24	100	blast	blast	NOUN
ajlm-1578	24	101	phases	phase	NOUN
ajlm-1578	24	102	,	,	PUNCT
ajlm-1578	24	103	as	as	SCONJ
ajlm-1578	24	104	defined	define	VERB
ajlm-1578	24	105	by	by	ADP
ajlm-1578	24	106	the	the	DET
ajlm-1578	24	107	world	world	PROPN
ajlm-1578	24	108	health	health	PROPN
ajlm-1578	24	109	organization	organization	PROPN
ajlm-1578	24	110	and	and	CCONJ
ajlm-1578	24	111	european	european	PROPN
ajlm-1578	24	112	leukaemianet	leukaemianet	PROPN
ajlm-1578	24	113	criteria.11,12,13,14,15	criteria.11,12,13,14,15	PROPN
ajlm-1578	24	114	tyrosine	tyrosine	NOUN
ajlm-1578	24	115	kinase	kinase	PROPN
ajlm-1578	24	116	inhibitors	inhibitor	NOUN
ajlm-1578	24	117	(	(	PUNCT
ajlm-1578	24	118	tkis	tkis	NOUN
ajlm-1578	24	119	)	)	PUNCT
ajlm-1578	24	120	were	be	AUX
ajlm-1578	24	121	the	the	DET
ajlm-1578	24	122	first	first	ADJ
ajlm-1578	24	123	targeted	target	VERB
ajlm-1578	24	124	therapies	therapy	NOUN
ajlm-1578	24	125	developed	develop	VERB
ajlm-1578	24	126	for	for	ADP
ajlm-1578	24	127	cml	cml	PROPN
ajlm-1578	24	128	.	.	PUNCT
ajlm-1578	25	1	the	the	DET
ajlm-1578	25	2	introduction	introduction	NOUN
ajlm-1578	25	3	of	of	ADP
ajlm-1578	25	4	the	the	DET
ajlm-1578	25	5	first	first	ADJ
ajlm-1578	25	6	-	-	PUNCT
ajlm-1578	25	7	generation	generation	NOUN
ajlm-1578	25	8	tkis	tkis	NOUN
ajlm-1578	25	9	as	as	SCONJ
ajlm-1578	25	10	the	the	DET
ajlm-1578	25	11	mainstay	mainstay	NOUN
ajlm-1578	25	12	therapy	therapy	NOUN
ajlm-1578	25	13	in	in	ADP
ajlm-1578	25	14	1998	1998	NUM
ajlm-1578	25	15	halted	halt	VERB
ajlm-1578	25	16	the	the	DET
ajlm-1578	25	17	natural	natural	ADJ
ajlm-1578	25	18	progression	progression	NOUN
ajlm-1578	25	19	of	of	ADP
ajlm-1578	25	20	the	the	DET
ajlm-1578	25	21	disease	disease	NOUN
ajlm-1578	25	22	.	.	PUNCT
ajlm-1578	26	1	this	this	PRON
ajlm-1578	26	2	has	have	AUX
ajlm-1578	26	3	allowed	allow	VERB
ajlm-1578	26	4	patients	patient	NOUN
ajlm-1578	26	5	to	to	PART
ajlm-1578	26	6	maintain	maintain	VERB
ajlm-1578	26	7	chronic	chronic	ADJ
ajlm-1578	26	8	phase	phase	NOUN
ajlm-1578	26	9	disease	disease	NOUN
ajlm-1578	26	10	with	with	ADP
ajlm-1578	26	11	the	the	DET
ajlm-1578	26	12	achievement	achievement	NOUN
ajlm-1578	26	13	of	of	ADP
ajlm-1578	26	14	morphological	morphological	ADJ
ajlm-1578	26	15	,	,	PUNCT
ajlm-1578	26	16	clinical	clinical	ADJ
ajlm-1578	26	17	,	,	PUNCT
ajlm-1578	26	18	and	and	CCONJ
ajlm-1578	26	19	molecular	molecular	ADJ
ajlm-1578	26	20	remission	remission	NOUN
ajlm-1578	26	21	targets	target	NOUN
ajlm-1578	26	22	.	.	PUNCT
ajlm-1578	27	1	since	since	SCONJ
ajlm-1578	27	2	the	the	DET
ajlm-1578	27	3	introduction	introduction	NOUN
ajlm-1578	27	4	of	of	ADP
ajlm-1578	27	5	second	second	ADJ
ajlm-1578	27	6	and	and	CCONJ
ajlm-1578	27	7	third	third	ADJ
ajlm-1578	27	8	-	-	PUNCT
ajlm-1578	27	9	generation	generation	NOUN
ajlm-1578	27	10	tkis	tkis	NOUN
ajlm-1578	27	11	,	,	PUNCT
ajlm-1578	27	12	there	there	PRON
ajlm-1578	27	13	has	have	AUX
ajlm-1578	27	14	been	be	AUX
ajlm-1578	27	15	advancement	advancement	NOUN
ajlm-1578	27	16	in	in	ADP
ajlm-1578	27	17	both	both	CCONJ
ajlm-1578	27	18	the	the	DET
ajlm-1578	27	19	speed	speed	NOUN
ajlm-1578	27	20	and	and	CCONJ
ajlm-1578	27	21	depth	depth	NOUN
ajlm-1578	27	22	of	of	ADP
ajlm-1578	27	23	molecular	molecular	ADJ
ajlm-1578	27	24	remission.16	remission.16	NOUN
ajlm-1578	27	25	in	in	ADP
ajlm-1578	27	26	the	the	DET
ajlm-1578	27	27	united	united	PROPN
ajlm-1578	27	28	states	states	PROPN
ajlm-1578	27	29	,	,	PUNCT
ajlm-1578	27	30	the	the	DET
ajlm-1578	27	31	overall	overall	ADJ
ajlm-1578	27	32	survival	survival	NOUN
ajlm-1578	27	33	(	(	PUNCT
ajlm-1578	27	34	os	os	NOUN
ajlm-1578	27	35	)	)	PUNCT
ajlm-1578	27	36	in	in	ADP
ajlm-1578	27	37	chronic	chronic	ADJ
ajlm-1578	27	38	phase	phase	NOUN
ajlm-1578	27	39	disease	disease	NOUN
ajlm-1578	27	40	is	be	AUX
ajlm-1578	27	41	nearly	nearly	ADV
ajlm-1578	27	42	equivalent	equivalent	ADJ
ajlm-1578	27	43	to	to	ADP
ajlm-1578	27	44	that	that	PRON
ajlm-1578	27	45	of	of	ADP
ajlm-1578	27	46	the	the	DET
ajlm-1578	27	47	general	general	ADJ
ajlm-1578	27	48	population	population	NOUN
ajlm-1578	27	49	when	when	SCONJ
ajlm-1578	27	50	response	response	NOUN
ajlm-1578	27	51	milestones	milestone	NOUN
ajlm-1578	27	52	are	be	AUX
ajlm-1578	27	53	achieved.17,18	achieved.17,18	ADJ
ajlm-1578	27	54	however	however	ADV
ajlm-1578	27	55	,	,	PUNCT
ajlm-1578	27	56	disease	disease	NOUN
ajlm-1578	27	57	progression	progression	NOUN
ajlm-1578	27	58	to	to	PART
ajlm-1578	27	59	accelerated	accelerated	VERB
ajlm-1578	27	60	or	or	CCONJ
ajlm-1578	27	61	blast	blast	NOUN
ajlm-1578	27	62	phase	phase	NOUN
ajlm-1578	27	63	still	still	ADV
ajlm-1578	27	64	occurs	occur	VERB
ajlm-1578	27	65	in	in	ADP
ajlm-1578	27	66	this	this	DET
ajlm-1578	27	67	era	era	NOUN
ajlm-1578	27	68	of	of	ADP
ajlm-1578	27	69	effective	effective	ADJ
ajlm-1578	27	70	targeted	target	VERB
ajlm-1578	27	71	therapy	therapy	NOUN
ajlm-1578	27	72	,	,	PUNCT
ajlm-1578	27	73	as	as	ADP
ajlm-1578	27	74	a	a	DET
ajlm-1578	27	75	result	result	NOUN
ajlm-1578	27	76	of	of	ADP
ajlm-1578	27	77	drug	drug	NOUN
ajlm-1578	27	78	resistance	resistance	NOUN
ajlm-1578	27	79	,	,	PUNCT
ajlm-1578	27	80	cessation	cessation	NOUN
ajlm-1578	27	81	of	of	ADP
ajlm-1578	27	82	therapy	therapy	NOUN
ajlm-1578	27	83	resulting	result	VERB
ajlm-1578	27	84	from	from	ADP
ajlm-1578	27	85	drug	drug	NOUN
ajlm-1578	27	86	intolerance	intolerance	NOUN
ajlm-1578	27	87	or	or	CCONJ
ajlm-1578	27	88	side	side	NOUN
ajlm-1578	27	89	effects	effect	NOUN
ajlm-1578	27	90	,	,	PUNCT
ajlm-1578	27	91	poor	poor	ADJ
ajlm-1578	27	92	compliance	compliance	NOUN
ajlm-1578	27	93	,	,	PUNCT
ajlm-1578	27	94	altered	alter	VERB
ajlm-1578	27	95	metabolism	metabolism	NOUN
ajlm-1578	27	96	,	,	PUNCT
ajlm-1578	27	97	and	and	CCONJ
ajlm-1578	27	98	drug	drug	NOUN
ajlm-1578	27	99	interactions	interaction	NOUN
ajlm-1578	27	100	.	.	PUNCT
ajlm-1578	28	1	in	in	ADP
ajlm-1578	28	2	contrast	contrast	NOUN
ajlm-1578	28	3	,	,	PUNCT
ajlm-1578	28	4	the	the	DET
ajlm-1578	28	5	diagnosis	diagnosis	NOUN
ajlm-1578	28	6	of	of	ADP
ajlm-1578	28	7	chronic	chronic	ADJ
ajlm-1578	28	8	myeloid	myeloid	NOUN
ajlm-1578	28	9	leukaemia	leukaemia	NOUN
ajlm-1578	28	10	in	in	ADP
ajlm-1578	28	11	blast	blast	NOUN
ajlm-1578	28	12	crises	crisis	NOUN
ajlm-1578	28	13	phase	phase	NOUN
ajlm-1578	28	14	(	(	PUNCT
ajlm-1578	28	15	bc	bc	PROPN
ajlm-1578	28	16	)	)	PUNCT
ajlm-1578	28	17	cml	cml	PROPN
ajlm-1578	28	18	has	have	AUX
ajlm-1578	28	19	been	be	AUX
ajlm-1578	28	20	associated	associate	VERB
ajlm-1578	28	21	with	with	ADP
ajlm-1578	28	22	a	a	DET
ajlm-1578	28	23	low	low	ADJ
ajlm-1578	28	24	median	median	ADJ
ajlm-1578	28	25	os	os	NOUN
ajlm-1578	28	26	of	of	ADP
ajlm-1578	28	27	12	12	NUM
ajlm-1578	28	28	months	month	NOUN
ajlm-1578	28	29	in	in	ADP
ajlm-1578	28	30	the	the	DET
ajlm-1578	28	31	united	united	PROPN
ajlm-1578	28	32	states	states	PROPN
ajlm-1578	28	33	.	.	PUNCT
ajlm-1578	29	1	combination	combination	NOUN
ajlm-1578	29	2	therapy	therapy	NOUN
ajlm-1578	29	3	with	with	ADP
ajlm-1578	29	4	tkis	tkis	NOUN
ajlm-1578	29	5	and	and	CCONJ
ajlm-1578	29	6	intensive	intensive	ADJ
ajlm-1578	29	7	chemotherapy	chemotherapy	NOUN
ajlm-1578	29	8	,	,	PUNCT
ajlm-1578	29	9	consolidated	consolidate	VERB
ajlm-1578	29	10	with	with	ADP
ajlm-1578	29	11	an	an	DET
ajlm-1578	29	12	allogeneic	allogeneic	ADJ
ajlm-1578	29	13	haemopoietic	haemopoietic	ADJ
ajlm-1578	29	14	stem	stem	NOUN
ajlm-1578	29	15	cell	cell	NOUN
ajlm-1578	29	16	transplant	transplant	NOUN
ajlm-1578	29	17	(	(	PUNCT
ajlm-1578	29	18	allosct	allosct	PROPN
ajlm-1578	29	19	)	)	PUNCT
ajlm-1578	29	20	,	,	PUNCT
ajlm-1578	29	21	offers	offer	VERB
ajlm-1578	29	22	patients	patient	NOUN
ajlm-1578	29	23	the	the	DET
ajlm-1578	29	24	most	most	ADV
ajlm-1578	29	25	favourable	favourable	ADJ
ajlm-1578	29	26	outcomes.19	outcomes.19	NOUN
ajlm-1578	29	27	in	in	ADP
ajlm-1578	29	28	africa	africa	PROPN
ajlm-1578	29	29	,	,	PUNCT
ajlm-1578	29	30	access	access	NOUN
ajlm-1578	29	31	to	to	ADP
ajlm-1578	29	32	second	second	ADJ
ajlm-1578	29	33	or	or	CCONJ
ajlm-1578	29	34	third	third	ADJ
ajlm-1578	29	35	generation	generation	NOUN
ajlm-1578	29	36	tkis	tkis	NOUN
ajlm-1578	29	37	and	and	CCONJ
ajlm-1578	29	38	allosct	allosct	PROPN
ajlm-1578	29	39	is	be	AUX
ajlm-1578	29	40	limited	limit	VERB
ajlm-1578	29	41	,	,	PUNCT
ajlm-1578	29	42	and	and	CCONJ
ajlm-1578	29	43	there	there	PRON
ajlm-1578	29	44	is	be	VERB
ajlm-1578	29	45	a	a	DET
ajlm-1578	29	46	paucity	paucity	NOUN
ajlm-1578	29	47	of	of	ADP
ajlm-1578	29	48	data	datum	NOUN
ajlm-1578	29	49	on	on	ADP
ajlm-1578	29	50	the	the	DET
ajlm-1578	29	51	prevalence	prevalence	NOUN
ajlm-1578	29	52	and	and	CCONJ
ajlm-1578	29	53	outcomes	outcome	NOUN
ajlm-1578	29	54	of	of	ADP
ajlm-1578	29	55	bc	bc	PROPN
ajlm-1578	29	56	-	-	PUNCT
ajlm-1578	29	57	cml	cml	PROPN
ajlm-1578	29	58	.	.	PUNCT
ajlm-1578	30	1	this	this	DET
ajlm-1578	30	2	study	study	NOUN
ajlm-1578	30	3	aimed	aim	VERB
ajlm-1578	30	4	to	to	PART
ajlm-1578	30	5	describe	describe	VERB
ajlm-1578	30	6	the	the	DET
ajlm-1578	30	7	disease	disease	NOUN
ajlm-1578	30	8	and	and	CCONJ
ajlm-1578	30	9	patient	patient	ADJ
ajlm-1578	30	10	characteristics	characteristic	NOUN
ajlm-1578	30	11	as	as	ADV
ajlm-1578	30	12	well	well	ADV
ajlm-1578	30	13	as	as	ADP
ajlm-1578	30	14	the	the	DET
ajlm-1578	30	15	os	os	NOUN
ajlm-1578	30	16	of	of	ADP
ajlm-1578	30	17	bc	bc	PROPN
ajlm-1578	30	18	-	-	PUNCT
ajlm-1578	30	19	cml	cml	PROPN
ajlm-1578	30	20	diagnosed	diagnose	VERB
ajlm-1578	30	21	in	in	ADP
ajlm-1578	30	22	the	the	DET
ajlm-1578	30	23	state	state	NOUN
ajlm-1578	30	24	sector	sector	NOUN
ajlm-1578	30	25	setting	setting	NOUN
ajlm-1578	30	26	in	in	ADP
ajlm-1578	30	27	johannesburg	johannesburg	PROPN
ajlm-1578	30	28	,	,	PUNCT
ajlm-1578	30	29	south	south	PROPN
ajlm-1578	30	30	africa	africa	PROPN
ajlm-1578	30	31	.	.	PUNCT
ajlm-1578	31	1	methods	method	NOUN
ajlm-1578	31	2	ethical	ethical	ADJ
ajlm-1578	31	3	considerations	consideration	NOUN
ajlm-1578	31	4	ethics	ethic	NOUN
ajlm-1578	31	5	clearance	clearance	NOUN
ajlm-1578	31	6	was	be	AUX
ajlm-1578	31	7	obtained	obtain	VERB
ajlm-1578	31	8	from	from	ADP
ajlm-1578	31	9	the	the	DET
ajlm-1578	31	10	university	university	NOUN
ajlm-1578	31	11	of	of	ADP
ajlm-1578	31	12	the	the	DET
ajlm-1578	31	13	witwatersrand	witwatersrand	NOUN
ajlm-1578	31	14	human	human	PROPN
ajlm-1578	31	15	ethics	ethics	PROPN
ajlm-1578	31	16	committee	committee	PROPN
ajlm-1578	31	17	(	(	PUNCT
ajlm-1578	31	18	protocol	protocol	NOUN
ajlm-1578	31	19	number	number	NOUN
ajlm-1578	31	20	m150160	m150160	PROPN
ajlm-1578	31	21	)	)	PUNCT
ajlm-1578	31	22	.	.	PUNCT
ajlm-1578	32	1	the	the	DET
ajlm-1578	32	2	study	study	NOUN
ajlm-1578	32	3	was	be	AUX
ajlm-1578	32	4	a	a	DET
ajlm-1578	32	5	retrospective	retrospective	ADJ
ajlm-1578	32	6	analysis	analysis	NOUN
ajlm-1578	32	7	of	of	ADP
ajlm-1578	32	8	laboratory	laboratory	NOUN
ajlm-1578	32	9	results	result	NOUN
ajlm-1578	32	10	obtained	obtain	VERB
ajlm-1578	32	11	from	from	ADP
ajlm-1578	32	12	the	the	DET
ajlm-1578	32	13	laboratory	laboratory	NOUN
ajlm-1578	32	14	information	information	NOUN
ajlm-1578	32	15	system	system	NOUN
ajlm-1578	32	16	(	(	PUNCT
ajlm-1578	32	17	lis	lis	PROPN
ajlm-1578	32	18	)	)	PUNCT
ajlm-1578	32	19	(	(	PUNCT
ajlm-1578	32	20	trakcare	trakcare	NOUN
ajlm-1578	32	21	,	,	PUNCT
ajlm-1578	32	22	intersystems	intersystem	NOUN
ajlm-1578	32	23	,	,	PUNCT
ajlm-1578	32	24	cambridge	cambridge	PROPN
ajlm-1578	32	25	,	,	PUNCT
ajlm-1578	32	26	massachusetts	massachusetts	PROPN
ajlm-1578	32	27	,	,	PUNCT
ajlm-1578	32	28	united	united	PROPN
ajlm-1578	32	29	states	states	PROPN
ajlm-1578	32	30	)	)	PUNCT
ajlm-1578	32	31	and	and	CCONJ
ajlm-1578	32	32	patient	patient	ADJ
ajlm-1578	32	33	consent	consent	NOUN
ajlm-1578	32	34	was	be	AUX
ajlm-1578	32	35	not	not	PART
ajlm-1578	32	36	a	a	DET
ajlm-1578	32	37	requisite	requisite	NOUN
ajlm-1578	32	38	.	.	PUNCT
ajlm-1578	33	1	patient	patient	ADJ
ajlm-1578	33	2	privacy	privacy	NOUN
ajlm-1578	33	3	was	be	AUX
ajlm-1578	33	4	ensured	ensure	VERB
ajlm-1578	33	5	through	through	ADP
ajlm-1578	33	6	the	the	DET
ajlm-1578	33	7	use	use	NOUN
ajlm-1578	33	8	of	of	ADP
ajlm-1578	33	9	unique	unique	ADJ
ajlm-1578	33	10	study	study	NOUN
ajlm-1578	33	11	numbers	number	NOUN
ajlm-1578	33	12	,	,	PUNCT
ajlm-1578	33	13	with	with	ADP
ajlm-1578	33	14	the	the	DET
ajlm-1578	33	15	link	link	NOUN
ajlm-1578	33	16	to	to	PART
ajlm-1578	33	17	patient	patient	VERB
ajlm-1578	33	18	identifying	identify	VERB
ajlm-1578	33	19	information	information	NOUN
ajlm-1578	33	20	kept	keep	VERB
ajlm-1578	33	21	in	in	ADP
ajlm-1578	33	22	a	a	DET
ajlm-1578	33	23	separate	separate	ADJ
ajlm-1578	33	24	,	,	PUNCT
ajlm-1578	33	25	password	password	NOUN
ajlm-1578	33	26	-	-	PUNCT
ajlm-1578	33	27	protected	protect	VERB
ajlm-1578	33	28	excel	excel	NOUN
ajlm-1578	33	29	spreadsheet	spreadsheet	NOUN
ajlm-1578	33	30	.	.	PUNCT
ajlm-1578	34	1	study	study	NOUN
ajlm-1578	34	2	design	design	NOUN
ajlm-1578	34	3	this	this	DET
ajlm-1578	34	4	study	study	NOUN
ajlm-1578	34	5	included	include	VERB
ajlm-1578	34	6	all	all	DET
ajlm-1578	34	7	new	new	ADJ
ajlm-1578	34	8	cases	case	NOUN
ajlm-1578	34	9	of	of	ADP
ajlm-1578	34	10	acute	acute	ADJ
ajlm-1578	34	11	leukaemia	leukaemia	NOUN
ajlm-1578	34	12	diagnosed	diagnose	VERB
ajlm-1578	34	13	by	by	ADP
ajlm-1578	34	14	flow	flow	NOUN
ajlm-1578	34	15	cytometry	cytometry	NOUN
ajlm-1578	34	16	at	at	ADP
ajlm-1578	34	17	the	the	DET
ajlm-1578	34	18	charlotte	charlotte	PROPN
ajlm-1578	34	19	maxeke	maxeke	PROPN
ajlm-1578	34	20	johannesburg	johannesburg	PROPN
ajlm-1578	34	21	academic	academic	PROPN
ajlm-1578	34	22	hospital	hospital	PROPN
ajlm-1578	34	23	(	(	PUNCT
ajlm-1578	34	24	cmjah	cmjah	PROPN
ajlm-1578	34	25	)	)	PUNCT
ajlm-1578	34	26	over	over	ADP
ajlm-1578	34	27	42	42	NUM
ajlm-1578	34	28	months	month	NOUN
ajlm-1578	34	29	,	,	PUNCT
ajlm-1578	34	30	between	between	ADP
ajlm-1578	34	31	08	08	NUM
ajlm-1578	34	32	april	april	PROPN
ajlm-1578	34	33	2016	2016	NUM
ajlm-1578	34	34	and	and	CCONJ
ajlm-1578	34	35	16	16	NUM
ajlm-1578	34	36	october	october	PROPN
ajlm-1578	34	37	2019	2019	NUM
ajlm-1578	34	38	.	.	PUNCT
ajlm-1578	35	1	these	these	DET
ajlm-1578	35	2	cases	case	NOUN
ajlm-1578	35	3	were	be	AUX
ajlm-1578	35	4	identified	identify	VERB
ajlm-1578	35	5	from	from	ADP
ajlm-1578	35	6	the	the	DET
ajlm-1578	35	7	flow	flow	NOUN
ajlm-1578	35	8	cytometry	cytometry	NOUN
ajlm-1578	35	9	register	register	VERB
ajlm-1578	35	10	with	with	ADP
ajlm-1578	35	11	the	the	DET
ajlm-1578	35	12	largest	large	ADJ
ajlm-1578	35	13	proportion	proportion	NOUN
ajlm-1578	35	14	of	of	ADP
ajlm-1578	35	15	cases	case	NOUN
ajlm-1578	35	16	received	receive	VERB
ajlm-1578	35	17	from	from	ADP
ajlm-1578	35	18	cmjah	cmjah	NOUN
ajlm-1578	35	19	,	,	PUNCT
ajlm-1578	35	20	chris	chris	PROPN
ajlm-1578	35	21	hani	hani	PROPN
ajlm-1578	35	22	baragwanath	baragwanath	PROPN
ajlm-1578	35	23	academic	academic	PROPN
ajlm-1578	35	24	hospital	hospital	NOUN
ajlm-1578	35	25	(	(	PUNCT
ajlm-1578	35	26	chbah	chbah	NOUN
ajlm-1578	35	27	)	)	PUNCT
ajlm-1578	35	28	and	and	CCONJ
ajlm-1578	35	29	helen	helen	PROPN
ajlm-1578	35	30	joseph	joseph	PROPN
ajlm-1578	35	31	hospital	hospital	PROPN
ajlm-1578	35	32	.	.	PUNCT
ajlm-1578	36	1	the	the	DET
ajlm-1578	36	2	lis	li	NOUN
ajlm-1578	36	3	was	be	AUX
ajlm-1578	36	4	used	use	VERB
ajlm-1578	36	5	to	to	PART
ajlm-1578	36	6	collect	collect	VERB
ajlm-1578	36	7	available	available	ADJ
ajlm-1578	36	8	clinical	clinical	ADJ
ajlm-1578	36	9	data	datum	NOUN
ajlm-1578	36	10	,	,	PUNCT
ajlm-1578	36	11	demographics	demographic	NOUN
ajlm-1578	36	12	,	,	PUNCT
ajlm-1578	36	13	laboratory	laboratory	NOUN
ajlm-1578	36	14	results	result	NOUN
ajlm-1578	36	15	,	,	PUNCT
ajlm-1578	36	16	treatment	treatment	NOUN
ajlm-1578	36	17	responses	response	NOUN
ajlm-1578	36	18	,	,	PUNCT
ajlm-1578	36	19	os	os	ADV
ajlm-1578	36	20	,	,	PUNCT
ajlm-1578	36	21	and	and	CCONJ
ajlm-1578	36	22	cause	cause	NOUN
ajlm-1578	36	23	of	of	ADP
ajlm-1578	36	24	death	death	NOUN
ajlm-1578	36	25	.	.	PUNCT
ajlm-1578	37	1	the	the	DET
ajlm-1578	37	2	results	result	NOUN
ajlm-1578	37	3	were	be	AUX
ajlm-1578	37	4	collated	collate	VERB
ajlm-1578	37	5	on	on	ADP
ajlm-1578	37	6	an	an	DET
ajlm-1578	37	7	excel	excel	NOUN
ajlm-1578	37	8	spreadsheet	spreadsheet	NOUN
ajlm-1578	37	9	(	(	PUNCT
ajlm-1578	37	10	microsoft	microsoft	PROPN
ajlm-1578	37	11	corporation	corporation	PROPN
ajlm-1578	37	12	,	,	PUNCT
ajlm-1578	37	13	santa	santa	PROPN
ajlm-1578	37	14	rosa	rosa	PROPN
ajlm-1578	37	15	,	,	PUNCT
ajlm-1578	37	16	california	california	PROPN
ajlm-1578	37	17	,	,	PUNCT
ajlm-1578	37	18	united	united	PROPN
ajlm-1578	37	19	states	states	PROPN
ajlm-1578	37	20	)	)	PUNCT
ajlm-1578	37	21	and	and	CCONJ
ajlm-1578	37	22	cases	case	NOUN
ajlm-1578	37	23	of	of	ADP
ajlm-1578	37	24	bc	bc	PROPN
ajlm-1578	37	25	-	-	PUNCT
ajlm-1578	37	26	cml	cml	PROPN
ajlm-1578	37	27	were	be	AUX
ajlm-1578	37	28	extracted	extract	VERB
ajlm-1578	37	29	.	.	PUNCT
ajlm-1578	38	1	inclusion	inclusion	NOUN
ajlm-1578	38	2	of	of	ADP
ajlm-1578	38	3	cases	case	NOUN
ajlm-1578	38	4	into	into	ADP
ajlm-1578	38	5	the	the	DET
ajlm-1578	38	6	bc	bc	PROPN
ajlm-1578	38	7	-	-	PUNCT
ajlm-1578	38	8	cml	cml	PROPN
ajlm-1578	38	9	category	category	NOUN
ajlm-1578	38	10	required	require	VERB
ajlm-1578	38	11	a	a	DET
ajlm-1578	38	12	preceding	precede	VERB
ajlm-1578	38	13	history	history	NOUN
ajlm-1578	38	14	of	of	ADP
ajlm-1578	38	15	cml	cml	PROPN
ajlm-1578	38	16	or	or	CCONJ
ajlm-1578	38	17	presence	presence	NOUN
ajlm-1578	38	18	of	of	ADP
ajlm-1578	38	19	the	the	DET
ajlm-1578	38	20	bcr	bcr	PROPN
ajlm-1578	38	21	-	-	PUNCT
ajlm-1578	38	22	abl1	abl1	ADJ
ajlm-1578	38	23	fusion	fusion	NOUN
ajlm-1578	38	24	gene	gene	NOUN
ajlm-1578	38	25	(	(	PUNCT
ajlm-1578	38	26	p210/	p210/	NOUN
ajlm-1578	38	27	p190	p190	NUM
ajlm-1578	38	28	)	)	PUNCT
ajlm-1578	38	29	in	in	ADP
ajlm-1578	38	30	the	the	DET
ajlm-1578	38	31	context	context	NOUN
ajlm-1578	38	32	of	of	ADP
ajlm-1578	38	33	splenomegaly	splenomegaly	ADJ
ajlm-1578	38	34	,	,	PUNCT
ajlm-1578	38	35	peripheral	peripheral	ADJ
ajlm-1578	38	36	smear	smear	NOUN
ajlm-1578	38	37	features	feature	NOUN
ajlm-1578	38	38	of	of	ADP
ajlm-1578	38	39	cml	cml	PROPN
ajlm-1578	38	40	(	(	PUNCT
ajlm-1578	38	41	leucocytosis	leucocytosis	NOUN
ajlm-1578	38	42	,	,	PUNCT
ajlm-1578	38	43	left	left	ADJ
ajlm-1578	38	44	shift	shift	NOUN
ajlm-1578	38	45	,	,	PUNCT
ajlm-1578	38	46	myelocyte	myelocyte	NOUN
ajlm-1578	38	47	peak	peak	NOUN
ajlm-1578	38	48	,	,	PUNCT
ajlm-1578	38	49	eosinophilia	eosinophilia	PROPN
ajlm-1578	38	50	and	and	CCONJ
ajlm-1578	38	51	basophilia	basophilia	PROPN
ajlm-1578	38	52	)	)	PUNCT
ajlm-1578	38	53	and	and	CCONJ
ajlm-1578	38	54	major	major	ADJ
ajlm-1578	38	55	molecular	molecular	ADJ
ajlm-1578	38	56	route	route	NOUN
ajlm-1578	38	57	abnormalities	abnormality	NOUN
ajlm-1578	38	58	on	on	ADP
ajlm-1578	38	59	conventional	conventional	ADJ
ajlm-1578	38	60	cytogenetics	cytogenetic	NOUN
ajlm-1578	38	61	(	(	PUNCT
ajlm-1578	38	62	ccy	ccy	PROPN
ajlm-1578	38	63	)	)	PUNCT
ajlm-1578	38	64	.	.	PUNCT
ajlm-1578	39	1	statistical	statistical	ADJ
ajlm-1578	39	2	analysis	analysis	NOUN
ajlm-1578	39	3	the	the	DET
ajlm-1578	39	4	data	datum	NOUN
ajlm-1578	39	5	were	be	AUX
ajlm-1578	39	6	analysed	analyse	VERB
ajlm-1578	39	7	using	use	VERB
ajlm-1578	39	8	stata	stata	NOUN
ajlm-1578	39	9	software	software	NOUN
ajlm-1578	39	10	,	,	PUNCT
ajlm-1578	39	11	version	version	NOUN
ajlm-1578	39	12	14.1	14.1	NUM
ajlm-1578	39	13	(	(	PUNCT
ajlm-1578	39	14	statistics	statistic	NOUN
ajlm-1578	39	15	/	/	SYM
ajlm-1578	39	16	data	datum	NOUN
ajlm-1578	39	17	analysis	analysis	NOUN
ajlm-1578	39	18	,	,	PUNCT
ajlm-1578	39	19	statacorp	statacorp	PROPN
ajlm-1578	39	20	llc	llc	PROPN
ajlm-1578	39	21	,	,	PUNCT
ajlm-1578	39	22	college	college	NOUN
ajlm-1578	39	23	station	station	NOUN
ajlm-1578	39	24	,	,	PUNCT
ajlm-1578	39	25	texas	texas	PROPN
ajlm-1578	39	26	,	,	PUNCT
ajlm-1578	39	27	united	united	PROPN
ajlm-1578	39	28	states	states	PROPN
ajlm-1578	39	29	)	)	PUNCT
ajlm-1578	39	30	.	.	PUNCT
ajlm-1578	40	1	continuous	continuous	ADJ
ajlm-1578	40	2	data	datum	NOUN
ajlm-1578	40	3	were	be	AUX
ajlm-1578	40	4	reported	report	VERB
ajlm-1578	40	5	as	as	ADP
ajlm-1578	40	6	the	the	DET
ajlm-1578	40	7	median	median	NOUN
ajlm-1578	40	8	(	(	PUNCT
ajlm-1578	40	9	interquartile	interquartile	PROPN
ajlm-1578	40	10	ranges	range	VERB
ajlm-1578	40	11	[	[	X
ajlm-1578	40	12	iqr	iqr	NOUN
ajlm-1578	40	13	]	]	X
ajlm-1578	40	14	)	)	PUNCT
ajlm-1578	40	15	and	and	CCONJ
ajlm-1578	40	16	categorical	categorical	ADJ
ajlm-1578	40	17	data	datum	NOUN
ajlm-1578	40	18	as	as	ADP
ajlm-1578	40	19	percentages	percentage	NOUN
ajlm-1578	40	20	and	and	CCONJ
ajlm-1578	40	21	frequencies	frequency	NOUN
ajlm-1578	40	22	.	.	PUNCT
ajlm-1578	41	1	the	the	DET
ajlm-1578	41	2	two	two	NUM
ajlm-1578	41	3	-	-	PUNCT
ajlm-1578	41	4	sample	sample	NOUN
ajlm-1578	41	5	wilcoxon	wilcoxon	VERB
ajlm-1578	41	6	rank	rank	NOUN
ajlm-1578	41	7	-	-	PUNCT
ajlm-1578	41	8	sum	sum	NOUN
ajlm-1578	41	9	(	(	PUNCT
ajlm-1578	41	10	mann	mann	PROPN
ajlm-1578	41	11	-	-	PUNCT
ajlm-1578	41	12	whitney	whitney	PROPN
ajlm-1578	41	13	)	)	PUNCT
ajlm-1578	41	14	test	test	NOUN
ajlm-1578	41	15	was	be	AUX
ajlm-1578	41	16	used	use	VERB
ajlm-1578	41	17	to	to	PART
ajlm-1578	41	18	compare	compare	VERB
ajlm-1578	41	19	continuous	continuous	ADJ
ajlm-1578	41	20	variables	variable	NOUN
ajlm-1578	41	21	.	.	PUNCT
ajlm-1578	42	1	statistical	statistical	ADJ
ajlm-1578	42	2	significance	significance	NOUN
ajlm-1578	42	3	was	be	AUX
ajlm-1578	42	4	accepted	accept	VERB
ajlm-1578	42	5	at	at	ADP
ajlm-1578	42	6	a	a	DET
ajlm-1578	42	7	two	two	NUM
ajlm-1578	42	8	-	-	PUNCT
ajlm-1578	42	9	sided	sided	ADJ
ajlm-1578	42	10	p	p	NOUN
ajlm-1578	42	11	-	-	PUNCT
ajlm-1578	42	12	value	value	NOUN
ajlm-1578	42	13	of	of	ADP
ajlm-1578	42	14	0.05	0.05	NUM
ajlm-1578	42	15	.	.	PUNCT
ajlm-1578	43	1	results	result	VERB
ajlm-1578	43	2	twenty	twenty	NUM
ajlm-1578	43	3	-	-	PUNCT
ajlm-1578	43	4	two	two	NUM
ajlm-1578	43	5	cases	case	NOUN
ajlm-1578	43	6	of	of	ADP
ajlm-1578	43	7	bc	bc	PROPN
ajlm-1578	43	8	-	-	PUNCT
ajlm-1578	43	9	cml	cml	PROPN
ajlm-1578	43	10	were	be	AUX
ajlm-1578	43	11	diagnosed	diagnose	VERB
ajlm-1578	43	12	by	by	ADP
ajlm-1578	43	13	flow	flow	NOUN
ajlm-1578	43	14	cytometry	cytometry	NOUN
ajlm-1578	43	15	in	in	ADP
ajlm-1578	43	16	the	the	DET
ajlm-1578	43	17	reviewed	review	VERB
ajlm-1578	43	18	period	period	NOUN
ajlm-1578	43	19	between	between	ADP
ajlm-1578	43	20	2016	2016	NUM
ajlm-1578	43	21	and	and	CCONJ
ajlm-1578	43	22	2019	2019	NUM
ajlm-1578	43	23	.	.	PUNCT
ajlm-1578	44	1	the	the	DET
ajlm-1578	44	2	rate	rate	NOUN
ajlm-1578	44	3	of	of	ADP
ajlm-1578	44	4	blastic	blastic	ADJ
ajlm-1578	44	5	transformation	transformation	NOUN
ajlm-1578	44	6	from	from	ADP
ajlm-1578	44	7	chronic	chronic	ADJ
ajlm-1578	44	8	and	and	CCONJ
ajlm-1578	44	9	accelerated	accelerate	VERB
ajlm-1578	44	10	phase	phase	NOUN
ajlm-1578	44	11	cml	cml	PROPN
ajlm-1578	44	12	could	could	AUX
ajlm-1578	44	13	not	not	PART
ajlm-1578	44	14	be	be	AUX
ajlm-1578	44	15	determined	determine	VERB
ajlm-1578	44	16	as	as	SCONJ
ajlm-1578	44	17	the	the	DET
ajlm-1578	44	18	prevalence	prevalence	NOUN
ajlm-1578	44	19	of	of	ADP
ajlm-1578	44	20	cml	cml	PROPN
ajlm-1578	44	21	was	be	AUX
ajlm-1578	44	22	unknown	unknown	ADJ
ajlm-1578	44	23	for	for	ADP
ajlm-1578	44	24	the	the	DET
ajlm-1578	44	25	referring	refer	VERB
ajlm-1578	44	26	centres	centre	NOUN
ajlm-1578	44	27	.	.	PUNCT
ajlm-1578	45	1	patient	patient	ADJ
ajlm-1578	45	2	demographics	demographic	NOUN
ajlm-1578	45	3	and	and	CCONJ
ajlm-1578	45	4	treatment	treatment	NOUN
ajlm-1578	45	5	history	history	NOUN
ajlm-1578	45	6	the	the	DET
ajlm-1578	45	7	median	median	ADJ
ajlm-1578	45	8	age	age	NOUN
ajlm-1578	45	9	was	be	AUX
ajlm-1578	45	10	34	34	NUM
ajlm-1578	45	11	years	year	NOUN
ajlm-1578	45	12	(	(	PUNCT
ajlm-1578	45	13	iqr	iqr	NOUN
ajlm-1578	45	14	:	:	PUNCT
ajlm-1578	45	15	21	21	NUM
ajlm-1578	45	16	years	year	NOUN
ajlm-1578	45	17	)	)	PUNCT
ajlm-1578	45	18	with	with	ADP
ajlm-1578	45	19	two	two	NUM
ajlm-1578	45	20	patients	patient	NOUN
ajlm-1578	45	21	aged	age	VERB
ajlm-1578	45	22	younger	young	ADJ
ajlm-1578	45	23	than	than	ADP
ajlm-1578	45	24	18	18	NUM
ajlm-1578	45	25	years	year	NOUN
ajlm-1578	45	26	,	,	PUNCT
ajlm-1578	45	27	and	and	CCONJ
ajlm-1578	45	28	a	a	DET
ajlm-1578	45	29	slight	slight	ADJ
ajlm-1578	45	30	predominance	predominance	NOUN
ajlm-1578	45	31	of	of	ADP
ajlm-1578	45	32	male	male	ADJ
ajlm-1578	45	33	patients	patient	NOUN
ajlm-1578	45	34	,	,	PUNCT
ajlm-1578	45	35	57	57	NUM
ajlm-1578	45	36	%	%	NOUN
ajlm-1578	45	37	(	(	PUNCT
ajlm-1578	45	38	n	n	NOUN
ajlm-1578	45	39	=	=	NOUN
ajlm-1578	45	40	12	12	NUM
ajlm-1578	45	41	)	)	PUNCT
ajlm-1578	45	42	.	.	PUNCT
ajlm-1578	46	1	hiv	hiv	PROPN
ajlm-1578	46	2	testing	testing	NOUN
ajlm-1578	46	3	was	be	AUX
ajlm-1578	46	4	performed	perform	VERB
ajlm-1578	46	5	in	in	ADP
ajlm-1578	46	6	less	less	ADJ
ajlm-1578	46	7	than	than	ADP
ajlm-1578	46	8	half	half	NOUN
ajlm-1578	46	9	(	(	PUNCT
ajlm-1578	46	10	n	n	NOUN
ajlm-1578	46	11	=	=	SYM
ajlm-1578	46	12	20	20	NUM
ajlm-1578	46	13	)	)	PUNCT
ajlm-1578	46	14	of	of	ADP
ajlm-1578	46	15	the	the	DET
ajlm-1578	46	16	patients	patient	NOUN
ajlm-1578	46	17	with	with	ADP
ajlm-1578	46	18	a	a	DET
ajlm-1578	46	19	50	50	NUM
ajlm-1578	46	20	%	%	NOUN
ajlm-1578	46	21	positivity	positivity	NOUN
ajlm-1578	46	22	(	(	PUNCT
ajlm-1578	46	23	table	table	NOUN
ajlm-1578	46	24	1	1	NUM
ajlm-1578	46	25	)	)	PUNCT
ajlm-1578	46	26	.	.	PUNCT
ajlm-1578	47	1	table	table	NOUN
ajlm-1578	47	2	1	1	NUM
ajlm-1578	47	3	:	:	PUNCT
ajlm-1578	47	4	 	 	SPACE
ajlm-1578	47	5	demographic	demographic	ADJ
ajlm-1578	47	6	and	and	CCONJ
ajlm-1578	47	7	laboratory	laboratory	NOUN
ajlm-1578	47	8	information	information	NOUN
ajlm-1578	47	9	for	for	ADP
ajlm-1578	47	10	patients	patient	NOUN
ajlm-1578	47	11	with	with	ADP
ajlm-1578	47	12	cml	cml	PROPN
ajlm-1578	47	13	in	in	ADP
ajlm-1578	47	14	blast	blast	NOUN
ajlm-1578	47	15	phase	phase	NOUN
ajlm-1578	47	16	,	,	PUNCT
ajlm-1578	47	17	johannesburg	johannesburg	PROPN
ajlm-1578	47	18	,	,	PUNCT
ajlm-1578	47	19	south	south	PROPN
ajlm-1578	47	20	africa	africa	PROPN
ajlm-1578	47	21	,	,	PUNCT
ajlm-1578	47	22	08	08	NUM
ajlm-1578	47	23	april	april	PROPN
ajlm-1578	47	24	2016	2016	NUM
ajlm-1578	47	25	to	to	ADP
ajlm-1578	47	26	16	16	NUM
ajlm-1578	47	27	october	october	PROPN
ajlm-1578	47	28	2019	2019	NUM
ajlm-1578	47	29	.	.	PUNCT
ajlm-1578	48	1	information	information	NOUN
ajlm-1578	48	2	on	on	ADP
ajlm-1578	48	3	the	the	DET
ajlm-1578	48	4	use	use	NOUN
ajlm-1578	48	5	of	of	ADP
ajlm-1578	48	6	tki	tki	NOUN
ajlm-1578	48	7	therapy	therapy	NOUN
ajlm-1578	48	8	was	be	AUX
ajlm-1578	48	9	limited	limit	VERB
ajlm-1578	48	10	to	to	ADP
ajlm-1578	48	11	that	that	PRON
ajlm-1578	48	12	documented	document	VERB
ajlm-1578	48	13	on	on	ADP
ajlm-1578	48	14	the	the	DET
ajlm-1578	48	15	lis	li	NOUN
ajlm-1578	48	16	.	.	PUNCT
ajlm-1578	49	1	imatinib	imatinib	NOUN
ajlm-1578	49	2	mesylate	mesylate	NOUN
ajlm-1578	49	3	therapy	therapy	NOUN
ajlm-1578	49	4	was	be	AUX
ajlm-1578	49	5	reported	report	VERB
ajlm-1578	49	6	in	in	ADP
ajlm-1578	49	7	one	one	NUM
ajlm-1578	49	8	patient	patient	NOUN
ajlm-1578	49	9	;	;	PUNCT
ajlm-1578	49	10	dasatinib	dasatinib	NOUN
ajlm-1578	49	11	in	in	ADP
ajlm-1578	49	12	three	three	NUM
ajlm-1578	49	13	;	;	PUNCT
ajlm-1578	49	14	and	and	CCONJ
ajlm-1578	49	15	nilotinib	nilotinib	NOUN
ajlm-1578	49	16	in	in	ADP
ajlm-1578	49	17	two	two	NUM
ajlm-1578	49	18	.	.	PUNCT
ajlm-1578	50	1	none	none	NOUN
ajlm-1578	50	2	of	of	ADP
ajlm-1578	50	3	the	the	DET
ajlm-1578	50	4	patients	patient	NOUN
ajlm-1578	50	5	had	have	AUX
ajlm-1578	50	6	been	be	AUX
ajlm-1578	50	7	managed	manage	VERB
ajlm-1578	50	8	with	with	ADP
ajlm-1578	50	9	a	a	DET
ajlm-1578	50	10	trial	trial	NOUN
ajlm-1578	50	11	of	of	ADP
ajlm-1578	50	12	treatment	treatment	NOUN
ajlm-1578	50	13	-	-	PUNCT
ajlm-1578	50	14	free	free	ADJ
ajlm-1578	50	15	remission	remission	NOUN
ajlm-1578	50	16	(	(	PUNCT
ajlm-1578	50	17	tfr	tfr	PROPN
ajlm-1578	50	18	)	)	PUNCT
ajlm-1578	50	19	.	.	PUNCT
ajlm-1578	51	1	molecular	molecular	ADJ
ajlm-1578	51	2	and	and	CCONJ
ajlm-1578	51	3	immunophenotypic	immunophenotypic	ADJ
ajlm-1578	51	4	results	result	NOUN
ajlm-1578	51	5	twenty	twenty	NUM
ajlm-1578	51	6	cases	case	NOUN
ajlm-1578	51	7	had	have	VERB
ajlm-1578	51	8	p210	p210	PROPN
ajlm-1578	51	9	bcr	bcr	PROPN
ajlm-1578	51	10	-	-	PUNCT
ajlm-1578	51	11	abl1	abl1	ADJ
ajlm-1578	51	12	fusion	fusion	NOUN
ajlm-1578	51	13	transcripts	transcript	NOUN
ajlm-1578	51	14	,	,	PUNCT
ajlm-1578	51	15	and	and	CCONJ
ajlm-1578	51	16	two	two	NUM
ajlm-1578	51	17	cases	case	NOUN
ajlm-1578	51	18	had	have	VERB
ajlm-1578	51	19	p190	p190	VERB
ajlm-1578	51	20	bcr	bcr	PROPN
ajlm-1578	51	21	-	-	PUNCT
ajlm-1578	51	22	abl1	abl1	PROPN
ajlm-1578	51	23	.	.	PUNCT
ajlm-1578	52	1	for	for	ADP
ajlm-1578	52	2	blast	blast	NOUN
ajlm-1578	52	3	lineage	lineage	NOUN
ajlm-1578	52	4	in	in	ADP
ajlm-1578	52	5	bc	bc	PROPN
ajlm-1578	52	6	-	-	PUNCT
ajlm-1578	52	7	cml	cml	PROPN
ajlm-1578	52	8	,	,	PUNCT
ajlm-1578	52	9	14	14	NUM
ajlm-1578	52	10	cases	case	NOUN
ajlm-1578	52	11	(	(	PUNCT
ajlm-1578	52	12	63.6	63.6	NUM
ajlm-1578	52	13	%	%	NOUN
ajlm-1578	52	14	)	)	PUNCT
ajlm-1578	52	15	were	be	AUX
ajlm-1578	52	16	myeloid	myeloid	ADJ
ajlm-1578	52	17	,	,	PUNCT
ajlm-1578	52	18	six	six	NUM
ajlm-1578	52	19	cases	case	NOUN
ajlm-1578	52	20	(	(	PUNCT
ajlm-1578	52	21	27.3	27.3	NUM
ajlm-1578	52	22	%	%	NOUN
ajlm-1578	52	23	)	)	PUNCT
ajlm-1578	52	24	were	be	AUX
ajlm-1578	52	25	lymphoid	lymphoid	ADJ
ajlm-1578	52	26	and	and	CCONJ
ajlm-1578	52	27	two	two	NUM
ajlm-1578	52	28	cases	case	NOUN
ajlm-1578	52	29	(	(	PUNCT
ajlm-1578	52	30	9.1	9.1	NUM
ajlm-1578	52	31	%	%	NOUN
ajlm-1578	52	32	)	)	PUNCT
ajlm-1578	52	33	were	be	AUX
ajlm-1578	52	34	ambiguous	ambiguous	ADJ
ajlm-1578	52	35	.	.	PUNCT
ajlm-1578	53	1	of	of	ADP
ajlm-1578	53	2	the	the	DET
ajlm-1578	53	3	lymphoid	lymphoid	ADJ
ajlm-1578	53	4	cases	case	NOUN
ajlm-1578	53	5	,	,	PUNCT
ajlm-1578	53	6	approximately	approximately	ADV
ajlm-1578	53	7	two	two	NUM
ajlm-1578	53	8	-	-	PUNCT
ajlm-1578	53	9	thirds	third	NOUN
ajlm-1578	53	10	(	(	PUNCT
ajlm-1578	53	11	n	n	NOUN
ajlm-1578	53	12	=	=	SYM
ajlm-1578	53	13	4	4	NUM
ajlm-1578	53	14	)	)	PUNCT
ajlm-1578	53	15	were	be	AUX
ajlm-1578	53	16	of	of	ADP
ajlm-1578	53	17	b	b	NOUN
ajlm-1578	53	18	lineage	lineage	NOUN
ajlm-1578	53	19	.	.	PUNCT
ajlm-1578	54	1	the	the	DET
ajlm-1578	54	2	p210	p210	PROPN
ajlm-1578	54	3	case	case	NOUN
ajlm-1578	54	4	lineages	lineage	NOUN
ajlm-1578	54	5	were	be	AUX
ajlm-1578	54	6	myeloid	myeloid	ADJ
ajlm-1578	54	7	in	in	ADP
ajlm-1578	54	8	13	13	NUM
ajlm-1578	54	9	cases	case	NOUN
ajlm-1578	54	10	;	;	PUNCT
ajlm-1578	54	11	t	t	X
ajlm-1578	54	12	in	in	ADP
ajlm-1578	54	13	one	one	NUM
ajlm-1578	54	14	case	case	NOUN
ajlm-1578	54	15	,	,	PUNCT
ajlm-1578	54	16	b	b	NOUN
ajlm-1578	54	17	in	in	ADP
ajlm-1578	54	18	four	four	NUM
ajlm-1578	54	19	cases	case	NOUN
ajlm-1578	54	20	;	;	PUNCT
ajlm-1578	54	21	and	and	CCONJ
ajlm-1578	54	22	ambiguous	ambiguous	ADJ
ajlm-1578	54	23	in	in	ADP
ajlm-1578	54	24	two	two	NUM
ajlm-1578	54	25	cases	case	NOUN
ajlm-1578	54	26	.	.	PUNCT
ajlm-1578	55	1	the	the	DET
ajlm-1578	55	2	p190	p190	PROPN
ajlm-1578	55	3	cases	case	NOUN
ajlm-1578	55	4	were	be	AUX
ajlm-1578	55	5	of	of	ADP
ajlm-1578	55	6	myeloid	myeloid	NOUN
ajlm-1578	55	7	and	and	CCONJ
ajlm-1578	55	8	t	t	NOUN
ajlm-1578	55	9	lineage	lineage	NOUN
ajlm-1578	55	10	,	,	PUNCT
ajlm-1578	55	11	with	with	ADP
ajlm-1578	55	12	the	the	DET
ajlm-1578	55	13	latter	latter	ADJ
ajlm-1578	55	14	relapsing	relapse	VERB
ajlm-1578	55	15	as	as	ADP
ajlm-1578	55	16	an	an	DET
ajlm-1578	55	17	ambiguous	ambiguous	ADJ
ajlm-1578	55	18	lineage	lineage	NOUN
ajlm-1578	55	19	acute	acute	NOUN
ajlm-1578	55	20	leukaemia	leukaemia	NOUN
ajlm-1578	55	21	(	(	PUNCT
ajlm-1578	55	22	t	t	NOUN
ajlm-1578	55	23	/	/	SYM
ajlm-1578	55	24	myeloid	myeloid	NOUN
ajlm-1578	55	25	)	)	PUNCT
ajlm-1578	55	26	.	.	PUNCT
ajlm-1578	56	1	additional	additional	ADJ
ajlm-1578	56	2	clonal	clonal	ADJ
ajlm-1578	56	3	chromosomal	chromosomal	ADJ
ajlm-1578	56	4	abnormalities	abnormality	NOUN
ajlm-1578	56	5	were	be	AUX
ajlm-1578	56	6	detected	detect	VERB
ajlm-1578	56	7	on	on	ADP
ajlm-1578	56	8	ccy	ccy	PROPN
ajlm-1578	56	9	in	in	ADP
ajlm-1578	56	10	11	11	NUM
ajlm-1578	56	11	of	of	ADP
ajlm-1578	56	12	the	the	DET
ajlm-1578	56	13	16	16	NUM
ajlm-1578	56	14	individuals	individual	NOUN
ajlm-1578	56	15	with	with	ADP
ajlm-1578	56	16	successful	successful	ADJ
ajlm-1578	56	17	karyotypes	karyotype	NOUN
ajlm-1578	56	18	.	.	PUNCT
ajlm-1578	57	1	complex	complex	ADJ
ajlm-1578	57	2	karyotypes	karyotype	NOUN
ajlm-1578	57	3	and	and	CCONJ
ajlm-1578	57	4	trisomy	trisomy	NOUN
ajlm-1578	57	5	8	8	NUM
ajlm-1578	57	6	were	be	AUX
ajlm-1578	57	7	the	the	DET
ajlm-1578	57	8	most	most	ADV
ajlm-1578	57	9	frequently	frequently	ADV
ajlm-1578	57	10	observed	observe	VERB
ajlm-1578	57	11	,	,	PUNCT
ajlm-1578	57	12	with	with	ADP
ajlm-1578	57	13	five	five	NUM
ajlm-1578	57	14	ccy	ccy	NOUN
ajlm-1578	57	15	demonstrating	demonstrate	VERB
ajlm-1578	57	16	multiple	multiple	ADJ
ajlm-1578	57	17	additional	additional	ADJ
ajlm-1578	57	18	clonal	clonal	ADJ
ajlm-1578	57	19	chromosomal	chromosomal	ADJ
ajlm-1578	57	20	abnormalities	abnormality	NOUN
ajlm-1578	57	21	(	(	PUNCT
ajlm-1578	57	22	figure	figure	NOUN
ajlm-1578	57	23	1	1	NUM
ajlm-1578	57	24	)	)	PUNCT
ajlm-1578	57	25	.	.	PUNCT
ajlm-1578	58	1	one	one	NUM
ajlm-1578	58	2	patient	patient	NOUN
ajlm-1578	58	3	bore	bear	VERB
ajlm-1578	58	4	the	the	DET
ajlm-1578	58	5	t315i	t315i	PROPN
ajlm-1578	58	6	mutation	mutation	NOUN
ajlm-1578	58	7	at	at	ADP
ajlm-1578	58	8	the	the	DET
ajlm-1578	58	9	time	time	NOUN
ajlm-1578	58	10	of	of	ADP
ajlm-1578	58	11	diagnosis	diagnosis	NOUN
ajlm-1578	58	12	of	of	ADP
ajlm-1578	58	13	bc	bc	PROPN
ajlm-1578	58	14	-	-	PUNCT
ajlm-1578	58	15	cml	cml	PROPN
ajlm-1578	58	16	with	with	ADP
ajlm-1578	58	17	a	a	DET
ajlm-1578	58	18	history	history	NOUN
ajlm-1578	58	19	of	of	ADP
ajlm-1578	58	20	treatment	treatment	NOUN
ajlm-1578	58	21	failure	failure	NOUN
ajlm-1578	58	22	on	on	ADP
ajlm-1578	58	23	both	both	DET
ajlm-1578	58	24	imatinib	imatinib	NOUN
ajlm-1578	58	25	mesylate	mesylate	NOUN
ajlm-1578	58	26	and	and	CCONJ
ajlm-1578	58	27	nilotinib	nilotinib	NOUN
ajlm-1578	58	28	.	.	PUNCT
ajlm-1578	59	1	figure	figure	VERB
ajlm-1578	59	2	1	1	NUM
ajlm-1578	59	3	:	:	PUNCT
ajlm-1578	59	4	frequency	frequency	NOUN
ajlm-1578	59	5	of	of	ADP
ajlm-1578	59	6	additional	additional	ADJ
ajlm-1578	59	7	clonal	clonal	ADJ
ajlm-1578	59	8	chromosomal	chromosomal	ADJ
ajlm-1578	59	9	abnormalities	abnormality	NOUN
ajlm-1578	59	10	in	in	ADP
ajlm-1578	59	11	patients	patient	NOUN
ajlm-1578	59	12	with	with	ADP
ajlm-1578	59	13	cml	cml	PROPN
ajlm-1578	59	14	in	in	ADP
ajlm-1578	59	15	blast	blast	NOUN
ajlm-1578	59	16	phase	phase	NOUN
ajlm-1578	59	17	(	(	PUNCT
ajlm-1578	59	18	n	n	NOUN
ajlm-1578	59	19	=	=	SYM
ajlm-1578	59	20	16	16	NUM
ajlm-1578	59	21	)	)	PUNCT
ajlm-1578	59	22	johannesburg	johannesburg	PROPN
ajlm-1578	59	23	,	,	PUNCT
ajlm-1578	59	24	south	south	PROPN
ajlm-1578	59	25	africa	africa	PROPN
ajlm-1578	59	26	,	,	PUNCT
ajlm-1578	59	27	08	08	NUM
ajlm-1578	59	28	april	april	PROPN
ajlm-1578	59	29	2016	2016	NUM
ajlm-1578	59	30	to	to	ADP
ajlm-1578	59	31	16	16	NUM
ajlm-1578	59	32	october	october	PROPN
ajlm-1578	59	33	2019	2019	NUM
ajlm-1578	59	34	.	.	PUNCT
ajlm-1578	60	1	cytogenetics	cytogenetic	NOUN
ajlm-1578	60	2	analysis	analysis	NOUN
ajlm-1578	60	3	was	be	AUX
ajlm-1578	60	4	available	available	ADJ
ajlm-1578	60	5	for	for	ADP
ajlm-1578	60	6	16	16	NUM
ajlm-1578	60	7	patients	patient	NOUN
ajlm-1578	60	8	.	.	PUNCT
ajlm-1578	61	1	additional	additional	ADJ
ajlm-1578	61	2	clonal	clonal	ADJ
ajlm-1578	61	3	chromosomal	chromosomal	ADJ
ajlm-1578	61	4	abnormalities	abnormality	NOUN
ajlm-1578	61	5	was	be	AUX
ajlm-1578	61	6	identified	identify	VERB
ajlm-1578	61	7	in	in	ADP
ajlm-1578	61	8	11	11	NUM
ajlm-1578	61	9	patients	patient	NOUN
ajlm-1578	61	10	.	.	PUNCT
ajlm-1578	62	1	five	five	NUM
ajlm-1578	62	2	of	of	ADP
ajlm-1578	62	3	the	the	DET
ajlm-1578	62	4	karyotypes	karyotype	NOUN
ajlm-1578	62	5	demonstrated	demonstrate	VERB
ajlm-1578	62	6	multiple	multiple	ADJ
ajlm-1578	62	7	additional	additional	ADJ
ajlm-1578	62	8	clonal	clonal	ADJ
ajlm-1578	62	9	chromosomal	chromosomal	ADJ
ajlm-1578	62	10	abnormalities	abnormality	NOUN
ajlm-1578	62	11	.	.	PUNCT
ajlm-1578	63	1	trisomy	trisomy	NOUN
ajlm-1578	63	2	19	19	NUM
ajlm-1578	63	3	and	and	CCONJ
ajlm-1578	63	4	isochromosome	isochromosome	PROPN
ajlm-1578	63	5	17q	17q	NOUN
ajlm-1578	63	6	were	be	AUX
ajlm-1578	63	7	always	always	ADV
ajlm-1578	63	8	present	present	ADJ
ajlm-1578	63	9	with	with	ADP
ajlm-1578	63	10	a	a	DET
ajlm-1578	63	11	trisomy	trisomy	NOUN
ajlm-1578	63	12	8	8	NUM
ajlm-1578	63	13	.	.	PUNCT
ajlm-1578	64	1	patient	patient	ADJ
ajlm-1578	64	2	outcomes	outcome	NOUN
ajlm-1578	64	3	there	there	PRON
ajlm-1578	64	4	was	be	VERB
ajlm-1578	64	5	a	a	DET
ajlm-1578	64	6	72.7	72.7	NUM
ajlm-1578	64	7	%	%	NOUN
ajlm-1578	64	8	(	(	PUNCT
ajlm-1578	64	9	16	16	NUM
ajlm-1578	64	10	cases	case	NOUN
ajlm-1578	64	11	)	)	PUNCT
ajlm-1578	64	12	mortality	mortality	NOUN
ajlm-1578	64	13	with	with	ADP
ajlm-1578	64	14	a	a	DET
ajlm-1578	64	15	median	median	ADJ
ajlm-1578	64	16	os	os	NOUN
ajlm-1578	64	17	of	of	ADP
ajlm-1578	64	18	7	7	NUM
ajlm-1578	64	19	months	month	NOUN
ajlm-1578	64	20	(	(	PUNCT
ajlm-1578	64	21	iqr	iqr	NOUN
ajlm-1578	64	22	:	:	PUNCT
ajlm-1578	64	23	13.6	13.6	NUM
ajlm-1578	64	24	months	month	NOUN
ajlm-1578	64	25	)	)	PUNCT
ajlm-1578	64	26	(	(	PUNCT
ajlm-1578	64	27	figure	figure	NOUN
ajlm-1578	64	28	2	2	NUM
ajlm-1578	64	29	)	)	PUNCT
ajlm-1578	64	30	.	.	PUNCT
ajlm-1578	65	1	the	the	DET
ajlm-1578	65	2	details	detail	NOUN
ajlm-1578	65	3	of	of	ADP
ajlm-1578	65	4	the	the	DET
ajlm-1578	65	5	therapeutic	therapeutic	ADJ
ajlm-1578	65	6	management	management	NOUN
ajlm-1578	65	7	of	of	ADP
ajlm-1578	65	8	each	each	DET
ajlm-1578	65	9	bc	bc	PROPN
ajlm-1578	65	10	-	-	PUNCT
ajlm-1578	65	11	cml	cml	PROPN
ajlm-1578	65	12	was	be	AUX
ajlm-1578	65	13	not	not	PART
ajlm-1578	65	14	available	available	ADJ
ajlm-1578	65	15	.	.	PUNCT
ajlm-1578	66	1	five	five	NUM
ajlm-1578	66	2	deaths	death	NOUN
ajlm-1578	66	3	occurred	occur	VERB
ajlm-1578	66	4	in	in	ADP
ajlm-1578	66	5	the	the	DET
ajlm-1578	66	6	first	first	ADJ
ajlm-1578	66	7	month	month	NOUN
ajlm-1578	66	8	with	with	ADP
ajlm-1578	66	9	sepsis	sepsis	NOUN
ajlm-1578	66	10	the	the	DET
ajlm-1578	66	11	predominant	predominant	ADJ
ajlm-1578	66	12	cause	cause	NOUN
ajlm-1578	66	13	in	in	ADP
ajlm-1578	66	14	80	80	NUM
ajlm-1578	66	15	%	%	NOUN
ajlm-1578	66	16	(	(	PUNCT
ajlm-1578	66	17	four	four	NUM
ajlm-1578	66	18	cases	case	NOUN
ajlm-1578	66	19	)	)	PUNCT
ajlm-1578	66	20	.	.	PUNCT
ajlm-1578	67	1	the	the	DET
ajlm-1578	67	2	remaining	remain	VERB
ajlm-1578	67	3	11	11	NUM
ajlm-1578	67	4	deaths	death	NOUN
ajlm-1578	67	5	occurred	occur	VERB
ajlm-1578	67	6	at	at	ADP
ajlm-1578	67	7	a	a	DET
ajlm-1578	67	8	median	median	NOUN
ajlm-1578	67	9	of	of	ADP
ajlm-1578	67	10	6.7	6.7	NUM
ajlm-1578	67	11	months	month	NOUN
ajlm-1578	67	12	(	(	PUNCT
ajlm-1578	67	13	iqr	iqr	NOUN
ajlm-1578	67	14	:	:	PUNCT
ajlm-1578	67	15	4.5	4.5	NUM
ajlm-1578	67	16	months	month	NOUN
ajlm-1578	67	17	)	)	PUNCT
ajlm-1578	67	18	with	with	ADP
ajlm-1578	67	19	two	two	NUM
ajlm-1578	67	20	-	-	PUNCT
ajlm-1578	67	21	thirds	third	NOUN
ajlm-1578	67	22	of	of	ADP
ajlm-1578	67	23	the	the	DET
ajlm-1578	67	24	deaths	death	NOUN
ajlm-1578	67	25	attributed	attribute	VERB
ajlm-1578	67	26	to	to	ADP
ajlm-1578	67	27	relapsed	relapse	VERB
ajlm-1578	67	28	and/or	and/or	CCONJ
ajlm-1578	67	29	refractory	refractory	NOUN
ajlm-1578	67	30	disease	disease	NOUN
ajlm-1578	67	31	,	,	PUNCT
ajlm-1578	67	32	and	and	CCONJ
ajlm-1578	67	33	one	one	NUM
ajlm-1578	67	34	-	-	PUNCT
ajlm-1578	67	35	third	third	NOUN
ajlm-1578	67	36	to	to	ADP
ajlm-1578	67	37	sepsis	sepsis	NOUN
ajlm-1578	67	38	.	.	PUNCT
ajlm-1578	68	1	patients	patient	NOUN
ajlm-1578	68	2	with	with	ADP
ajlm-1578	68	3	the	the	DET
ajlm-1578	68	4	p190	p190	PROPN
ajlm-1578	68	5	bcr	bcr	PROPN
ajlm-1578	68	6	-	-	PUNCT
ajlm-1578	68	7	abl1	abl1	ADJ
ajlm-1578	68	8	fusion	fusion	NOUN
ajlm-1578	68	9	transcript	transcript	NOUN
ajlm-1578	68	10	survived	survive	VERB
ajlm-1578	68	11	a	a	DET
ajlm-1578	68	12	median	median	NOUN
ajlm-1578	68	13	of	of	ADP
ajlm-1578	68	14	6.1	6.1	NUM
ajlm-1578	68	15	months	month	NOUN
ajlm-1578	68	16	(	(	PUNCT
ajlm-1578	68	17	iqr	iqr	NOUN
ajlm-1578	68	18	:	:	PUNCT
ajlm-1578	68	19	3.3	3.3	NUM
ajlm-1578	68	20	months	month	NOUN
ajlm-1578	68	21	)	)	PUNCT
ajlm-1578	68	22	with	with	ADP
ajlm-1578	68	23	relapsed	relapse	VERB
ajlm-1578	68	24	disease	disease	NOUN
ajlm-1578	68	25	as	as	ADP
ajlm-1578	68	26	cause	cause	NOUN
ajlm-1578	68	27	of	of	ADP
ajlm-1578	68	28	death	death	NOUN
ajlm-1578	68	29	.	.	PUNCT
ajlm-1578	69	1	figure	figure	VERB
ajlm-1578	69	2	2	2	NUM
ajlm-1578	69	3	:	:	PUNCT
ajlm-1578	69	4	overall	overall	ADJ
ajlm-1578	69	5	survival	survival	NOUN
ajlm-1578	69	6	of	of	ADP
ajlm-1578	69	7	patients	patient	NOUN
ajlm-1578	69	8	with	with	ADP
ajlm-1578	69	9	cml	cml	PROPN
ajlm-1578	69	10	in	in	ADP
ajlm-1578	69	11	blast	blast	NOUN
ajlm-1578	69	12	phase	phase	NOUN
ajlm-1578	69	13	johannesburg	johannesburg	PROPN
ajlm-1578	69	14	,	,	PUNCT
ajlm-1578	69	15	south	south	PROPN
ajlm-1578	69	16	africa	africa	PROPN
ajlm-1578	69	17	,	,	PUNCT
ajlm-1578	69	18	08	08	NUM
ajlm-1578	69	19	april	april	PROPN
ajlm-1578	69	20	2016	2016	NUM
ajlm-1578	69	21	to	to	ADP
ajlm-1578	69	22	16	16	NUM
ajlm-1578	69	23	october	october	PROPN
ajlm-1578	69	24	2019	2019	NUM
ajlm-1578	69	25	,	,	PUNCT
ajlm-1578	69	26	excluding	exclude	VERB
ajlm-1578	69	27	one	one	NUM
ajlm-1578	69	28	patient	patient	NOUN
ajlm-1578	69	29	,	,	PUNCT
ajlm-1578	69	30	who	who	PRON
ajlm-1578	69	31	was	be	AUX
ajlm-1578	69	32	lost	lose	VERB
ajlm-1578	69	33	to	to	PART
ajlm-1578	69	34	follow	follow	VERB
ajlm-1578	69	35	-	-	PUNCT
ajlm-1578	69	36	up	up	NOUN
ajlm-1578	69	37	.	.	PUNCT
ajlm-1578	70	1	at	at	ADP
ajlm-1578	70	2	the	the	DET
ajlm-1578	70	3	time	time	NOUN
ajlm-1578	70	4	of	of	ADP
ajlm-1578	70	5	the	the	DET
ajlm-1578	70	6	study	study	NOUN
ajlm-1578	70	7	,	,	PUNCT
ajlm-1578	70	8	remission	remission	NOUN
ajlm-1578	70	9	with	with	ADP
ajlm-1578	70	10	reversion	reversion	NOUN
ajlm-1578	70	11	to	to	ADP
ajlm-1578	70	12	chronic	chronic	ADJ
ajlm-1578	70	13	phase	phase	NOUN
ajlm-1578	70	14	cml	cml	PROPN
ajlm-1578	70	15	(	(	PUNCT
ajlm-1578	70	16	based	base	VERB
ajlm-1578	70	17	on	on	ADP
ajlm-1578	70	18	laboratory	laboratory	NOUN
ajlm-1578	70	19	parameters	parameter	NOUN
ajlm-1578	70	20	)	)	PUNCT
ajlm-1578	70	21	was	be	AUX
ajlm-1578	70	22	achieved	achieve	VERB
ajlm-1578	70	23	in	in	ADP
ajlm-1578	70	24	22.7	22.7	NUM
ajlm-1578	70	25	%	%	NOUN
ajlm-1578	70	26	(	(	PUNCT
ajlm-1578	70	27	five	five	NUM
ajlm-1578	70	28	cases	case	NOUN
ajlm-1578	70	29	)	)	PUNCT
ajlm-1578	70	30	with	with	ADP
ajlm-1578	70	31	a	a	DET
ajlm-1578	70	32	median	median	ADJ
ajlm-1578	70	33	remission	remission	NOUN
ajlm-1578	70	34	time	time	NOUN
ajlm-1578	70	35	of	of	ADP
ajlm-1578	70	36	25.6	25.6	NUM
ajlm-1578	70	37	months	month	NOUN
ajlm-1578	70	38	(	(	PUNCT
ajlm-1578	70	39	iqr	iqr	NOUN
ajlm-1578	70	40	:	:	PUNCT
ajlm-1578	70	41	12.5	12.5	NUM
ajlm-1578	70	42	months	month	NOUN
ajlm-1578	70	43	)	)	PUNCT
ajlm-1578	70	44	.	.	PUNCT
ajlm-1578	71	1	the	the	DET
ajlm-1578	71	2	disease	disease	NOUN
ajlm-1578	71	3	characteristics	characteristic	VERB
ajlm-1578	71	4	in	in	ADP
ajlm-1578	71	5	the	the	DET
ajlm-1578	71	6	remission	remission	NOUN
ajlm-1578	71	7	group	group	NOUN
ajlm-1578	71	8	included	include	VERB
ajlm-1578	71	9	a	a	DET
ajlm-1578	71	10	dominance	dominance	NOUN
ajlm-1578	71	11	of	of	ADP
ajlm-1578	71	12	myeloid	myeloid	ADJ
ajlm-1578	71	13	lineage	lineage	NOUN
ajlm-1578	71	14	(	(	PUNCT
ajlm-1578	71	15	80	80	NUM
ajlm-1578	71	16	%	%	NOUN
ajlm-1578	71	17	,	,	PUNCT
ajlm-1578	71	18	four	four	NUM
ajlm-1578	71	19	cases	case	NOUN
ajlm-1578	71	20	)	)	PUNCT
ajlm-1578	71	21	with	with	ADP
ajlm-1578	71	22	a	a	DET
ajlm-1578	71	23	second	second	ADJ
ajlm-1578	71	24	philadelphia	philadelphia	PROPN
ajlm-1578	71	25	(	(	PUNCT
ajlm-1578	71	26	ph	ph	NOUN
ajlm-1578	71	27	)	)	PUNCT
ajlm-1578	71	28	chromosome	chromosome	NOUN
ajlm-1578	71	29	being	be	AUX
ajlm-1578	71	30	the	the	DET
ajlm-1578	71	31	only	only	ADJ
ajlm-1578	71	32	additional	additional	ADJ
ajlm-1578	71	33	abnormality	abnormality	NOUN
ajlm-1578	71	34	present	present	NOUN
ajlm-1578	71	35	in	in	ADP
ajlm-1578	71	36	one	one	NUM
ajlm-1578	71	37	of	of	ADP
ajlm-1578	71	38	the	the	DET
ajlm-1578	71	39	three	three	NUM
ajlm-1578	71	40	patients	patient	NOUN
ajlm-1578	71	41	with	with	ADP
ajlm-1578	71	42	successful	successful	ADJ
ajlm-1578	71	43	ccy	ccy	NOUN
ajlm-1578	71	44	.	.	PUNCT
ajlm-1578	72	1	the	the	DET
ajlm-1578	72	2	molecular	molecular	ADJ
ajlm-1578	72	3	responses	response	NOUN
ajlm-1578	72	4	by	by	ADP
ajlm-1578	72	5	quantitative	quantitative	ADJ
ajlm-1578	72	6	reverse	reverse	ADJ
ajlm-1578	72	7	transcriptase	transcriptase	NOUN
ajlm-1578	72	8	-	-	PUNCT
ajlm-1578	72	9	polymerase	polymerase	NOUN
ajlm-1578	72	10	chain	chain	NOUN
ajlm-1578	72	11	reaction	reaction	NOUN
ajlm-1578	72	12	were	be	AUX
ajlm-1578	72	13	extremely	extremely	ADV
ajlm-1578	72	14	varied	varied	ADJ
ajlm-1578	72	15	from	from	ADP
ajlm-1578	72	16	undetectable	undetectable	ADJ
ajlm-1578	72	17	transcript	transcript	NOUN
ajlm-1578	72	18	levels	level	NOUN
ajlm-1578	72	19	to	to	ADP
ajlm-1578	72	20	no	no	DET
ajlm-1578	72	21	molecular	molecular	ADJ
ajlm-1578	72	22	response	response	NOUN
ajlm-1578	72	23	(	(	PUNCT
ajlm-1578	72	24	figure	figure	NOUN
ajlm-1578	72	25	3	3	NUM
ajlm-1578	72	26	)	)	PUNCT
ajlm-1578	72	27	.	.	PUNCT
ajlm-1578	73	1	one	one	NUM
ajlm-1578	73	2	patient	patient	NOUN
ajlm-1578	73	3	was	be	AUX
ajlm-1578	73	4	lost	lose	VERB
ajlm-1578	73	5	to	to	PART
ajlm-1578	73	6	follow	follow	VERB
ajlm-1578	73	7	-	-	PUNCT
ajlm-1578	73	8	up	up	NOUN
ajlm-1578	73	9	at	at	ADP
ajlm-1578	73	10	one	one	NUM
ajlm-1578	73	11	year	year	NOUN
ajlm-1578	73	12	with	with	ADP
ajlm-1578	73	13	achievement	achievement	NOUN
ajlm-1578	73	14	of	of	ADP
ajlm-1578	73	15	a	a	DET
ajlm-1578	73	16	major	major	ADJ
ajlm-1578	73	17	cytogenetic	cytogenetic	ADJ
ajlm-1578	73	18	response	response	NOUN
ajlm-1578	73	19	at	at	ADP
ajlm-1578	73	20	this	this	DET
ajlm-1578	73	21	time	time	NOUN
ajlm-1578	73	22	point	point	NOUN
ajlm-1578	73	23	.	.	PUNCT
ajlm-1578	74	1	figure	figure	VERB
ajlm-1578	74	2	3	3	NUM
ajlm-1578	74	3	:	:	PUNCT
ajlm-1578	74	4	cumulative	cumulative	ADJ
ajlm-1578	74	5	quantitative	quantitative	ADJ
ajlm-1578	74	6	reverse	reverse	ADJ
ajlm-1578	74	7	transcriptase	transcriptase	NOUN
ajlm-1578	74	8	-	-	PUNCT
ajlm-1578	74	9	polymerase	polymerase	NOUN
ajlm-1578	74	10	chain	chain	NOUN
ajlm-1578	74	11	reaction	reaction	NOUN
ajlm-1578	74	12	results	result	NOUN
ajlm-1578	74	13	for	for	ADP
ajlm-1578	74	14	patients	patient	NOUN
ajlm-1578	74	15	in	in	ADP
ajlm-1578	74	16	remission	remission	NOUN
ajlm-1578	74	17	,	,	PUNCT
ajlm-1578	74	18	from	from	ADP
ajlm-1578	74	19	time	time	NOUN
ajlm-1578	74	20	of	of	ADP
ajlm-1578	74	21	diagnosis	diagnosis	NOUN
ajlm-1578	74	22	of	of	ADP
ajlm-1578	74	23	cml	cml	PROPN
ajlm-1578	74	24	in	in	ADP
ajlm-1578	74	25	blast	blast	NOUN
ajlm-1578	74	26	phase	phase	NOUN
ajlm-1578	74	27	(	(	PUNCT
ajlm-1578	74	28	n	n	NOUN
ajlm-1578	74	29	=	=	SYM
ajlm-1578	74	30	5	5	NUM
ajlm-1578	74	31	)	)	PUNCT
ajlm-1578	74	32	,	,	PUNCT
ajlm-1578	74	33	johannesburg	johannesburg	PROPN
ajlm-1578	74	34	,	,	PUNCT
ajlm-1578	74	35	south	south	PROPN
ajlm-1578	74	36	africa	africa	PROPN
ajlm-1578	74	37	,	,	PUNCT
ajlm-1578	74	38	08	08	NUM
ajlm-1578	74	39	april	april	PROPN
ajlm-1578	74	40	2016	2016	NUM
ajlm-1578	74	41	to	to	ADP
ajlm-1578	74	42	16	16	NUM
ajlm-1578	74	43	october	october	PROPN
ajlm-1578	74	44	2019	2019	NUM
ajlm-1578	74	45	.	.	PUNCT
ajlm-1578	75	1	the	the	DET
ajlm-1578	75	2	following	follow	VERB
ajlm-1578	75	3	were	be	AUX
ajlm-1578	75	4	the	the	DET
ajlm-1578	75	5	demographics	demographic	NOUN
ajlm-1578	75	6	of	of	ADP
ajlm-1578	75	7	patients	patient	NOUN
ajlm-1578	75	8	1	1	NUM
ajlm-1578	75	9	to	to	ADP
ajlm-1578	75	10	5	5	NUM
ajlm-1578	75	11	;	;	PUNCT
ajlm-1578	75	12	patient	patient	NOUN
ajlm-1578	75	13	1	1	NUM
ajlm-1578	75	14	:	:	PUNCT
ajlm-1578	75	15	51	51	NUM
ajlm-1578	75	16	-	-	PUNCT
ajlm-1578	75	17	year	year	NOUN
ajlm-1578	75	18	-	-	PUNCT
ajlm-1578	75	19	old	old	ADJ
ajlm-1578	75	20	female	female	NOUN
ajlm-1578	75	21	;	;	PUNCT
ajlm-1578	75	22	patient	patient	NOUN
ajlm-1578	75	23	2	2	NUM
ajlm-1578	75	24	:	:	SYM
ajlm-1578	75	25	26	26	NUM
ajlm-1578	75	26	-	-	PUNCT
ajlm-1578	75	27	year	year	NOUN
ajlm-1578	75	28	-	-	PUNCT
ajlm-1578	75	29	old	old	ADJ
ajlm-1578	75	30	hiv	hiv	NOUN
ajlm-1578	75	31	-	-	PUNCT
ajlm-1578	75	32	positive	positive	ADJ
ajlm-1578	75	33	male	male	NOUN
ajlm-1578	75	34	;	;	PUNCT
ajlm-1578	75	35	patient	patient	ADJ
ajlm-1578	75	36	3	3	NUM
ajlm-1578	75	37	:	:	SYM
ajlm-1578	75	38	19	19	NUM
ajlm-1578	75	39	-	-	PUNCT
ajlm-1578	75	40	year	year	NOUN
ajlm-1578	75	41	-	-	PUNCT
ajlm-1578	75	42	old	old	ADJ
ajlm-1578	75	43	hiv	hiv	NOUN
ajlm-1578	75	44	-	-	PUNCT
ajlm-1578	75	45	negative	negative	ADJ
ajlm-1578	75	46	female	female	NOUN
ajlm-1578	75	47	;	;	PUNCT
ajlm-1578	75	48	patient	patient	NOUN
ajlm-1578	75	49	4	4	NUM
ajlm-1578	75	50	:	:	PUNCT
ajlm-1578	75	51	54	54	NUM
ajlm-1578	75	52	-	-	PUNCT
ajlm-1578	75	53	year	year	NOUN
ajlm-1578	75	54	-	-	PUNCT
ajlm-1578	75	55	old	old	ADJ
ajlm-1578	75	56	male	male	NOUN
ajlm-1578	75	57	;	;	PUNCT
ajlm-1578	75	58	patient	patient	NOUN
ajlm-1578	75	59	5	5	NUM
ajlm-1578	75	60	:	:	PUNCT
ajlm-1578	75	61	37	37	NUM
ajlm-1578	75	62	-	-	PUNCT
ajlm-1578	75	63	year	year	NOUN
ajlm-1578	75	64	-	-	PUNCT
ajlm-1578	75	65	old	old	ADJ
ajlm-1578	75	66	male	male	NOUN
ajlm-1578	75	67	.	.	PUNCT
ajlm-1578	76	1	all	all	DET
ajlm-1578	76	2	patients	patient	NOUN
ajlm-1578	76	3	had	have	VERB
ajlm-1578	76	4	a	a	DET
ajlm-1578	76	5	p210	p210	PROPN
ajlm-1578	76	6	bc	bc	PROPN
ajlm-1578	76	7	-	-	PUNCT
ajlm-1578	76	8	cmlrabl1	cmlrabl1	NOUN
ajlm-1578	76	9	transcript	transcript	NOUN
ajlm-1578	76	10	,	,	PUNCT
ajlm-1578	76	11	the	the	DET
ajlm-1578	76	12	blast	blast	NOUN
ajlm-1578	76	13	lineage	lineage	NOUN
ajlm-1578	76	14	was	be	AUX
ajlm-1578	76	15	t	t	NOUN
ajlm-1578	76	16	in	in	ADP
ajlm-1578	76	17	patient	patient	NOUN
ajlm-1578	76	18	2	2	NUM
ajlm-1578	76	19	and	and	CCONJ
ajlm-1578	76	20	myeloid	myeloid	NOUN
ajlm-1578	76	21	in	in	ADP
ajlm-1578	76	22	the	the	DET
ajlm-1578	76	23	remainder	remainder	NOUN
ajlm-1578	76	24	.	.	PUNCT
ajlm-1578	77	1	johannesburg	johannesburg	PROPN
ajlm-1578	77	2	,	,	PUNCT
ajlm-1578	77	3	south	south	PROPN
ajlm-1578	77	4	africa	africa	PROPN
ajlm-1578	77	5	,	,	PUNCT
ajlm-1578	77	6	08	08	NUM
ajlm-1578	77	7	april	april	PROPN
ajlm-1578	77	8	2016	2016	NUM
ajlm-1578	77	9	to16	to16	PROPN
ajlm-1578	77	10	october	october	PROPN
ajlm-1578	77	11	2019	2019	NUM
ajlm-1578	77	12	.	.	PUNCT
ajlm-1578	78	1	the	the	DET
ajlm-1578	78	2	median	median	ADJ
ajlm-1578	78	3	peripheral	peripheral	ADJ
ajlm-1578	78	4	blood	blood	NOUN
ajlm-1578	78	5	blast	blast	NOUN
ajlm-1578	78	6	percentage	percentage	NOUN
ajlm-1578	78	7	at	at	ADP
ajlm-1578	78	8	diagnosis	diagnosis	NOUN
ajlm-1578	78	9	was	be	AUX
ajlm-1578	78	10	significantly	significantly	ADV
ajlm-1578	78	11	higher	high	ADJ
ajlm-1578	78	12	in	in	ADP
ajlm-1578	78	13	patients	patient	NOUN
ajlm-1578	78	14	who	who	PRON
ajlm-1578	78	15	died	die	VERB
ajlm-1578	78	16	,	,	PUNCT
ajlm-1578	78	17	56	56	NUM
ajlm-1578	78	18	%	%	NOUN
ajlm-1578	78	19	(	(	PUNCT
ajlm-1578	78	20	16	16	NUM
ajlm-1578	78	21	cases	case	NOUN
ajlm-1578	78	22	)	)	PUNCT
ajlm-1578	78	23	versus	versus	ADP
ajlm-1578	78	24	those	those	PRON
ajlm-1578	78	25	in	in	ADP
ajlm-1578	78	26	remission	remission	NOUN
ajlm-1578	78	27	18	18	NUM
ajlm-1578	78	28	%	%	NOUN
ajlm-1578	78	29	(	(	PUNCT
ajlm-1578	78	30	five	five	NUM
ajlm-1578	78	31	cases	case	NOUN
ajlm-1578	78	32	)	)	PUNCT
ajlm-1578	78	33	(	(	PUNCT
ajlm-1578	78	34	p	p	X
ajlm-1578	78	35	=	=	NOUN
ajlm-1578	78	36	0.03	0.03	NUM
ajlm-1578	78	37	)	)	PUNCT
ajlm-1578	78	38	.	.	PUNCT
ajlm-1578	79	1	conversely	conversely	ADV
ajlm-1578	79	2	,	,	PUNCT
ajlm-1578	79	3	the	the	DET
ajlm-1578	79	4	white	white	ADJ
ajlm-1578	79	5	cell	cell	NOUN
ajlm-1578	79	6	and	and	CCONJ
ajlm-1578	79	7	platelet	platelet	NOUN
ajlm-1578	79	8	counts	count	NOUN
ajlm-1578	79	9	at	at	ADP
ajlm-1578	79	10	diagnosis	diagnosis	NOUN
ajlm-1578	79	11	were	be	AUX
ajlm-1578	79	12	lower	low	ADJ
ajlm-1578	79	13	among	among	ADP
ajlm-1578	79	14	patients	patient	NOUN
ajlm-1578	79	15	who	who	PRON
ajlm-1578	79	16	died	die	VERB
ajlm-1578	79	17	,	,	PUNCT
ajlm-1578	79	18	but	but	CCONJ
ajlm-1578	79	19	the	the	DET
ajlm-1578	79	20	difference	difference	NOUN
ajlm-1578	79	21	was	be	AUX
ajlm-1578	79	22	not	not	PART
ajlm-1578	79	23	statistically	statistically	ADV
ajlm-1578	79	24	significant	significant	ADJ
ajlm-1578	79	25	(	(	PUNCT
ajlm-1578	79	26	white	white	ADJ
ajlm-1578	79	27	cell	cell	NOUN
ajlm-1578	79	28	count	count	NOUN
ajlm-1578	79	29	for	for	ADP
ajlm-1578	79	30	deceased	deceased	ADJ
ajlm-1578	79	31	patients	patient	NOUN
ajlm-1578	79	32	:	:	PUNCT
ajlm-1578	79	33	median	median	NOUN
ajlm-1578	79	34	=	=	SYM
ajlm-1578	79	35	37.3	37.3	NUM
ajlm-1578	79	36	(	(	PUNCT
ajlm-1578	79	37	iqr	iqr	NOUN
ajlm-1578	79	38	:	:	PUNCT
ajlm-1578	79	39	175.4	175.4	NUM
ajlm-1578	79	40	)	)	PUNCT
ajlm-1578	79	41	versus	versus	ADP
ajlm-1578	79	42	for	for	ADP
ajlm-1578	79	43	patients	patient	NOUN
ajlm-1578	79	44	in	in	ADP
ajlm-1578	79	45	remission	remission	NOUN
ajlm-1578	79	46	:	:	PUNCT
ajlm-1578	79	47	median	median	NOUN
ajlm-1578	79	48	,	,	PUNCT
ajlm-1578	79	49	144.2	144.2	NUM
ajlm-1578	79	50	(	(	PUNCT
ajlm-1578	79	51	iqr	iqr	NOUN
ajlm-1578	79	52	:	:	PUNCT
ajlm-1578	79	53	367.4	367.4	NUM
ajlm-1578	79	54	,	,	PUNCT
ajlm-1578	79	55	p	p	NOUN
ajlm-1578	79	56	=	=	NOUN
ajlm-1578	79	57	0.52	0.52	NUM
ajlm-1578	79	58	)	)	PUNCT
ajlm-1578	79	59	and	and	CCONJ
ajlm-1578	79	60	the	the	DET
ajlm-1578	79	61	platelet	platelet	NOUN
ajlm-1578	79	62	count	count	NOUN
ajlm-1578	79	63	for	for	ADP
ajlm-1578	79	64	deceased	deceased	ADJ
ajlm-1578	79	65	patients	patient	NOUN
ajlm-1578	79	66	:	:	PUNCT
ajlm-1578	79	67	median	median	ADJ
ajlm-1578	79	68	,	,	PUNCT
ajlm-1578	79	69	31	31	NUM
ajlm-1578	79	70	(	(	PUNCT
ajlm-1578	79	71	iqr	iqr	NOUN
ajlm-1578	79	72	:	:	PUNCT
ajlm-1578	79	73	177	177	NUM
ajlm-1578	79	74	)	)	PUNCT
ajlm-1578	79	75	versus	versus	ADP
ajlm-1578	79	76	for	for	ADP
ajlm-1578	79	77	patients	patient	NOUN
ajlm-1578	79	78	in	in	ADP
ajlm-1578	79	79	remission	remission	NOUN
ajlm-1578	79	80	:	:	PUNCT
ajlm-1578	79	81	median	median	PROPN
ajlm-1578	79	82	,	,	PUNCT
ajlm-1578	79	83	101	101	NUM
ajlm-1578	79	84	(	(	PUNCT
ajlm-1578	79	85	iqr	iqr	NOUN
ajlm-1578	79	86	:	:	PUNCT
ajlm-1578	79	87	324	324	NUM
ajlm-1578	79	88	,	,	PUNCT
ajlm-1578	79	89	p	p	NOUN
ajlm-1578	79	90	=	=	NOUN
ajlm-1578	79	91	0.54	0.54	NUM
ajlm-1578	79	92	)	)	PUNCT
ajlm-1578	79	93	(	(	PUNCT
ajlm-1578	79	94	table	table	NOUN
ajlm-1578	79	95	1	1	NUM
ajlm-1578	79	96	)	)	PUNCT
ajlm-1578	79	97	.	.	PUNCT
ajlm-1578	80	1	discussion	discussion	NOUN
ajlm-1578	80	2	this	this	DET
ajlm-1578	80	3	retrospective	retrospective	ADJ
ajlm-1578	80	4	laboratory	laboratory	NOUN
ajlm-1578	80	5	report	report	NOUN
ajlm-1578	80	6	review	review	NOUN
ajlm-1578	80	7	determined	determine	VERB
ajlm-1578	80	8	the	the	DET
ajlm-1578	80	9	disease	disease	NOUN
ajlm-1578	80	10	charatersistics	charatersistic	NOUN
ajlm-1578	80	11	and	and	CCONJ
ajlm-1578	80	12	overall	overall	ADJ
ajlm-1578	80	13	survival	survival	NOUN
ajlm-1578	80	14	of	of	ADP
ajlm-1578	80	15	bc	bc	PROPN
ajlm-1578	80	16	-	-	PUNCT
ajlm-1578	80	17	cml	cml	PROPN
ajlm-1578	80	18	in	in	ADP
ajlm-1578	80	19	south	south	PROPN
ajlm-1578	80	20	africa	africa	PROPN
ajlm-1578	80	21	.	.	PUNCT
ajlm-1578	81	1	the	the	DET
ajlm-1578	81	2	median	median	ADJ
ajlm-1578	81	3	age	age	NOUN
ajlm-1578	81	4	of	of	ADP
ajlm-1578	81	5	bc	bc	PROPN
ajlm-1578	81	6	-	-	PUNCT
ajlm-1578	81	7	cml	cml	PROPN
ajlm-1578	81	8	in	in	ADP
ajlm-1578	81	9	our	our	PRON
ajlm-1578	81	10	study	study	NOUN
ajlm-1578	81	11	was	be	AUX
ajlm-1578	81	12	significantly	significantly	ADV
ajlm-1578	81	13	lower	low	ADJ
ajlm-1578	81	14	than	than	ADP
ajlm-1578	81	15	the	the	DET
ajlm-1578	81	16	61	61	NUM
ajlm-1578	81	17	years	year	NOUN
ajlm-1578	81	18	reported	report	VERB
ajlm-1578	81	19	internationally	internationally	ADV
ajlm-1578	81	20	and	and	CCONJ
ajlm-1578	81	21	corresponds	correspond	VERB
ajlm-1578	81	22	with	with	ADP
ajlm-1578	81	23	the	the	DET
ajlm-1578	81	24	younger	young	ADJ
ajlm-1578	81	25	age	age	NOUN
ajlm-1578	81	26	at	at	ADP
ajlm-1578	81	27	diagnosis	diagnosis	NOUN
ajlm-1578	81	28	of	of	ADP
ajlm-1578	81	29	cml	cml	PROPN
ajlm-1578	81	30	in	in	ADP
ajlm-1578	81	31	our	our	PRON
ajlm-1578	81	32	setting.20,21,22	setting.20,21,22	NOUN
ajlm-1578	81	33	this	this	DET
ajlm-1578	81	34	finding	finding	NOUN
ajlm-1578	81	35	may	may	AUX
ajlm-1578	81	36	be	be	AUX
ajlm-1578	81	37	reflective	reflective	ADJ
ajlm-1578	81	38	of	of	ADP
ajlm-1578	81	39	south	south	ADJ
ajlm-1578	81	40	african	african	ADJ
ajlm-1578	81	41	demographics	demographic	NOUN
ajlm-1578	81	42	,	,	PUNCT
ajlm-1578	81	43	which	which	PRON
ajlm-1578	81	44	are	be	AUX
ajlm-1578	81	45	characterised	characterise	VERB
ajlm-1578	81	46	by	by	ADP
ajlm-1578	81	47	a	a	DET
ajlm-1578	81	48	young	young	ADJ
ajlm-1578	81	49	age	age	NOUN
ajlm-1578	81	50	structure	structure	NOUN
ajlm-1578	81	51	of	of	ADP
ajlm-1578	81	52	the	the	DET
ajlm-1578	81	53	population	population	NOUN
ajlm-1578	81	54	or	or	CCONJ
ajlm-1578	81	55	alternatively	alternatively	ADV
ajlm-1578	81	56	this	this	PRON
ajlm-1578	81	57	may	may	AUX
ajlm-1578	81	58	be	be	AUX
ajlm-1578	81	59	the	the	DET
ajlm-1578	81	60	result	result	NOUN
ajlm-1578	81	61	of	of	ADP
ajlm-1578	81	62	unknown	unknown	ADJ
ajlm-1578	81	63	environmental	environmental	ADJ
ajlm-1578	81	64	exposures	exposure	NOUN
ajlm-1578	81	65	or	or	CCONJ
ajlm-1578	81	66	unique	unique	ADJ
ajlm-1578	81	67	genetic	genetic	ADJ
ajlm-1578	81	68	/	/	SYM
ajlm-1578	81	69	biological	biological	ADJ
ajlm-1578	81	70	characteristics	characteristic	NOUN
ajlm-1578	81	71	.	.	PUNCT
ajlm-1578	82	1	consequently	consequently	ADV
ajlm-1578	82	2	,	,	PUNCT
ajlm-1578	82	3	this	this	DET
ajlm-1578	82	4	young	young	ADJ
ajlm-1578	82	5	age	age	NOUN
ajlm-1578	82	6	at	at	ADP
ajlm-1578	82	7	diagnosis	diagnosis	NOUN
ajlm-1578	82	8	has	have	VERB
ajlm-1578	82	9	a	a	DET
ajlm-1578	82	10	financial	financial	ADJ
ajlm-1578	82	11	impact	impact	NOUN
ajlm-1578	82	12	upon	upon	SCONJ
ajlm-1578	82	13	the	the	DET
ajlm-1578	82	14	public	public	ADJ
ajlm-1578	82	15	health	health	NOUN
ajlm-1578	82	16	sector	sector	NOUN
ajlm-1578	82	17	,	,	PUNCT
ajlm-1578	82	18	in	in	ADP
ajlm-1578	82	19	particular	particular	ADJ
ajlm-1578	82	20	for	for	ADP
ajlm-1578	82	21	chronic	chronic	ADJ
ajlm-1578	82	22	phase	phase	NOUN
ajlm-1578	82	23	cml	cml	PROPN
ajlm-1578	82	24	.	.	PUNCT
ajlm-1578	83	1	the	the	DET
ajlm-1578	83	2	cost	cost	NOUN
ajlm-1578	83	3	resulting	result	VERB
ajlm-1578	83	4	from	from	ADP
ajlm-1578	83	5	the	the	DET
ajlm-1578	83	6	earlier	early	ADJ
ajlm-1578	83	7	initiation	initiation	NOUN
ajlm-1578	83	8	,	,	PUNCT
ajlm-1578	83	9	and	and	CCONJ
ajlm-1578	83	10	thus	thus	ADV
ajlm-1578	83	11	additional	additional	ADJ
ajlm-1578	83	12	years	year	NOUN
ajlm-1578	83	13	on	on	ADP
ajlm-1578	83	14	tki	tki	NOUN
ajlm-1578	83	15	therapy	therapy	NOUN
ajlm-1578	83	16	,	,	PUNCT
ajlm-1578	83	17	is	be	AUX
ajlm-1578	83	18	substantial	substantial	ADJ
ajlm-1578	83	19	.	.	PUNCT
ajlm-1578	84	1	the	the	DET
ajlm-1578	84	2	risk	risk	NOUN
ajlm-1578	84	3	factors	factor	NOUN
ajlm-1578	84	4	for	for	ADP
ajlm-1578	84	5	the	the	DET
ajlm-1578	84	6	development	development	NOUN
ajlm-1578	84	7	of	of	ADP
ajlm-1578	84	8	cml	cml	PROPN
ajlm-1578	84	9	remain	remain	VERB
ajlm-1578	84	10	largely	largely	ADV
ajlm-1578	84	11	unknown	unknown	ADJ
ajlm-1578	84	12	with	with	ADP
ajlm-1578	84	13	acute	acute	ADJ
ajlm-1578	84	14	radiation	radiation	NOUN
ajlm-1578	84	15	exposure	exposure	NOUN
ajlm-1578	84	16	and	and	CCONJ
ajlm-1578	84	17	rare	rare	ADJ
ajlm-1578	84	18	cases	case	NOUN
ajlm-1578	84	19	of	of	ADP
ajlm-1578	84	20	possible	possible	ADJ
ajlm-1578	84	21	familial	familial	ADJ
ajlm-1578	84	22	predisposition	predisposition	NOUN
ajlm-1578	84	23	reported.19	reported.19	NOUN
ajlm-1578	84	24	to	to	ADP
ajlm-1578	84	25	our	our	PRON
ajlm-1578	84	26	knowledge	knowledge	NOUN
ajlm-1578	84	27	there	there	PRON
ajlm-1578	84	28	were	be	VERB
ajlm-1578	84	29	no	no	DET
ajlm-1578	84	30	cases	case	NOUN
ajlm-1578	84	31	of	of	ADP
ajlm-1578	84	32	familial	familial	ADJ
ajlm-1578	84	33	cml	cml	NOUN
ajlm-1578	84	34	in	in	ADP
ajlm-1578	84	35	our	our	PRON
ajlm-1578	84	36	study	study	NOUN
ajlm-1578	84	37	nor	nor	CCONJ
ajlm-1578	84	38	have	have	AUX
ajlm-1578	84	39	there	there	PRON
ajlm-1578	84	40	been	be	AUX
ajlm-1578	84	41	published	publish	VERB
ajlm-1578	84	42	cases	case	NOUN
ajlm-1578	84	43	from	from	ADP
ajlm-1578	84	44	south	south	PROPN
ajlm-1578	84	45	africa	africa	PROPN
ajlm-1578	84	46	.	.	PUNCT
ajlm-1578	85	1	progression	progression	NOUN
ajlm-1578	85	2	from	from	ADP
ajlm-1578	85	3	chronic	chronic	ADJ
ajlm-1578	85	4	phase	phase	NOUN
ajlm-1578	85	5	cml	cml	PROPN
ajlm-1578	85	6	to	to	ADP
ajlm-1578	85	7	bc	bc	PROPN
ajlm-1578	85	8	-	-	PUNCT
ajlm-1578	85	9	cml	cml	PROPN
ajlm-1578	85	10	could	could	AUX
ajlm-1578	85	11	not	not	PART
ajlm-1578	85	12	be	be	AUX
ajlm-1578	85	13	determined	determine	VERB
ajlm-1578	85	14	from	from	ADP
ajlm-1578	85	15	our	our	PRON
ajlm-1578	85	16	study	study	NOUN
ajlm-1578	85	17	as	as	ADP
ajlm-1578	85	18	a	a	DET
ajlm-1578	85	19	result	result	NOUN
ajlm-1578	85	20	of	of	ADP
ajlm-1578	85	21	the	the	DET
ajlm-1578	85	22	paucity	paucity	NOUN
ajlm-1578	85	23	of	of	ADP
ajlm-1578	85	24	local	local	ADJ
ajlm-1578	85	25	prevalence	prevalence	NOUN
ajlm-1578	85	26	data	datum	NOUN
ajlm-1578	85	27	.	.	PUNCT
ajlm-1578	86	1	indirectly	indirectly	ADV
ajlm-1578	86	2	,	,	PUNCT
ajlm-1578	86	3	the	the	DET
ajlm-1578	86	4	rates	rate	NOUN
ajlm-1578	86	5	of	of	ADP
ajlm-1578	86	6	transformation	transformation	NOUN
ajlm-1578	86	7	at	at	ADP
ajlm-1578	86	8	the	the	DET
ajlm-1578	86	9	chbah	chbah	NOUN
ajlm-1578	86	10	appear	appear	VERB
ajlm-1578	86	11	high	high	ADJ
ajlm-1578	86	12	as	as	SCONJ
ajlm-1578	86	13	compared	compare	VERB
ajlm-1578	86	14	with	with	ADP
ajlm-1578	86	15	international	international	ADJ
ajlm-1578	86	16	reports	report	NOUN
ajlm-1578	86	17	(	(	PUNCT
ajlm-1578	86	18	~2	~2	NOUN
ajlm-1578	86	19	%	%	NOUN
ajlm-1578	86	20	)	)	PUNCT
ajlm-1578	86	21	,	,	PUNCT
ajlm-1578	86	22	with	with	ADP
ajlm-1578	86	23	a	a	DET
ajlm-1578	86	24	yearly	yearly	ADJ
ajlm-1578	86	25	number	number	NOUN
ajlm-1578	86	26	of	of	ADP
ajlm-1578	86	27	~3	~3	NOUN
ajlm-1578	86	28	new	new	ADJ
ajlm-1578	86	29	adult	adult	NOUN
ajlm-1578	86	30	cases	case	NOUN
ajlm-1578	86	31	of	of	ADP
ajlm-1578	86	32	bc	bc	PROPN
ajlm-1578	86	33	-	-	PUNCT
ajlm-1578	86	34	cml	cml	PROPN
ajlm-1578	86	35	,	,	PUNCT
ajlm-1578	86	36	in	in	ADP
ajlm-1578	86	37	a	a	DET
ajlm-1578	86	38	background	background	NOUN
ajlm-1578	86	39	of	of	ADP
ajlm-1578	86	40	~12	~12	VERB
ajlm-1578	86	41	new	new	ADJ
ajlm-1578	86	42	cases	case	NOUN
ajlm-1578	86	43	of	of	ADP
ajlm-1578	86	44	cml	cml	PROPN
ajlm-1578	86	45	per	per	ADP
ajlm-1578	86	46	year.20,23	year.20,23	NOUN
ajlm-1578	86	47	plausible	plausible	ADJ
ajlm-1578	86	48	reasons	reason	NOUN
ajlm-1578	86	49	for	for	ADP
ajlm-1578	86	50	higher	high	ADJ
ajlm-1578	86	51	rates	rate	NOUN
ajlm-1578	86	52	of	of	ADP
ajlm-1578	86	53	transformation	transformation	NOUN
ajlm-1578	86	54	include	include	VERB
ajlm-1578	86	55	the	the	DET
ajlm-1578	86	56	development	development	NOUN
ajlm-1578	86	57	of	of	ADP
ajlm-1578	86	58	tki	tki	PROPN
ajlm-1578	86	59	resistance	resistance	NOUN
ajlm-1578	86	60	in	in	ADP
ajlm-1578	86	61	the	the	DET
ajlm-1578	86	62	initial	initial	ADJ
ajlm-1578	86	63	stages	stage	NOUN
ajlm-1578	86	64	of	of	ADP
ajlm-1578	86	65	cml	cml	PROPN
ajlm-1578	86	66	as	as	ADP
ajlm-1578	86	67	a	a	DET
ajlm-1578	86	68	result	result	NOUN
ajlm-1578	86	69	of	of	ADP
ajlm-1578	86	70	poor	poor	ADJ
ajlm-1578	86	71	compliance	compliance	NOUN
ajlm-1578	86	72	or	or	CCONJ
ajlm-1578	86	73	treatment	treatment	NOUN
ajlm-1578	86	74	interruptions	interruption	NOUN
ajlm-1578	86	75	,	,	PUNCT
ajlm-1578	86	76	and	and	CCONJ
ajlm-1578	86	77	late	late	ADJ
ajlm-1578	86	78	presentation	presentation	NOUN
ajlm-1578	86	79	of	of	ADP
ajlm-1578	86	80	patients	patient	NOUN
ajlm-1578	86	81	to	to	ADP
ajlm-1578	86	82	medical	medical	ADJ
ajlm-1578	86	83	facilities	facility	NOUN
ajlm-1578	86	84	resulting	result	VERB
ajlm-1578	86	85	in	in	ADP
ajlm-1578	86	86	more	more	ADV
ajlm-1578	86	87	advanced	advanced	ADJ
ajlm-1578	86	88	stage	stage	NOUN
ajlm-1578	86	89	disease	disease	NOUN
ajlm-1578	86	90	.	.	PUNCT
ajlm-1578	87	1	the	the	DET
ajlm-1578	87	2	lineage	lineage	NOUN
ajlm-1578	87	3	distribution	distribution	NOUN
ajlm-1578	87	4	of	of	ADP
ajlm-1578	87	5	bc	bc	PROPN
ajlm-1578	87	6	-	-	PUNCT
ajlm-1578	87	7	cml	cml	PROPN
ajlm-1578	87	8	in	in	ADP
ajlm-1578	87	9	this	this	DET
ajlm-1578	87	10	study	study	NOUN
ajlm-1578	87	11	is	be	AUX
ajlm-1578	87	12	similar	similar	ADJ
ajlm-1578	87	13	to	to	ADP
ajlm-1578	87	14	that	that	PRON
ajlm-1578	87	15	reported	report	VERB
ajlm-1578	87	16	in	in	ADP
ajlm-1578	87	17	the	the	DET
ajlm-1578	87	18	literature	literature	NOUN
ajlm-1578	87	19	with	with	ADP
ajlm-1578	87	20	myeloid	myeloid	ADJ
ajlm-1578	87	21	lineage	lineage	NOUN
ajlm-1578	87	22	accounting	account	VERB
ajlm-1578	87	23	for	for	ADP
ajlm-1578	87	24	around	around	ADV
ajlm-1578	87	25	~52	~52	NUM
ajlm-1578	87	26	%	%	NOUN
ajlm-1578	87	27	to	to	PART
ajlm-1578	87	28	67	67	NUM
ajlm-1578	87	29	%	%	NOUN
ajlm-1578	87	30	and	and	CCONJ
ajlm-1578	87	31	lymphoid	lymphoid	VERB
ajlm-1578	87	32	for	for	ADP
ajlm-1578	87	33	around	around	ADV
ajlm-1578	87	34	~19	~19	NOUN
ajlm-1578	87	35	%	%	NOUN
ajlm-1578	87	36	to	to	ADP
ajlm-1578	87	37	35%.24,25	35%.24,25	NUM
ajlm-1578	87	38	the	the	DET
ajlm-1578	87	39	proportion	proportion	NOUN
ajlm-1578	87	40	of	of	ADP
ajlm-1578	87	41	ambiguous	ambiguous	ADJ
ajlm-1578	87	42	lineage	lineage	NOUN
ajlm-1578	87	43	cases	case	NOUN
ajlm-1578	87	44	in	in	ADP
ajlm-1578	87	45	our	our	PRON
ajlm-1578	87	46	setting	setting	NOUN
ajlm-1578	87	47	was	be	AUX
ajlm-1578	87	48	similar	similar	ADJ
ajlm-1578	87	49	to	to	ADP
ajlm-1578	87	50	that	that	PRON
ajlm-1578	87	51	seen	see	VERB
ajlm-1578	87	52	in	in	ADP
ajlm-1578	87	53	studies	study	NOUN
ajlm-1578	87	54	performed	perform	VERB
ajlm-1578	87	55	in	in	ADP
ajlm-1578	87	56	taiwan	taiwan	PROPN
ajlm-1578	87	57	and	and	CCONJ
ajlm-1578	87	58	mexico	mexico	PROPN
ajlm-1578	87	59	,	,	PUNCT
ajlm-1578	87	60	reported	report	VERB
ajlm-1578	87	61	at	at	ADP
ajlm-1578	87	62	~12	~12	NOUN
ajlm-1578	87	63	%	%	NOUN
ajlm-1578	87	64	to	to	ADP
ajlm-1578	87	65	14%.24,25	14%.24,25	NUM
ajlm-1578	87	66	for	for	ADP
ajlm-1578	87	67	the	the	DET
ajlm-1578	87	68	lymphoid	lymphoid	ADJ
ajlm-1578	87	69	lineage	lineage	NOUN
ajlm-1578	87	70	,	,	PUNCT
ajlm-1578	87	71	an	an	DET
ajlm-1578	87	72	expected	expect	VERB
ajlm-1578	87	73	ratio	ratio	NOUN
ajlm-1578	87	74	of	of	ADP
ajlm-1578	87	75	b	b	NOUN
ajlm-1578	87	76	to	to	ADP
ajlm-1578	87	77	t	t	NOUN
ajlm-1578	87	78	cases	case	NOUN
ajlm-1578	87	79	was	be	AUX
ajlm-1578	87	80	present	present	ADJ
ajlm-1578	87	81	in	in	ADP
ajlm-1578	87	82	our	our	PRON
ajlm-1578	87	83	study.24,25	study.24,25	NOUN
ajlm-1578	87	84	this	this	PRON
ajlm-1578	87	85	suggests	suggest	VERB
ajlm-1578	87	86	a	a	DET
ajlm-1578	87	87	similar	similar	ADJ
ajlm-1578	87	88	disease	disease	NOUN
ajlm-1578	87	89	biology	biology	NOUN
ajlm-1578	87	90	and	and	CCONJ
ajlm-1578	87	91	accordingly	accordingly	ADV
ajlm-1578	87	92	supports	support	VERB
ajlm-1578	87	93	the	the	DET
ajlm-1578	87	94	use	use	NOUN
ajlm-1578	87	95	of	of	ADP
ajlm-1578	87	96	international	international	ADJ
ajlm-1578	87	97	treatment	treatment	NOUN
ajlm-1578	87	98	approaches	approach	NOUN
ajlm-1578	87	99	/	/	SYM
ajlm-1578	87	100	guidelines	guideline	NOUN
ajlm-1578	87	101	for	for	ADP
ajlm-1578	87	102	bc	bc	PROPN
ajlm-1578	87	103	-	-	PUNCT
ajlm-1578	87	104	cml	cml	PROPN
ajlm-1578	87	105	,	,	PUNCT
ajlm-1578	87	106	with	with	ADP
ajlm-1578	87	107	the	the	DET
ajlm-1578	87	108	ability	ability	NOUN
ajlm-1578	87	109	to	to	PART
ajlm-1578	87	110	compare	compare	VERB
ajlm-1578	87	111	treatment	treatment	NOUN
ajlm-1578	87	112	and	and	CCONJ
ajlm-1578	87	113	survival	survival	NOUN
ajlm-1578	87	114	endpoints	endpoint	NOUN
ajlm-1578	87	115	.	.	PUNCT
ajlm-1578	88	1	the	the	DET
ajlm-1578	88	2	p210	p210	PROPN
ajlm-1578	88	3	bcr	bcr	PROPN
ajlm-1578	88	4	-	-	PUNCT
ajlm-1578	88	5	abl1	abl1	ADJ
ajlm-1578	88	6	fusion	fusion	NOUN
ajlm-1578	88	7	(	(	PUNCT
ajlm-1578	88	8	e13a1	e13a1	X
ajlm-1578	88	9	[	[	X
ajlm-1578	88	10	b2a2]/e14a2	b2a2]/e14a2	X
ajlm-1578	88	11	[	[	X
ajlm-1578	88	12	b3a2	b3a2	X
ajlm-1578	88	13	]	]	X
ajlm-1578	88	14	)	)	PUNCT
ajlm-1578	88	15	is	be	AUX
ajlm-1578	88	16	the	the	DET
ajlm-1578	88	17	most	most	ADV
ajlm-1578	88	18	common	common	ADJ
ajlm-1578	88	19	transcript	transcript	NOUN
ajlm-1578	88	20	seen	see	VERB
ajlm-1578	88	21	in	in	ADP
ajlm-1578	88	22	cml	cml	PROPN
ajlm-1578	88	23	.	.	PUNCT
ajlm-1578	88	24	co	co	NOUN
ajlm-1578	88	25	-	-	NOUN
ajlm-1578	88	26	expression	expression	NOUN
ajlm-1578	88	27	of	of	ADP
ajlm-1578	88	28	p210	p210	PROPN
ajlm-1578	88	29	with	with	ADP
ajlm-1578	88	30	p190	p190	PROPN
ajlm-1578	88	31	(	(	PUNCT
ajlm-1578	88	32	e1a2	e1a2	X
ajlm-1578	88	33	)	)	PUNCT
ajlm-1578	88	34	is	be	AUX
ajlm-1578	88	35	described	describe	VERB
ajlm-1578	88	36	,	,	PUNCT
ajlm-1578	88	37	but	but	CCONJ
ajlm-1578	88	38	a	a	DET
ajlm-1578	88	39	very	very	ADV
ajlm-1578	88	40	rare	rare	ADJ
ajlm-1578	88	41	phenomenon	phenomenon	NOUN
ajlm-1578	88	42	.	.	PUNCT
ajlm-1578	89	1	rarer	rarer	ADV
ajlm-1578	89	2	still	still	ADV
ajlm-1578	89	3	is	be	AUX
ajlm-1578	89	4	an	an	DET
ajlm-1578	89	5	isolated	isolated	ADJ
ajlm-1578	89	6	p190	p190	PROPN
ajlm-1578	89	7	bcr	bcr	ADJ
ajlm-1578	89	8	-	-	PUNCT
ajlm-1578	89	9	abl1	abl1	ADJ
ajlm-1578	89	10	fusion	fusion	NOUN
ajlm-1578	89	11	which	which	PRON
ajlm-1578	89	12	has	have	AUX
ajlm-1578	89	13	been	be	AUX
ajlm-1578	89	14	described	describe	VERB
ajlm-1578	89	15	in	in	ADP
ajlm-1578	89	16	1	1	NUM
ajlm-1578	89	17	%	%	NOUN
ajlm-1578	89	18	of	of	ADP
ajlm-1578	89	19	cml	cml	PROPN
ajlm-1578	89	20	.	.	PUNCT
ajlm-1578	90	1	this	this	DET
ajlm-1578	90	2	latter	latter	ADJ
ajlm-1578	90	3	group	group	NOUN
ajlm-1578	90	4	is	be	AUX
ajlm-1578	90	5	associated	associate	VERB
ajlm-1578	90	6	with	with	ADP
ajlm-1578	90	7	poor	poor	ADJ
ajlm-1578	90	8	response	response	NOUN
ajlm-1578	90	9	to	to	ADP
ajlm-1578	90	10	tki	tki	PROPN
ajlm-1578	90	11	therapy	therapy	NOUN
ajlm-1578	90	12	and	and	CCONJ
ajlm-1578	90	13	disease	disease	NOUN
ajlm-1578	90	14	progression	progression	NOUN
ajlm-1578	90	15	in	in	ADP
ajlm-1578	90	16	greater	great	ADJ
ajlm-1578	90	17	than	than	ADP
ajlm-1578	90	18	80	80	NUM
ajlm-1578	90	19	%	%	NOUN
ajlm-1578	90	20	of	of	ADP
ajlm-1578	90	21	the	the	DET
ajlm-1578	90	22	group.26	group.26	ADJ
ajlm-1578	90	23	these	these	DET
ajlm-1578	90	24	characteristics	characteristic	NOUN
ajlm-1578	90	25	likely	likely	ADV
ajlm-1578	90	26	explain	explain	VERB
ajlm-1578	90	27	the	the	DET
ajlm-1578	90	28	higher	high	ADJ
ajlm-1578	90	29	than	than	SCONJ
ajlm-1578	90	30	expected	expect	VERB
ajlm-1578	90	31	number	number	NOUN
ajlm-1578	90	32	of	of	ADP
ajlm-1578	90	33	p190	p190	PROPN
ajlm-1578	90	34	bc	bc	PROPN
ajlm-1578	90	35	-	-	PUNCT
ajlm-1578	90	36	cml	cml	PROPN
ajlm-1578	90	37	cases	case	NOUN
ajlm-1578	90	38	in	in	ADP
ajlm-1578	90	39	this	this	DET
ajlm-1578	90	40	study	study	NOUN
ajlm-1578	90	41	(	(	PUNCT
ajlm-1578	90	42	9.1	9.1	NUM
ajlm-1578	90	43	%	%	NOUN
ajlm-1578	90	44	)	)	PUNCT
ajlm-1578	90	45	.	.	PUNCT
ajlm-1578	91	1	the	the	DET
ajlm-1578	91	2	median	median	PROPN
ajlm-1578	91	3	(	(	PUNCT
ajlm-1578	91	4	iqr	iqr	NOUN
ajlm-1578	91	5	)	)	PUNCT
ajlm-1578	91	6	os	os	NOUN
ajlm-1578	91	7	in	in	ADP
ajlm-1578	91	8	these	these	DET
ajlm-1578	91	9	cases	case	NOUN
ajlm-1578	91	10	is	be	AUX
ajlm-1578	91	11	reported	report	VERB
ajlm-1578	91	12	at	at	ADP
ajlm-1578	91	13	~13	~13	X
ajlm-1578	91	14	months	month	NOUN
ajlm-1578	91	15	(	(	PUNCT
ajlm-1578	91	16	8–40	8–40	PROPN
ajlm-1578	91	17	)	)	PUNCT
ajlm-1578	91	18	,	,	PUNCT
ajlm-1578	91	19	a	a	DET
ajlm-1578	91	20	figure	figure	NOUN
ajlm-1578	91	21	which	which	PRON
ajlm-1578	91	22	is	be	AUX
ajlm-1578	91	23	double	double	ADJ
ajlm-1578	91	24	that	that	PRON
ajlm-1578	91	25	seen	see	VERB
ajlm-1578	91	26	in	in	ADP
ajlm-1578	91	27	our	our	PRON
ajlm-1578	91	28	study	study	NOUN
ajlm-1578	91	29	.	.	PUNCT
ajlm-1578	92	1	the	the	DET
ajlm-1578	92	2	reason	reason	NOUN
ajlm-1578	92	3	for	for	ADP
ajlm-1578	92	4	this	this	DET
ajlm-1578	92	5	difference	difference	NOUN
ajlm-1578	92	6	likely	likely	ADV
ajlm-1578	92	7	reflects	reflect	VERB
ajlm-1578	92	8	a	a	DET
ajlm-1578	92	9	lack	lack	NOUN
ajlm-1578	92	10	of	of	ADP
ajlm-1578	92	11	alternative	alternative	ADJ
ajlm-1578	92	12	or	or	CCONJ
ajlm-1578	92	13	novel	novel	ADJ
ajlm-1578	92	14	treatment	treatment	NOUN
ajlm-1578	92	15	options	option	NOUN
ajlm-1578	92	16	for	for	ADP
ajlm-1578	92	17	relapsed	relapse	VERB
ajlm-1578	92	18	/	/	SYM
ajlm-1578	92	19	refractory	refractory	NOUN
ajlm-1578	92	20	disease	disease	NOUN
ajlm-1578	92	21	in	in	ADP
ajlm-1578	92	22	the	the	DET
ajlm-1578	92	23	south	south	ADJ
ajlm-1578	92	24	african	african	ADJ
ajlm-1578	92	25	public	public	ADJ
ajlm-1578	92	26	health	health	PROPN
ajlm-1578	92	27	sector.27	sector.27	PROPN
ajlm-1578	92	28	given	give	VERB
ajlm-1578	92	29	the	the	DET
ajlm-1578	92	30	high	high	ADJ
ajlm-1578	92	31	risk	risk	NOUN
ajlm-1578	92	32	of	of	ADP
ajlm-1578	92	33	this	this	DET
ajlm-1578	92	34	subgroup	subgroup	NOUN
ajlm-1578	92	35	of	of	ADP
ajlm-1578	92	36	patients	patient	NOUN
ajlm-1578	92	37	,	,	PUNCT
ajlm-1578	92	38	close	close	ADJ
ajlm-1578	92	39	monitoring	monitoring	NOUN
ajlm-1578	92	40	of	of	ADP
ajlm-1578	92	41	the	the	DET
ajlm-1578	92	42	therapeutic	therapeutic	ADJ
ajlm-1578	92	43	response	response	NOUN
ajlm-1578	92	44	is	be	AUX
ajlm-1578	92	45	imperative	imperative	ADJ
ajlm-1578	92	46	(	(	PUNCT
ajlm-1578	92	47	especially	especially	ADV
ajlm-1578	92	48	during	during	ADP
ajlm-1578	92	49	the	the	DET
ajlm-1578	92	50	early	early	ADJ
ajlm-1578	92	51	phases	phase	NOUN
ajlm-1578	92	52	of	of	ADP
ajlm-1578	92	53	cml	cml	PROPN
ajlm-1578	92	54	)	)	PUNCT
ajlm-1578	92	55	,	,	PUNCT
ajlm-1578	92	56	with	with	ADP
ajlm-1578	92	57	early	early	ADJ
ajlm-1578	92	58	intervention	intervention	NOUN
ajlm-1578	92	59	should	should	AUX
ajlm-1578	92	60	the	the	DET
ajlm-1578	92	61	response	response	NOUN
ajlm-1578	92	62	be	be	AUX
ajlm-1578	92	63	lost.26	lost.26	ADJ
ajlm-1578	92	64	high	high	ADJ
ajlm-1578	92	65	-	-	PUNCT
ajlm-1578	92	66	risk	risk	NOUN
ajlm-1578	92	67	cytogenetic	cytogenetic	ADJ
ajlm-1578	92	68	abnormalities	abnormality	NOUN
ajlm-1578	92	69	in	in	ADP
ajlm-1578	92	70	cml	cml	PROPN
ajlm-1578	92	71	include	include	VERB
ajlm-1578	92	72	a	a	DET
ajlm-1578	92	73	complex	complex	ADJ
ajlm-1578	92	74	karyotype	karyotype	NOUN
ajlm-1578	92	75	and	and	CCONJ
ajlm-1578	92	76	major	major	ADJ
ajlm-1578	92	77	molecular	molecular	ADJ
ajlm-1578	92	78	route	route	NOUN
ajlm-1578	92	79	abnormalities	abnormality	NOUN
ajlm-1578	92	80	which	which	PRON
ajlm-1578	92	81	are	be	AUX
ajlm-1578	92	82	markers	marker	NOUN
ajlm-1578	92	83	of	of	ADP
ajlm-1578	92	84	disease	disease	NOUN
ajlm-1578	92	85	acceleration	acceleration	NOUN
ajlm-1578	92	86	.	.	PUNCT
ajlm-1578	93	1	this	this	PRON
ajlm-1578	93	2	is	be	AUX
ajlm-1578	93	3	associated	associate	VERB
ajlm-1578	93	4	with	with	ADP
ajlm-1578	93	5	more	more	ADV
ajlm-1578	93	6	rapid	rapid	ADJ
ajlm-1578	93	7	disease	disease	NOUN
ajlm-1578	93	8	progression	progression	NOUN
ajlm-1578	93	9	,	,	PUNCT
ajlm-1578	93	10	treatment	treatment	NOUN
ajlm-1578	93	11	resistance	resistance	NOUN
ajlm-1578	93	12	or	or	CCONJ
ajlm-1578	93	13	suboptimal	suboptimal	ADJ
ajlm-1578	93	14	treatment	treatment	NOUN
ajlm-1578	93	15	response.28	response.28	VERB
ajlm-1578	93	16	the	the	DET
ajlm-1578	93	17	major	major	ADJ
ajlm-1578	93	18	molecular	molecular	ADJ
ajlm-1578	93	19	route	route	NOUN
ajlm-1578	93	20	abnormalities	abnormality	NOUN
ajlm-1578	93	21	include	include	VERB
ajlm-1578	93	22	a	a	DET
ajlm-1578	93	23	second	second	ADJ
ajlm-1578	93	24	philadelphia	philadelphia	PROPN
ajlm-1578	93	25	chromosome	chromosome	NOUN
ajlm-1578	93	26	,	,	PUNCT
ajlm-1578	93	27	isochromosome	isochromosome	VERB
ajlm-1578	93	28	i	i	PRON
ajlm-1578	93	29	(	(	PUNCT
ajlm-1578	93	30	17q	17q	NOUN
ajlm-1578	93	31	)	)	PUNCT
ajlm-1578	93	32	,	,	PUNCT
ajlm-1578	93	33	trisomy	trisomy	NOUN
ajlm-1578	93	34	8	8	NUM
ajlm-1578	93	35	,	,	PUNCT
ajlm-1578	93	36	and	and	CCONJ
ajlm-1578	93	37	19.29	19.29	NUM
ajlm-1578	93	38	unsurprisingly	unsurprisingly	ADJ
ajlm-1578	93	39	,	,	PUNCT
ajlm-1578	93	40	a	a	DET
ajlm-1578	93	41	high	high	ADJ
ajlm-1578	93	42	percentage	percentage	NOUN
ajlm-1578	93	43	of	of	ADP
ajlm-1578	93	44	the	the	DET
ajlm-1578	93	45	bc	bc	PROPN
ajlm-1578	93	46	-	-	PUNCT
ajlm-1578	93	47	cml	cml	PROPN
ajlm-1578	93	48	cases	case	NOUN
ajlm-1578	93	49	with	with	ADP
ajlm-1578	93	50	existing	exist	VERB
ajlm-1578	93	51	ccy	ccy	NOUN
ajlm-1578	93	52	bore	bear	VERB
ajlm-1578	93	53	these	these	DET
ajlm-1578	93	54	abnormalities	abnormality	NOUN
ajlm-1578	93	55	.	.	PUNCT
ajlm-1578	94	1	as	as	ADP
ajlm-1578	94	2	a	a	DET
ajlm-1578	94	3	result	result	NOUN
ajlm-1578	94	4	of	of	ADP
ajlm-1578	94	5	the	the	DET
ajlm-1578	94	6	low	low	ADJ
ajlm-1578	94	7	number	number	NOUN
ajlm-1578	94	8	of	of	ADP
ajlm-1578	94	9	cases	case	NOUN
ajlm-1578	94	10	in	in	ADP
ajlm-1578	94	11	remission	remission	NOUN
ajlm-1578	94	12	and	and	CCONJ
ajlm-1578	94	13	with	with	ADP
ajlm-1578	94	14	ccy	ccy	PROPN
ajlm-1578	94	15	,	,	PUNCT
ajlm-1578	94	16	correlations	correlation	NOUN
ajlm-1578	94	17	between	between	ADP
ajlm-1578	94	18	molecular	molecular	ADJ
ajlm-1578	94	19	characteristics	characteristic	NOUN
ajlm-1578	94	20	and	and	CCONJ
ajlm-1578	94	21	outcomes	outcome	NOUN
ajlm-1578	94	22	could	could	AUX
ajlm-1578	94	23	not	not	PART
ajlm-1578	94	24	be	be	AUX
ajlm-1578	94	25	made	make	VERB
ajlm-1578	94	26	.	.	PUNCT
ajlm-1578	95	1	however	however	ADV
ajlm-1578	95	2	,	,	PUNCT
ajlm-1578	95	3	a	a	DET
ajlm-1578	95	4	second	second	ADJ
ajlm-1578	95	5	philadelphia	philadelphia	PROPN
ajlm-1578	95	6	chromosome	chromosome	NOUN
ajlm-1578	95	7	was	be	AUX
ajlm-1578	95	8	the	the	DET
ajlm-1578	95	9	only	only	ADJ
ajlm-1578	95	10	additional	additional	ADJ
ajlm-1578	95	11	chromosomal	chromosomal	ADJ
ajlm-1578	95	12	abnormality	abnormality	NOUN
ajlm-1578	95	13	present	present	ADJ
ajlm-1578	95	14	.	.	PUNCT
ajlm-1578	96	1	notably	notably	ADV
ajlm-1578	96	2	,	,	PUNCT
ajlm-1578	96	3	in	in	ADP
ajlm-1578	96	4	~30	~30	NOUN
ajlm-1578	96	5	%	%	NOUN
ajlm-1578	96	6	of	of	ADP
ajlm-1578	96	7	cases	case	NOUN
ajlm-1578	96	8	,	,	PUNCT
ajlm-1578	96	9	no	no	DET
ajlm-1578	96	10	sample	sample	NOUN
ajlm-1578	96	11	was	be	AUX
ajlm-1578	96	12	submitted	submit	VERB
ajlm-1578	96	13	for	for	ADP
ajlm-1578	96	14	ccy	ccy	NOUN
ajlm-1578	96	15	or	or	CCONJ
ajlm-1578	96	16	the	the	DET
ajlm-1578	96	17	procedure	procedure	NOUN
ajlm-1578	96	18	was	be	AUX
ajlm-1578	96	19	unsuccessful	unsuccessful	ADJ
ajlm-1578	96	20	.	.	PUNCT
ajlm-1578	97	1	ccy	ccy	PROPN
ajlm-1578	97	2	is	be	AUX
ajlm-1578	97	3	critical	critical	ADJ
ajlm-1578	97	4	to	to	ADP
ajlm-1578	97	5	prognostication	prognostication	NOUN
ajlm-1578	97	6	,	,	PUNCT
ajlm-1578	97	7	detection	detection	NOUN
ajlm-1578	97	8	of	of	ADP
ajlm-1578	97	9	clonal	clonal	ADJ
ajlm-1578	97	10	evolution	evolution	NOUN
ajlm-1578	97	11	,	,	PUNCT
ajlm-1578	97	12	monitoring	monitor	VERB
ajlm-1578	97	13	treatment	treatment	NOUN
ajlm-1578	97	14	response	response	NOUN
ajlm-1578	97	15	and	and	CCONJ
ajlm-1578	97	16	directing	direct	VERB
ajlm-1578	97	17	therapeutic	therapeutic	ADJ
ajlm-1578	97	18	decisions	decision	NOUN
ajlm-1578	97	19	.	.	PUNCT
ajlm-1578	98	1	practically	practically	ADV
ajlm-1578	98	2	,	,	PUNCT
ajlm-1578	98	3	in	in	ADP
ajlm-1578	98	4	such	such	ADJ
ajlm-1578	98	5	cases	case	NOUN
ajlm-1578	98	6	,	,	PUNCT
ajlm-1578	98	7	peripheral	peripheral	ADJ
ajlm-1578	98	8	blood	blood	NOUN
ajlm-1578	98	9	may	may	AUX
ajlm-1578	98	10	serve	serve	VERB
ajlm-1578	98	11	as	as	ADP
ajlm-1578	98	12	an	an	DET
ajlm-1578	98	13	easily	easily	ADV
ajlm-1578	98	14	accessible	accessible	ADJ
ajlm-1578	98	15	,	,	PUNCT
ajlm-1578	98	16	alternative	alternative	ADJ
ajlm-1578	98	17	source	source	NOUN
ajlm-1578	98	18	for	for	ADP
ajlm-1578	98	19	ccy	ccy	NOUN
ajlm-1578	98	20	.	.	PUNCT
ajlm-1578	99	1	cognisance	cognisance	NOUN
ajlm-1578	99	2	of	of	ADP
ajlm-1578	99	3	this	this	PRON
ajlm-1578	99	4	would	would	AUX
ajlm-1578	99	5	help	help	VERB
ajlm-1578	99	6	to	to	PART
ajlm-1578	99	7	limit	limit	VERB
ajlm-1578	99	8	the	the	DET
ajlm-1578	99	9	number	number	NOUN
ajlm-1578	99	10	of	of	ADP
ajlm-1578	99	11	cases	case	NOUN
ajlm-1578	99	12	missing	miss	VERB
ajlm-1578	99	13	valuable	valuable	ADJ
ajlm-1578	99	14	molecular	molecular	ADJ
ajlm-1578	99	15	information	information	NOUN
ajlm-1578	99	16	.	.	PUNCT
ajlm-1578	100	1	notably	notably	ADV
ajlm-1578	100	2	,	,	PUNCT
ajlm-1578	100	3	but	but	CCONJ
ajlm-1578	100	4	not	not	PART
ajlm-1578	100	5	unexpectedly	unexpectedly	ADV
ajlm-1578	100	6	,	,	PUNCT
ajlm-1578	100	7	alternative	alternative	ADJ
ajlm-1578	100	8	markers	marker	NOUN
ajlm-1578	100	9	of	of	ADP
ajlm-1578	100	10	high	high	ADJ
ajlm-1578	100	11	-	-	PUNCT
ajlm-1578	100	12	risk	risk	NOUN
ajlm-1578	100	13	cml	cml	PROPN
ajlm-1578	100	14	were	be	AUX
ajlm-1578	100	15	present	present	ADJ
ajlm-1578	100	16	in	in	ADP
ajlm-1578	100	17	this	this	DET
ajlm-1578	100	18	cohort	cohort	NOUN
ajlm-1578	100	19	;	;	PUNCT
ajlm-1578	100	20	these	these	PRON
ajlm-1578	100	21	included	include	VERB
ajlm-1578	100	22	peripheral	peripheral	ADJ
ajlm-1578	100	23	blood	blood	NOUN
ajlm-1578	100	24	blast	blast	NOUN
ajlm-1578	100	25	percentages	percentage	NOUN
ajlm-1578	100	26	of	of	ADP
ajlm-1578	100	27	>	>	X
ajlm-1578	100	28	10	10	NUM
ajlm-1578	100	29	%	%	NOUN
ajlm-1578	100	30	,	,	PUNCT
ajlm-1578	100	31	p190	p190	PROPN
ajlm-1578	100	32	bcr	bcr	PROPN
ajlm-1578	100	33	-	-	PUNCT
ajlm-1578	100	34	abl1	abl1	ADJ
ajlm-1578	100	35	transcripts	transcript	NOUN
ajlm-1578	100	36	and	and	CCONJ
ajlm-1578	100	37	platelet	platelet	NOUN
ajlm-1578	100	38	counts	count	NOUN
ajlm-1578	100	39	of	of	ADP
ajlm-1578	100	40	<	<	X
ajlm-1578	100	41	102	102	NUM
ajlm-1578	100	42	×	×	NOUN
ajlm-1578	100	43	10	10	NUM
ajlm-1578	100	44	^	^	SYM
ajlm-1578	100	45	9	9	NUM
ajlm-1578	100	46	/	/	SYM
ajlm-1578	100	47	l.19,30	l.19,30	NOUN
ajlm-1578	100	48	the	the	DET
ajlm-1578	100	49	tkis	tkis	NOUN
ajlm-1578	100	50	for	for	ADP
ajlm-1578	100	51	the	the	DET
ajlm-1578	100	52	treatment	treatment	NOUN
ajlm-1578	100	53	of	of	ADP
ajlm-1578	100	54	chronic	chronic	ADJ
ajlm-1578	100	55	phase	phase	NOUN
ajlm-1578	100	56	cml	cml	PROPN
ajlm-1578	100	57	at	at	ADP
ajlm-1578	100	58	the	the	DET
ajlm-1578	100	59	time	time	NOUN
ajlm-1578	100	60	of	of	ADP
ajlm-1578	100	61	this	this	DET
ajlm-1578	100	62	study	study	NOUN
ajlm-1578	100	63	included	include	VERB
ajlm-1578	100	64	:	:	PUNCT
ajlm-1578	100	65	the	the	DET
ajlm-1578	100	66	first	first	ADJ
ajlm-1578	100	67	-	-	PUNCT
ajlm-1578	100	68	generation	generation	NOUN
ajlm-1578	100	69	tki	tki	NOUN
ajlm-1578	100	70	,	,	PUNCT
ajlm-1578	100	71	imatinib	imatinib	NOUN
ajlm-1578	100	72	mesylate	mesylate	NOUN
ajlm-1578	100	73	and	and	CCONJ
ajlm-1578	100	74	second	second	ADJ
ajlm-1578	100	75	-	-	PUNCT
ajlm-1578	100	76	generation	generation	NOUN
ajlm-1578	100	77	tki	tki	NOUN
ajlm-1578	100	78	,	,	PUNCT
ajlm-1578	100	79	dasatinib	dasatinib	NOUN
ajlm-1578	100	80	(	(	PUNCT
ajlm-1578	100	81	on	on	ADP
ajlm-1578	100	82	a	a	DET
ajlm-1578	100	83	compassionate	compassionate	ADJ
ajlm-1578	100	84	basis	basis	NOUN
ajlm-1578	100	85	)	)	PUNCT
ajlm-1578	100	86	and	and	CCONJ
ajlm-1578	100	87	nilotinib	nilotinib	NOUN
ajlm-1578	100	88	.	.	PUNCT
ajlm-1578	101	1	currently	currently	ADV
ajlm-1578	101	2	,	,	PUNCT
ajlm-1578	101	3	in	in	ADP
ajlm-1578	101	4	the	the	DET
ajlm-1578	101	5	south	south	ADJ
ajlm-1578	101	6	african	african	ADJ
ajlm-1578	101	7	state	state	NOUN
ajlm-1578	101	8	sector	sector	NOUN
ajlm-1578	101	9	,	,	PUNCT
ajlm-1578	101	10	imatinib	imatinib	NOUN
ajlm-1578	101	11	mesylate	mesylate	NOUN
ajlm-1578	101	12	remains	remain	VERB
ajlm-1578	101	13	the	the	DET
ajlm-1578	101	14	first	first	ADJ
ajlm-1578	101	15	-	-	PUNCT
ajlm-1578	101	16	line	line	NOUN
ajlm-1578	101	17	therapy	therapy	NOUN
ajlm-1578	101	18	together	together	ADV
ajlm-1578	101	19	with	with	ADP
ajlm-1578	101	20	hydroxyurea	hydroxyurea	PROPN
ajlm-1578	101	21	(	(	PUNCT
ajlm-1578	101	22	for	for	ADP
ajlm-1578	101	23	cytoreduction	cytoreduction	NOUN
ajlm-1578	101	24	)	)	PUNCT
ajlm-1578	101	25	in	in	ADP
ajlm-1578	101	26	chronic	chronic	ADJ
ajlm-1578	101	27	phase	phase	NOUN
ajlm-1578	101	28	cml	cml	PROPN
ajlm-1578	102	1	.	.	PUNCT
ajlm-1578	102	2	nilotinib	nilotinib	PROPN
ajlm-1578	102	3	is	be	AUX
ajlm-1578	102	4	the	the	DET
ajlm-1578	102	5	second	second	ADJ
ajlm-1578	102	6	line	line	NOUN
ajlm-1578	102	7	tki	tki	NOUN
ajlm-1578	102	8	and	and	CCONJ
ajlm-1578	102	9	is	be	AUX
ajlm-1578	102	10	used	use	VERB
ajlm-1578	102	11	in	in	ADP
ajlm-1578	102	12	situations	situation	NOUN
ajlm-1578	102	13	of	of	ADP
ajlm-1578	102	14	treatment	treatment	NOUN
ajlm-1578	102	15	failure	failure	NOUN
ajlm-1578	102	16	.	.	PUNCT
ajlm-1578	103	1	dasatinib	dasatinib	NOUN
ajlm-1578	103	2	is	be	AUX
ajlm-1578	103	3	no	no	ADV
ajlm-1578	103	4	longer	long	ADV
ajlm-1578	103	5	available	available	ADJ
ajlm-1578	103	6	on	on	ADP
ajlm-1578	103	7	compassionate	compassionate	ADJ
ajlm-1578	103	8	grounds	ground	NOUN
ajlm-1578	103	9	.	.	PUNCT
ajlm-1578	104	1	importantly	importantly	ADV
ajlm-1578	104	2	,	,	PUNCT
ajlm-1578	104	3	comparable	comparable	ADJ
ajlm-1578	104	4	response	response	NOUN
ajlm-1578	104	5	rates	rate	NOUN
ajlm-1578	104	6	and	and	CCONJ
ajlm-1578	104	7	survival	survival	NOUN
ajlm-1578	104	8	outcomes	outcome	NOUN
ajlm-1578	104	9	have	have	AUX
ajlm-1578	104	10	been	be	AUX
ajlm-1578	104	11	demonstrated	demonstrate	VERB
ajlm-1578	104	12	for	for	ADP
ajlm-1578	104	13	these	these	DET
ajlm-1578	104	14	second	second	ADJ
ajlm-1578	104	15	-	-	PUNCT
ajlm-1578	104	16	generation	generation	NOUN
ajlm-1578	104	17	tkis.31	tkis.31	NOUN
ajlm-1578	104	18	despite	despite	SCONJ
ajlm-1578	104	19	a	a	DET
ajlm-1578	104	20	minimal	minimal	ADJ
ajlm-1578	104	21	risk	risk	NOUN
ajlm-1578	104	22	of	of	ADP
ajlm-1578	104	23	worsening	worsen	VERB
ajlm-1578	104	24	renal	renal	ADJ
ajlm-1578	104	25	dysfunction	dysfunction	NOUN
ajlm-1578	104	26	and	and	CCONJ
ajlm-1578	104	27	bleeding	bleed	VERB
ajlm-1578	104	28	in	in	ADP
ajlm-1578	104	29	those	those	PRON
ajlm-1578	104	30	with	with	ADP
ajlm-1578	104	31	pre	pre	ADJ
ajlm-1578	104	32	-	-	ADJ
ajlm-1578	104	33	existing	existing	ADJ
ajlm-1578	104	34	renal	renal	ADJ
ajlm-1578	104	35	dysfunction	dysfunction	NOUN
ajlm-1578	104	36	,	,	PUNCT
ajlm-1578	104	37	treated	treat	VERB
ajlm-1578	104	38	with	with	ADP
ajlm-1578	104	39	nilotinib	nilotinib	NOUN
ajlm-1578	104	40	or	or	CCONJ
ajlm-1578	104	41	dasatinib	dasatinib	NOUN
ajlm-1578	104	42	,	,	PUNCT
ajlm-1578	104	43	both	both	DET
ajlm-1578	104	44	agents	agent	NOUN
ajlm-1578	104	45	can	can	AUX
ajlm-1578	104	46	be	be	AUX
ajlm-1578	104	47	used	use	VERB
ajlm-1578	104	48	in	in	ADP
ajlm-1578	104	49	the	the	DET
ajlm-1578	104	50	majority	majority	NOUN
ajlm-1578	104	51	of	of	ADP
ajlm-1578	104	52	patients	patient	NOUN
ajlm-1578	104	53	with	with	ADP
ajlm-1578	104	54	mild	mild	ADJ
ajlm-1578	104	55	to	to	ADP
ajlm-1578	104	56	moderate	moderate	ADJ
ajlm-1578	104	57	renal	renal	ADJ
ajlm-1578	104	58	dysfunction	dysfunction	NOUN
ajlm-1578	104	59	as	as	ADV
ajlm-1578	104	60	well	well	ADV
ajlm-1578	104	61	as	as	ADP
ajlm-1578	104	62	those	those	PRON
ajlm-1578	104	63	with	with	ADP
ajlm-1578	104	64	mild	mild	ADJ
ajlm-1578	104	65	liver	liver	NOUN
ajlm-1578	104	66	dysfunction.32	dysfunction.32	NOUN
ajlm-1578	104	67	in	in	ADP
ajlm-1578	104	68	the	the	DET
ajlm-1578	104	69	situation	situation	NOUN
ajlm-1578	104	70	of	of	ADP
ajlm-1578	104	71	a	a	DET
ajlm-1578	104	72	t315i	t315i	NOUN
ajlm-1578	104	73	mutation	mutation	NOUN
ajlm-1578	104	74	or	or	CCONJ
ajlm-1578	104	75	treatment	treatment	NOUN
ajlm-1578	104	76	resistance	resistance	NOUN
ajlm-1578	104	77	to	to	ADP
ajlm-1578	104	78	two	two	NUM
ajlm-1578	104	79	sequential	sequential	ADJ
ajlm-1578	104	80	tkis	tkis	NOUN
ajlm-1578	104	81	,	,	PUNCT
ajlm-1578	104	82	motivation	motivation	NOUN
ajlm-1578	104	83	can	can	AUX
ajlm-1578	104	84	be	be	AUX
ajlm-1578	104	85	made	make	VERB
ajlm-1578	104	86	for	for	ADP
ajlm-1578	104	87	the	the	DET
ajlm-1578	104	88	potent	potent	ADJ
ajlm-1578	104	89	third	third	ADJ
ajlm-1578	104	90	-	-	PUNCT
ajlm-1578	104	91	generation	generation	NOUN
ajlm-1578	104	92	tki	tki	NOUN
ajlm-1578	104	93	,	,	PUNCT
ajlm-1578	104	94	ponatinib	ponatinib	NOUN
ajlm-1578	104	95	.	.	PUNCT
ajlm-1578	105	1	with	with	ADP
ajlm-1578	105	2	life	life	NOUN
ajlm-1578	105	3	expectancies	expectancy	NOUN
ajlm-1578	105	4	nearing	near	VERB
ajlm-1578	105	5	that	that	PRON
ajlm-1578	105	6	of	of	ADP
ajlm-1578	105	7	the	the	DET
ajlm-1578	105	8	general	general	ADJ
ajlm-1578	105	9	population	population	NOUN
ajlm-1578	105	10	and	and	CCONJ
ajlm-1578	105	11	the	the	DET
ajlm-1578	105	12	associated	associated	ADJ
ajlm-1578	105	13	chronicity	chronicity	NOUN
ajlm-1578	105	14	of	of	ADP
ajlm-1578	105	15	treatment	treatment	NOUN
ajlm-1578	105	16	,	,	PUNCT
ajlm-1578	105	17	the	the	DET
ajlm-1578	105	18	practice	practice	NOUN
ajlm-1578	105	19	of	of	ADP
ajlm-1578	105	20	tfr	tfr	PROPN
ajlm-1578	105	21	was	be	AUX
ajlm-1578	105	22	introduced	introduce	VERB
ajlm-1578	105	23	.	.	PUNCT
ajlm-1578	106	1	this	this	PRON
ajlm-1578	106	2	refers	refer	VERB
ajlm-1578	106	3	to	to	ADP
ajlm-1578	106	4	the	the	DET
ajlm-1578	106	5	discontinuation	discontinuation	NOUN
ajlm-1578	106	6	of	of	ADP
ajlm-1578	106	7	tki	tki	NOUN
ajlm-1578	106	8	therapy	therapy	NOUN
ajlm-1578	106	9	with	with	ADP
ajlm-1578	106	10	a	a	DET
ajlm-1578	106	11	durable	durable	ADJ
ajlm-1578	106	12	off	off	ADP
ajlm-1578	106	13	-	-	PUNCT
ajlm-1578	106	14	treatment	treatment	NOUN
ajlm-1578	106	15	molecular	molecular	ADJ
ajlm-1578	106	16	response	response	NOUN
ajlm-1578	106	17	.	.	PUNCT
ajlm-1578	107	1	treatment	treatment	NOUN
ajlm-1578	107	2	-	-	PUNCT
ajlm-1578	107	3	free	free	ADJ
ajlm-1578	107	4	remission	remission	NOUN
ajlm-1578	107	5	aims	aim	VERB
ajlm-1578	107	6	to	to	PART
ajlm-1578	107	7	limit	limit	VERB
ajlm-1578	107	8	drug	drug	NOUN
ajlm-1578	107	9	toxicities	toxicity	NOUN
ajlm-1578	107	10	and	and	CCONJ
ajlm-1578	107	11	adverse	adverse	ADJ
ajlm-1578	107	12	effects	effect	NOUN
ajlm-1578	107	13	,	,	PUNCT
ajlm-1578	107	14	reduce	reduce	VERB
ajlm-1578	107	15	the	the	DET
ajlm-1578	107	16	financial	financial	ADJ
ajlm-1578	107	17	burden	burden	NOUN
ajlm-1578	107	18	of	of	ADP
ajlm-1578	107	19	therapy	therapy	NOUN
ajlm-1578	107	20	and	and	CCONJ
ajlm-1578	107	21	prevent	prevent	VERB
ajlm-1578	107	22	teratogenicity	teratogenicity	NOUN
ajlm-1578	107	23	.	.	PUNCT
ajlm-1578	108	1	several	several	ADJ
ajlm-1578	108	2	guidelines	guideline	NOUN
ajlm-1578	108	3	have	have	AUX
ajlm-1578	108	4	been	be	AUX
ajlm-1578	108	5	developed	develop	VERB
ajlm-1578	108	6	to	to	PART
ajlm-1578	108	7	identify	identify	VERB
ajlm-1578	108	8	patients	patient	NOUN
ajlm-1578	108	9	eligible	eligible	ADJ
ajlm-1578	108	10	for	for	ADP
ajlm-1578	108	11	tfr	tfr	PROPN
ajlm-1578	108	12	;	;	PUNCT
ajlm-1578	108	13	the	the	DET
ajlm-1578	108	14	criteria	criterion	NOUN
ajlm-1578	108	15	include	include	VERB
ajlm-1578	108	16	age	age	PROPN
ajlm-1578	108	17	≥	≥	NUM
ajlm-1578	108	18	18	18	NUM
ajlm-1578	108	19	years	year	NOUN
ajlm-1578	108	20	,	,	PUNCT
ajlm-1578	108	21	the	the	DET
ajlm-1578	108	22	presence	presence	NOUN
ajlm-1578	108	23	of	of	ADP
ajlm-1578	108	24	typical	typical	ADJ
ajlm-1578	108	25	bcr	bcr	PROPN
ajlm-1578	108	26	-	-	ADJ
ajlm-1578	108	27	abl1	abl1	ADJ
ajlm-1578	108	28	transcripts	transcript	NOUN
ajlm-1578	108	29	,	,	PUNCT
ajlm-1578	108	30	tki	tki	X
ajlm-1578	108	31	therapy	therapy	NOUN
ajlm-1578	108	32	used	use	VERB
ajlm-1578	108	33	for	for	ADP
ajlm-1578	108	34	a	a	DET
ajlm-1578	108	35	minimum	minimum	NOUN
ajlm-1578	108	36	of	of	ADP
ajlm-1578	108	37	five	five	NUM
ajlm-1578	108	38	years	year	NOUN
ajlm-1578	108	39	,	,	PUNCT
ajlm-1578	108	40	the	the	DET
ajlm-1578	108	41	achievement	achievement	NOUN
ajlm-1578	108	42	of	of	ADP
ajlm-1578	108	43	a	a	DET
ajlm-1578	108	44	deep	deep	ADJ
ajlm-1578	108	45	molecular	molecular	ADJ
ajlm-1578	108	46	response	response	NOUN
ajlm-1578	108	47	(	(	PUNCT
ajlm-1578	108	48	dmr	dmr	NOUN
ajlm-1578	108	49	)	)	PUNCT
ajlm-1578	108	50	≤	≤	NUM
ajlm-1578	108	51	4.5	4.5	NUM
ajlm-1578	108	52	,	,	PUNCT
ajlm-1578	108	53	a	a	DET
ajlm-1578	108	54	sustained	sustained	ADJ
ajlm-1578	108	55	dmr	dmr	NOUN
ajlm-1578	108	56	of	of	ADP
ajlm-1578	108	57	≤	≤	NUM
ajlm-1578	108	58	4–4.5	4–4.5	PROPN
ajlm-1578	108	59	for	for	ADP
ajlm-1578	108	60	≥	≥	NOUN
ajlm-1578	108	61	2–3	2–3	NUM
ajlm-1578	108	62	years	year	NOUN
ajlm-1578	108	63	,	,	PUNCT
ajlm-1578	108	64	no	no	DET
ajlm-1578	108	65	prior	prior	ADJ
ajlm-1578	108	66	history	history	NOUN
ajlm-1578	108	67	of	of	ADP
ajlm-1578	108	68	accelerated	accelerate	VERB
ajlm-1578	108	69	or	or	CCONJ
ajlm-1578	108	70	bc	bc	PROPN
ajlm-1578	108	71	-	-	PUNCT
ajlm-1578	108	72	cml	cml	PROPN
ajlm-1578	108	73	and	and	CCONJ
ajlm-1578	108	74	the	the	DET
ajlm-1578	108	75	ability	ability	NOUN
ajlm-1578	108	76	to	to	PART
ajlm-1578	108	77	perform	perform	VERB
ajlm-1578	108	78	frequent	frequent	ADJ
ajlm-1578	108	79	(	(	PUNCT
ajlm-1578	108	80	monthly	monthly	ADJ
ajlm-1578	108	81	initially	initially	ADV
ajlm-1578	108	82	)	)	PUNCT
ajlm-1578	108	83	responses	response	NOUN
ajlm-1578	108	84	by	by	ADP
ajlm-1578	108	85	quantitative	quantitative	ADJ
ajlm-1578	108	86	reverse	reverse	ADJ
ajlm-1578	108	87	transcriptase	transcriptase	NOUN
ajlm-1578	108	88	-	-	PUNCT
ajlm-1578	108	89	polymerase	polymerase	NOUN
ajlm-1578	108	90	chain	chain	NOUN
ajlm-1578	108	91	reaction	reaction	NOUN
ajlm-1578	108	92	testing	testing	NOUN
ajlm-1578	108	93	which	which	PRON
ajlm-1578	108	94	is	be	AUX
ajlm-1578	108	95	both	both	PRON
ajlm-1578	108	96	sensitive	sensitive	ADJ
ajlm-1578	108	97	(	(	PUNCT
ajlm-1578	108	98	minimum	minimum	NOUN
ajlm-1578	108	99	mr	mr	PROPN
ajlm-1578	108	100	4.5	4.5	NUM
ajlm-1578	108	101	)	)	PUNCT
ajlm-1578	108	102	and	and	CCONJ
ajlm-1578	108	103	delivered	deliver	VERB
ajlm-1578	108	104	within	within	ADP
ajlm-1578	108	105	a	a	DET
ajlm-1578	108	106	rapid	rapid	ADJ
ajlm-1578	108	107	turnaround	turnaround	NOUN
ajlm-1578	108	108	time.33,34,35	time.33,34,35	NOUN
ajlm-1578	108	109	given	give	VERB
ajlm-1578	108	110	these	these	DET
ajlm-1578	108	111	requirements	requirement	NOUN
ajlm-1578	108	112	,	,	PUNCT
ajlm-1578	108	113	tfr	tfr	PROPN
ajlm-1578	108	114	is	be	AUX
ajlm-1578	108	115	not	not	PART
ajlm-1578	108	116	commonplace	commonplace	ADJ
ajlm-1578	108	117	in	in	ADP
ajlm-1578	108	118	the	the	DET
ajlm-1578	108	119	south	south	ADJ
ajlm-1578	108	120	african	african	ADJ
ajlm-1578	108	121	public	public	ADJ
ajlm-1578	108	122	sector	sector	NOUN
ajlm-1578	108	123	,	,	PUNCT
ajlm-1578	108	124	because	because	SCONJ
ajlm-1578	108	125	it	it	PRON
ajlm-1578	108	126	requires	require	VERB
ajlm-1578	108	127	frequent	frequent	ADJ
ajlm-1578	108	128	follow	follow	NOUN
ajlm-1578	108	129	-	-	PUNCT
ajlm-1578	108	130	ups	up	NOUN
ajlm-1578	108	131	and	and	CCONJ
ajlm-1578	108	132	timeous	timeous	ADJ
ajlm-1578	108	133	molecular	molecular	ADJ
ajlm-1578	108	134	results	result	NOUN
ajlm-1578	108	135	.	.	PUNCT
ajlm-1578	109	1	the	the	DET
ajlm-1578	109	2	reported	report	VERB
ajlm-1578	109	3	success	success	NOUN
ajlm-1578	109	4	of	of	ADP
ajlm-1578	109	5	tfr	tfr	PROPN
ajlm-1578	109	6	is	be	AUX
ajlm-1578	109	7	about	about	ADV
ajlm-1578	109	8	40	40	NUM
ajlm-1578	109	9	%	%	NOUN
ajlm-1578	109	10	to	to	PART
ajlm-1578	109	11	60	60	NUM
ajlm-1578	109	12	%	%	NOUN
ajlm-1578	109	13	,	,	PUNCT
ajlm-1578	109	14	with	with	ADP
ajlm-1578	109	15	the	the	DET
ajlm-1578	109	16	possibility	possibility	NOUN
ajlm-1578	109	17	to	to	PART
ajlm-1578	109	18	regain	regain	VERB
ajlm-1578	109	19	a	a	DET
ajlm-1578	109	20	dmr	dmr	NOUN
ajlm-1578	109	21	in	in	ADP
ajlm-1578	109	22	those	those	PRON
ajlm-1578	109	23	who	who	PRON
ajlm-1578	109	24	fail	fail	VERB
ajlm-1578	109	25	if	if	SCONJ
ajlm-1578	109	26	intervention	intervention	NOUN
ajlm-1578	109	27	is	be	AUX
ajlm-1578	109	28	prompt.36	prompt.36	NOUN
ajlm-1578	109	29	thus	thus	ADV
ajlm-1578	109	30	future	future	ADJ
ajlm-1578	109	31	studies	study	NOUN
ajlm-1578	109	32	should	should	AUX
ajlm-1578	109	33	aim	aim	VERB
ajlm-1578	109	34	to	to	PART
ajlm-1578	109	35	identify	identify	VERB
ajlm-1578	109	36	factors	factor	NOUN
ajlm-1578	109	37	that	that	PRON
ajlm-1578	109	38	can	can	AUX
ajlm-1578	109	39	predict	predict	VERB
ajlm-1578	109	40	a	a	DET
ajlm-1578	109	41	successful	successful	ADJ
ajlm-1578	109	42	tfr	tfr	X
ajlm-1578	109	43	.	.	PUNCT
ajlm-1578	110	1	the	the	DET
ajlm-1578	110	2	median	median	PROPN
ajlm-1578	110	3	os	os	NOUN
ajlm-1578	110	4	in	in	ADP
ajlm-1578	110	5	our	our	PRON
ajlm-1578	110	6	cohort	cohort	NOUN
ajlm-1578	110	7	was	be	AUX
ajlm-1578	110	8	almost	almost	ADV
ajlm-1578	110	9	half	half	NOUN
ajlm-1578	110	10	of	of	ADP
ajlm-1578	110	11	that	that	PRON
ajlm-1578	110	12	reported	report	VERB
ajlm-1578	110	13	in	in	ADP
ajlm-1578	110	14	a	a	DET
ajlm-1578	110	15	united	united	ADJ
ajlm-1578	110	16	states	states	PROPN
ajlm-1578	110	17	-	-	PUNCT
ajlm-1578	110	18	based	base	VERB
ajlm-1578	110	19	study	study	NOUN
ajlm-1578	110	20	(	(	PUNCT
ajlm-1578	110	21	7	7	NUM
ajlm-1578	110	22	vs	vs	ADP
ajlm-1578	110	23	12	12	NUM
ajlm-1578	110	24	months	month	NOUN
ajlm-1578	110	25	)	)	PUNCT
ajlm-1578	110	26	,	,	PUNCT
ajlm-1578	110	27	driven	drive	VERB
ajlm-1578	110	28	by	by	ADP
ajlm-1578	110	29	a	a	DET
ajlm-1578	110	30	substantial	substantial	ADJ
ajlm-1578	110	31	proportion	proportion	NOUN
ajlm-1578	110	32	of	of	ADP
ajlm-1578	110	33	patients	patient	NOUN
ajlm-1578	110	34	with	with	ADP
ajlm-1578	110	35	early	early	ADJ
ajlm-1578	110	36	deaths	death	NOUN
ajlm-1578	110	37	(	(	PUNCT
ajlm-1578	110	38	defined	define	VERB
ajlm-1578	110	39	as	as	ADP
ajlm-1578	110	40	deaths	death	NOUN
ajlm-1578	110	41	within	within	ADP
ajlm-1578	110	42	the	the	DET
ajlm-1578	110	43	first	first	ADJ
ajlm-1578	110	44	month	month	NOUN
ajlm-1578	110	45	of	of	ADP
ajlm-1578	110	46	diagnosis).19	diagnosis).19	PROPN
ajlm-1578	110	47	these	these	PRON
ajlm-1578	110	48	were	be	AUX
ajlm-1578	110	49	predominantly	predominantly	ADV
ajlm-1578	110	50	sepsis	sepsis	NOUN
ajlm-1578	110	51	-	-	PUNCT
ajlm-1578	110	52	related	relate	VERB
ajlm-1578	110	53	,	,	PUNCT
ajlm-1578	110	54	highlighting	highlight	VERB
ajlm-1578	110	55	the	the	DET
ajlm-1578	110	56	need	need	NOUN
ajlm-1578	110	57	for	for	ADP
ajlm-1578	110	58	improved	improved	ADJ
ajlm-1578	110	59	and	and	CCONJ
ajlm-1578	110	60	optimised	optimise	VERB
ajlm-1578	110	61	supportive	supportive	ADJ
ajlm-1578	110	62	care	care	NOUN
ajlm-1578	110	63	for	for	ADP
ajlm-1578	110	64	these	these	DET
ajlm-1578	110	65	patients	patient	NOUN
ajlm-1578	110	66	.	.	PUNCT
ajlm-1578	111	1	in	in	ADP
ajlm-1578	111	2	our	our	PRON
ajlm-1578	111	3	setting	setting	NOUN
ajlm-1578	111	4	,	,	PUNCT
ajlm-1578	111	5	bc	bc	PROPN
ajlm-1578	111	6	-	-	PUNCT
ajlm-1578	111	7	cml	cml	PROPN
ajlm-1578	111	8	is	be	AUX
ajlm-1578	111	9	treated	treat	VERB
ajlm-1578	111	10	with	with	ADP
ajlm-1578	111	11	high	high	ADJ
ajlm-1578	111	12	dose	dose	NOUN
ajlm-1578	111	13	imatinib	imatinib	NOUN
ajlm-1578	111	14	mesylate	mesylate	NOUN
ajlm-1578	111	15	and	and	CCONJ
ajlm-1578	111	16	combination	combination	NOUN
ajlm-1578	111	17	chemotherapy	chemotherapy	NOUN
ajlm-1578	111	18	,	,	PUNCT
ajlm-1578	111	19	the	the	DET
ajlm-1578	111	20	latter	latter	ADJ
ajlm-1578	111	21	determined	determine	VERB
ajlm-1578	111	22	by	by	ADP
ajlm-1578	111	23	the	the	DET
ajlm-1578	111	24	blast	blast	NOUN
ajlm-1578	111	25	lineage.37	lineage.37	NOUN
ajlm-1578	111	26	additionally	additionally	ADV
ajlm-1578	111	27	,	,	PUNCT
ajlm-1578	111	28	intrathecal	intrathecal	ADJ
ajlm-1578	111	29	chemotherapy	chemotherapy	NOUN
ajlm-1578	111	30	is	be	AUX
ajlm-1578	111	31	initiated	initiate	VERB
ajlm-1578	111	32	in	in	ADP
ajlm-1578	111	33	patients	patient	NOUN
ajlm-1578	111	34	with	with	ADP
ajlm-1578	111	35	lymphoid	lymphoid	ADJ
ajlm-1578	111	36	bc	bc	PROPN
ajlm-1578	111	37	-	-	PUNCT
ajlm-1578	111	38	cml	cml	PROPN
ajlm-1578	111	39	.	.	PUNCT
ajlm-1578	112	1	at	at	ADP
ajlm-1578	112	2	the	the	DET
ajlm-1578	112	3	time	time	NOUN
ajlm-1578	112	4	of	of	ADP
ajlm-1578	112	5	the	the	DET
ajlm-1578	112	6	study	study	NOUN
ajlm-1578	112	7	,	,	PUNCT
ajlm-1578	112	8	allosct	allosct	PROPN
ajlm-1578	112	9	was	be	AUX
ajlm-1578	112	10	not	not	PART
ajlm-1578	112	11	routinely	routinely	ADV
ajlm-1578	112	12	available	available	ADJ
ajlm-1578	112	13	at	at	ADP
ajlm-1578	112	14	any	any	PRON
ajlm-1578	112	15	of	of	ADP
ajlm-1578	112	16	the	the	DET
ajlm-1578	112	17	treatment	treatment	NOUN
ajlm-1578	112	18	centres	centre	NOUN
ajlm-1578	112	19	in	in	ADP
ajlm-1578	112	20	this	this	DET
ajlm-1578	112	21	cohort	cohort	NOUN
ajlm-1578	112	22	,	,	PUNCT
ajlm-1578	112	23	further	far	ADV
ajlm-1578	112	24	driving	drive	VERB
ajlm-1578	112	25	the	the	DET
ajlm-1578	112	26	poor	poor	ADJ
ajlm-1578	112	27	outcomes.38,39,40,41	outcomes.38,39,40,41	NOUN
ajlm-1578	112	28	reports	report	NOUN
ajlm-1578	112	29	suggest	suggest	VERB
ajlm-1578	112	30	that	that	SCONJ
ajlm-1578	112	31	allosct	allosct	PROPN
ajlm-1578	112	32	gives	give	VERB
ajlm-1578	112	33	the	the	DET
ajlm-1578	112	34	best	good	ADJ
ajlm-1578	112	35	chance	chance	NOUN
ajlm-1578	112	36	of	of	ADP
ajlm-1578	112	37	long	long	ADJ
ajlm-1578	112	38	-	-	PUNCT
ajlm-1578	112	39	term	term	NOUN
ajlm-1578	112	40	remission	remission	NOUN
ajlm-1578	112	41	.	.	PUNCT
ajlm-1578	113	1	however	however	ADV
ajlm-1578	113	2	,	,	PUNCT
ajlm-1578	113	3	in	in	ADP
ajlm-1578	113	4	a	a	DET
ajlm-1578	113	5	minority	minority	NOUN
ajlm-1578	113	6	,	,	PUNCT
ajlm-1578	113	7	there	there	PRON
ajlm-1578	113	8	could	could	AUX
ajlm-1578	113	9	be	be	AUX
ajlm-1578	113	10	a	a	DET
ajlm-1578	113	11	return	return	NOUN
ajlm-1578	113	12	to	to	ADP
ajlm-1578	113	13	pre	pre	ADJ
ajlm-1578	113	14	-	-	ADJ
ajlm-1578	113	15	transplantation	transplantation	ADJ
ajlm-1578	113	16	chronic	chronic	ADJ
ajlm-1578	113	17	phase	phase	NOUN
ajlm-1578	113	18	disease.37,42	disease.37,42	NOUN
ajlm-1578	113	19	globally	globally	ADV
ajlm-1578	113	20	,	,	PUNCT
ajlm-1578	113	21	the	the	DET
ajlm-1578	113	22	outcomes	outcome	NOUN
ajlm-1578	113	23	of	of	ADP
ajlm-1578	113	24	bc	bc	PROPN
ajlm-1578	113	25	-	-	PUNCT
ajlm-1578	113	26	cml	cml	PROPN
ajlm-1578	113	27	are	be	AUX
ajlm-1578	113	28	poor	poor	ADJ
ajlm-1578	113	29	and	and	CCONJ
ajlm-1578	113	30	novel	novel	ADJ
ajlm-1578	113	31	treatment	treatment	NOUN
ajlm-1578	113	32	approaches	approach	NOUN
ajlm-1578	113	33	are	be	AUX
ajlm-1578	113	34	needed	need	VERB
ajlm-1578	113	35	.	.	PUNCT
ajlm-1578	114	1	experience	experience	NOUN
ajlm-1578	114	2	in	in	ADP
ajlm-1578	114	3	the	the	DET
ajlm-1578	114	4	united	united	PROPN
ajlm-1578	114	5	states	states	PROPN
ajlm-1578	114	6	with	with	ADP
ajlm-1578	114	7	dasatinib	dasatinib	NOUN
ajlm-1578	114	8	monotherapy	monotherapy	NOUN
ajlm-1578	114	9	showed	show	VERB
ajlm-1578	114	10	a	a	DET
ajlm-1578	114	11	median	median	ADJ
ajlm-1578	114	12	os	os	NOUN
ajlm-1578	114	13	of	of	ADP
ajlm-1578	114	14	11.8	11.8	NUM
ajlm-1578	114	15	months	month	NOUN
ajlm-1578	114	16	in	in	ADP
ajlm-1578	114	17	myeloid	myeloid	NOUN
ajlm-1578	114	18	and	and	CCONJ
ajlm-1578	114	19	and	and	CCONJ
ajlm-1578	114	20	5.3	5.3	NUM
ajlm-1578	114	21	months	month	NOUN
ajlm-1578	114	22	in	in	ADP
ajlm-1578	114	23	lymphoid	lymphoid	ADJ
ajlm-1578	114	24	bc	bc	PROPN
ajlm-1578	114	25	-	-	NOUN
ajlm-1578	114	26	cml.43	cml.43	VERB
ajlm-1578	114	27	the	the	DET
ajlm-1578	114	28	combination	combination	NOUN
ajlm-1578	114	29	of	of	ADP
ajlm-1578	114	30	hyper	hyper	NOUN
ajlm-1578	114	31	-	-	NOUN
ajlm-1578	114	32	cvad	cvad	NOUN
ajlm-1578	114	33	(	(	PUNCT
ajlm-1578	114	34	hyperfractionated	hyperfractionated	ADJ
ajlm-1578	114	35	cyclophosphamide	cyclophosphamide	NOUN
ajlm-1578	114	36	,	,	PUNCT
ajlm-1578	114	37	vincristine	vincristine	NOUN
ajlm-1578	114	38	sulfate	sulfate	NOUN
ajlm-1578	114	39	,	,	PUNCT
ajlm-1578	114	40	doxorubicin	doxorubicin	PROPN
ajlm-1578	114	41	hydrochloride	hydrochloride	NOUN
ajlm-1578	114	42	,	,	PUNCT
ajlm-1578	114	43	and	and	CCONJ
ajlm-1578	114	44	dexamethasone	dexamethasone	NOUN
ajlm-1578	114	45	)	)	PUNCT
ajlm-1578	114	46	with	with	ADP
ajlm-1578	114	47	dasatinib	dasatinib	NOUN
ajlm-1578	114	48	in	in	ADP
ajlm-1578	114	49	lymphoid	lymphoid	ADJ
ajlm-1578	114	50	bc	bc	PROPN
ajlm-1578	114	51	-	-	PUNCT
ajlm-1578	114	52	cml	cml	PROPN
ajlm-1578	114	53	resulted	result	VERB
ajlm-1578	114	54	in	in	ADP
ajlm-1578	114	55	a	a	DET
ajlm-1578	114	56	5	5	NUM
ajlm-1578	114	57	-	-	PUNCT
ajlm-1578	114	58	year	year	NOUN
ajlm-1578	114	59	os	os	NOUN
ajlm-1578	114	60	rate	rate	NOUN
ajlm-1578	114	61	approaching	approach	VERB
ajlm-1578	114	62	60	60	NUM
ajlm-1578	114	63	%	%	NOUN
ajlm-1578	114	64	,	,	PUNCT
ajlm-1578	114	65	which	which	PRON
ajlm-1578	114	66	was	be	AUX
ajlm-1578	114	67	further	far	ADV
ajlm-1578	114	68	improved	improve	VERB
ajlm-1578	114	69	to	to	ADP
ajlm-1578	114	70	88	88	NUM
ajlm-1578	114	71	%	%	NOUN
ajlm-1578	114	72	when	when	SCONJ
ajlm-1578	114	73	followed	follow	VERB
ajlm-1578	114	74	by	by	ADP
ajlm-1578	114	75	allosct	allosct	PROPN
ajlm-1578	114	76	in	in	ADP
ajlm-1578	114	77	the	the	DET
ajlm-1578	114	78	first	first	ADJ
ajlm-1578	114	79	remission.40,44	remission.40,44	NOUN
ajlm-1578	114	80	use	use	NOUN
ajlm-1578	114	81	of	of	ADP
ajlm-1578	114	82	the	the	DET
ajlm-1578	114	83	selective	selective	ADJ
ajlm-1578	114	84	bcl2	bcl2	NOUN
ajlm-1578	114	85	inhibitor	inhibitor	NOUN
ajlm-1578	114	86	venetoclax	venetoclax	NOUN
ajlm-1578	114	87	has	have	AUX
ajlm-1578	114	88	shown	show	VERB
ajlm-1578	114	89	synergistic	synergistic	ADJ
ajlm-1578	114	90	effect	effect	NOUN
ajlm-1578	114	91	when	when	SCONJ
ajlm-1578	114	92	used	use	VERB
ajlm-1578	114	93	in	in	ADP
ajlm-1578	114	94	combination	combination	NOUN
ajlm-1578	114	95	with	with	ADP
ajlm-1578	114	96	dasatinib	dasatinib	NOUN
ajlm-1578	114	97	in	in	ADP
ajlm-1578	114	98	heavily	heavily	ADV
ajlm-1578	114	99	pre	pre	ADJ
ajlm-1578	114	100	-	-	ADJ
ajlm-1578	114	101	treated	treat	VERB
ajlm-1578	114	102	patients	patient	NOUN
ajlm-1578	114	103	with	with	ADP
ajlm-1578	114	104	bc	bc	PROPN
ajlm-1578	114	105	-	-	PUNCT
ajlm-1578	114	106	cml	cml	PROPN
ajlm-1578	114	107	(	(	PUNCT
ajlm-1578	114	108	myeloid	myeloid	NOUN
ajlm-1578	114	109	)	)	PUNCT
ajlm-1578	114	110	,	,	PUNCT
ajlm-1578	114	111	with	with	ADP
ajlm-1578	114	112	a	a	DET
ajlm-1578	114	113	median	median	ADJ
ajlm-1578	114	114	os	os	NOUN
ajlm-1578	114	115	of	of	ADP
ajlm-1578	114	116	10.9	10.9	NUM
ajlm-1578	114	117	months	month	NOUN
ajlm-1578	114	118	(	(	PUNCT
ajlm-1578	114	119	with	with	ADP
ajlm-1578	114	120	particular	particular	ADJ
ajlm-1578	114	121	benefit	benefit	NOUN
ajlm-1578	114	122	noted	note	VERB
ajlm-1578	114	123	in	in	ADP
ajlm-1578	114	124	those	those	PRON
ajlm-1578	114	125	with	with	ADP
ajlm-1578	114	126	a	a	DET
ajlm-1578	114	127	dominant	dominant	ADJ
ajlm-1578	114	128	bc	bc	ADJ
ajlm-1578	114	129	-	-	PUNCT
ajlm-1578	114	130	cmlr	cmlr	NOUN
ajlm-1578	114	131	-	-	PUNCT
ajlm-1578	114	132	abl1	abl1	NOUN
ajlm-1578	114	133	clone).45	clone).45	PROPN
ajlm-1578	114	134	unfortunately	unfortunately	ADV
ajlm-1578	114	135	,	,	PUNCT
ajlm-1578	114	136	these	these	DET
ajlm-1578	114	137	novel	novel	ADJ
ajlm-1578	114	138	agents	agent	NOUN
ajlm-1578	114	139	and	and	CCONJ
ajlm-1578	114	140	combination	combination	NOUN
ajlm-1578	114	141	therapies	therapy	NOUN
ajlm-1578	114	142	are	be	AUX
ajlm-1578	114	143	not	not	PART
ajlm-1578	114	144	available	available	ADJ
ajlm-1578	114	145	within	within	ADP
ajlm-1578	114	146	the	the	DET
ajlm-1578	114	147	south	south	ADJ
ajlm-1578	114	148	african	african	ADJ
ajlm-1578	114	149	state	state	NOUN
ajlm-1578	114	150	sector	sector	NOUN
ajlm-1578	114	151	and	and	CCONJ
ajlm-1578	114	152	allosct	allosct	PROPN
ajlm-1578	114	153	is	be	AUX
ajlm-1578	114	154	not	not	PART
ajlm-1578	114	155	uniformly	uniformly	ADV
ajlm-1578	114	156	accessible	accessible	ADJ
ajlm-1578	114	157	.	.	PUNCT
ajlm-1578	115	1	there	there	PRON
ajlm-1578	115	2	is	be	VERB
ajlm-1578	115	3	a	a	DET
ajlm-1578	115	4	great	great	ADJ
ajlm-1578	115	5	need	need	NOUN
ajlm-1578	115	6	to	to	PART
ajlm-1578	115	7	advocate	advocate	VERB
ajlm-1578	115	8	for	for	ADP
ajlm-1578	115	9	these	these	DET
ajlm-1578	115	10	new	new	ADJ
ajlm-1578	115	11	and	and	CCONJ
ajlm-1578	115	12	novel	novel	ADJ
ajlm-1578	115	13	approaches	approach	NOUN
ajlm-1578	115	14	to	to	PART
ajlm-1578	115	15	improve	improve	VERB
ajlm-1578	115	16	the	the	DET
ajlm-1578	115	17	currently	currently	ADV
ajlm-1578	115	18	dismal	dismal	ADJ
ajlm-1578	115	19	outcome	outcome	NOUN
ajlm-1578	115	20	of	of	ADP
ajlm-1578	115	21	this	this	DET
ajlm-1578	115	22	disease	disease	NOUN
ajlm-1578	115	23	in	in	ADP
ajlm-1578	115	24	our	our	PRON
ajlm-1578	115	25	setting.37	setting.37	NOUN
ajlm-1578	115	26	a	a	DET
ajlm-1578	115	27	separate	separate	ADJ
ajlm-1578	115	28	challenge	challenge	NOUN
ajlm-1578	115	29	faced	face	VERB
ajlm-1578	115	30	for	for	ADP
ajlm-1578	115	31	clinicians	clinician	NOUN
ajlm-1578	115	32	in	in	ADP
ajlm-1578	115	33	the	the	DET
ajlm-1578	115	34	management	management	NOUN
ajlm-1578	115	35	of	of	ADP
ajlm-1578	115	36	cml	cml	PROPN
ajlm-1578	115	37	is	be	AUX
ajlm-1578	115	38	the	the	DET
ajlm-1578	115	39	need	need	NOUN
ajlm-1578	115	40	to	to	PART
ajlm-1578	115	41	screen	screen	VERB
ajlm-1578	115	42	and	and	CCONJ
ajlm-1578	115	43	monitor	monitor	VERB
ajlm-1578	115	44	for	for	ADP
ajlm-1578	115	45	the	the	DET
ajlm-1578	115	46	development	development	NOUN
ajlm-1578	115	47	of	of	ADP
ajlm-1578	115	48	cardovascular	cardovascular	ADJ
ajlm-1578	115	49	events	event	NOUN
ajlm-1578	115	50	and	and	CCONJ
ajlm-1578	115	51	second	second	ADJ
ajlm-1578	115	52	malignancies.46	malignancies.46	NOUN
ajlm-1578	115	53	there	there	PRON
ajlm-1578	115	54	is	be	VERB
ajlm-1578	115	55	a	a	DET
ajlm-1578	115	56	significantly	significantly	ADV
ajlm-1578	115	57	increased	increase	VERB
ajlm-1578	115	58	incidence	incidence	NOUN
ajlm-1578	115	59	of	of	ADP
ajlm-1578	115	60	cardiovascular	cardiovascular	ADJ
ajlm-1578	115	61	and	and	CCONJ
ajlm-1578	115	62	arteriothrombotic	arteriothrombotic	ADJ
ajlm-1578	115	63	events	event	NOUN
ajlm-1578	115	64	(	(	PUNCT
ajlm-1578	115	65	incidence	incidence	NOUN
ajlm-1578	115	66	ratio	ratio	NOUN
ajlm-1578	115	67	95	95	NUM
ajlm-1578	115	68	%	%	NOUN
ajlm-1578	115	69	confidence	confidence	NOUN
ajlm-1578	115	70	interval	interval	NOUN
ajlm-1578	115	71	:	:	PUNCT
ajlm-1578	115	72	for	for	ADP
ajlm-1578	115	73	cardiovascular	cardiovascular	NOUN
ajlm-1578	115	74	of	of	ADP
ajlm-1578	115	75	8.6	8.6	NUM
ajlm-1578	116	1	[	[	X
ajlm-1578	116	2	7.6–9.8	7.6–9.8	X
ajlm-1578	116	3	]	]	X
ajlm-1578	116	4	,	,	PUNCT
ajlm-1578	116	5	and	and	CCONJ
ajlm-1578	116	6	for	for	ADP
ajlm-1578	116	7	arteriothrombotic	arteriothrombotic	NOUN
ajlm-1578	116	8	of	of	ADP
ajlm-1578	116	9	1.7	1.7	NUM
ajlm-1578	117	1	[	[	X
ajlm-1578	117	2	1.2–2.2	1.2–2.2	X
ajlm-1578	117	3	]	]	X
ajlm-1578	117	4	)	)	PUNCT
ajlm-1578	117	5	in	in	ADP
ajlm-1578	117	6	patients	patient	NOUN
ajlm-1578	117	7	using	use	VERB
ajlm-1578	117	8	second	second	ADJ
ajlm-1578	117	9	and	and	CCONJ
ajlm-1578	117	10	third	third	ADJ
ajlm-1578	117	11	-	-	PUNCT
ajlm-1578	117	12	generation	generation	NOUN
ajlm-1578	117	13	tkis	tkis	NOUN
ajlm-1578	117	14	(	(	PUNCT
ajlm-1578	117	15	except	except	SCONJ
ajlm-1578	117	16	bosutinib	bosutinib	NOUN
ajlm-1578	117	17	)	)	PUNCT
ajlm-1578	117	18	and	and	CCONJ
ajlm-1578	117	19	in	in	ADP
ajlm-1578	117	20	individuals	individual	NOUN
ajlm-1578	117	21	with	with	ADP
ajlm-1578	117	22	pre	pre	ADJ
ajlm-1578	117	23	-	-	ADJ
ajlm-1578	117	24	existing	exist	VERB
ajlm-1578	117	25	cardiovascular	cardiovascular	ADJ
ajlm-1578	117	26	risk	risk	NOUN
ajlm-1578	117	27	factors.46,47	factors.46,47	NOUN
ajlm-1578	117	28	in	in	ADP
ajlm-1578	117	29	regard	regard	NOUN
ajlm-1578	117	30	to	to	ADP
ajlm-1578	117	31	second	second	ADJ
ajlm-1578	117	32	malignancies	malignancy	NOUN
ajlm-1578	117	33	,	,	PUNCT
ajlm-1578	117	34	a	a	DET
ajlm-1578	117	35	large	large	ADJ
ajlm-1578	117	36	united	united	ADJ
ajlm-1578	117	37	states	states	PROPN
ajlm-1578	117	38	-	-	PUNCT
ajlm-1578	117	39	based	base	VERB
ajlm-1578	117	40	study	study	NOUN
ajlm-1578	117	41	reported	report	VERB
ajlm-1578	117	42	a	a	DET
ajlm-1578	117	43	slightly	slightly	ADV
ajlm-1578	117	44	increased	increase	VERB
ajlm-1578	117	45	risk	risk	NOUN
ajlm-1578	117	46	of	of	ADP
ajlm-1578	117	47	cml	cml	PROPN
ajlm-1578	117	48	(	(	PUNCT
ajlm-1578	117	49	overall	overall	ADJ
ajlm-1578	117	50	standardised	standardised	ADJ
ajlm-1578	117	51	incidence	incidence	NOUN
ajlm-1578	117	52	ratio	ratio	NOUN
ajlm-1578	117	53	of	of	ADP
ajlm-1578	117	54	1.204	1.204	NUM
ajlm-1578	117	55	,	,	PUNCT
ajlm-1578	117	56	95	95	NUM
ajlm-1578	117	57	%	%	NOUN
ajlm-1578	117	58	confidence	confidence	NOUN
ajlm-1578	117	59	interval	interval	NOUN
ajlm-1578	117	60	:	:	PUNCT
ajlm-1578	117	61	1.108–1.301	1.108–1.301	NUM
ajlm-1578	117	62	,	,	PUNCT
ajlm-1578	117	63	except	except	SCONJ
ajlm-1578	117	64	breast	breast	NOUN
ajlm-1578	117	65	cancer	cancer	NOUN
ajlm-1578	117	66	)	)	PUNCT
ajlm-1578	117	67	and	and	CCONJ
ajlm-1578	117	68	a	a	DET
ajlm-1578	117	69	higher	high	ADJ
ajlm-1578	117	70	risk	risk	NOUN
ajlm-1578	117	71	of	of	ADP
ajlm-1578	117	72	death	death	NOUN
ajlm-1578	117	73	in	in	ADP
ajlm-1578	117	74	this	this	DET
ajlm-1578	117	75	group.44	group.44	NOUN
ajlm-1578	117	76	the	the	DET
ajlm-1578	117	77	most	most	ADV
ajlm-1578	117	78	common	common	ADJ
ajlm-1578	117	79	sites	site	NOUN
ajlm-1578	117	80	of	of	ADP
ajlm-1578	117	81	involvement	involvement	NOUN
ajlm-1578	117	82	included	include	VERB
ajlm-1578	117	83	the	the	DET
ajlm-1578	117	84	digestive	digestive	NOUN
ajlm-1578	117	85	,	,	PUNCT
ajlm-1578	117	86	skin	skin	NOUN
ajlm-1578	117	87	,	,	PUNCT
ajlm-1578	117	88	and	and	CCONJ
ajlm-1578	117	89	urinary	urinary	ADJ
ajlm-1578	117	90	systems	system	NOUN
ajlm-1578	117	91	.	.	PUNCT
ajlm-1578	118	1	the	the	DET
ajlm-1578	118	2	reason	reason	NOUN
ajlm-1578	118	3	for	for	ADP
ajlm-1578	118	4	this	this	DET
ajlm-1578	118	5	increased	increase	VERB
ajlm-1578	118	6	incidence	incidence	NOUN
ajlm-1578	118	7	is	be	AUX
ajlm-1578	118	8	unknown	unknown	ADJ
ajlm-1578	118	9	but	but	CCONJ
ajlm-1578	118	10	may	may	AUX
ajlm-1578	118	11	reflect	reflect	VERB
ajlm-1578	118	12	a	a	DET
ajlm-1578	118	13	patient	patient	NOUN
ajlm-1578	118	14	-	-	PUNCT
ajlm-1578	118	15	specific	specific	ADJ
ajlm-1578	118	16	risk	risk	NOUN
ajlm-1578	118	17	of	of	ADP
ajlm-1578	118	18	malignancy	malignancy	NOUN
ajlm-1578	118	19	(	(	PUNCT
ajlm-1578	118	20	genetic	genetic	ADJ
ajlm-1578	118	21	/	/	SYM
ajlm-1578	118	22	exposure).46	exposure).46	PROPN
ajlm-1578	118	23	given	give	VERB
ajlm-1578	118	24	these	these	DET
ajlm-1578	118	25	findings	finding	NOUN
ajlm-1578	118	26	it	it	PRON
ajlm-1578	118	27	is	be	AUX
ajlm-1578	118	28	imperative	imperative	ADJ
ajlm-1578	118	29	to	to	PART
ajlm-1578	118	30	identify	identify	VERB
ajlm-1578	118	31	and	and	CCONJ
ajlm-1578	118	32	aggressively	aggressively	ADV
ajlm-1578	118	33	manage	manage	VERB
ajlm-1578	118	34	cardiovascular	cardiovascular	ADJ
ajlm-1578	118	35	risk	risk	NOUN
ajlm-1578	118	36	factors	factor	NOUN
ajlm-1578	118	37	at	at	ADP
ajlm-1578	118	38	baseline	baseline	NOUN
ajlm-1578	118	39	to	to	PART
ajlm-1578	118	40	prevent	prevent	VERB
ajlm-1578	118	41	morbidity	morbidity	NOUN
ajlm-1578	118	42	and	and	CCONJ
ajlm-1578	118	43	mortality	mortality	NOUN
ajlm-1578	118	44	.	.	PUNCT
ajlm-1578	119	1	screening	screen	VERB
ajlm-1578	119	2	for	for	ADP
ajlm-1578	119	3	second	second	ADJ
ajlm-1578	119	4	malignancies	malignancy	NOUN
ajlm-1578	119	5	poses	pose	VERB
ajlm-1578	119	6	more	more	ADJ
ajlm-1578	119	7	of	of	ADP
ajlm-1578	119	8	a	a	DET
ajlm-1578	119	9	challenge	challenge	NOUN
ajlm-1578	119	10	as	as	ADP
ajlm-1578	119	11	a	a	DET
ajlm-1578	119	12	result	result	NOUN
ajlm-1578	119	13	of	of	ADP
ajlm-1578	119	14	the	the	DET
ajlm-1578	119	15	varied	varied	ADJ
ajlm-1578	119	16	sites	site	NOUN
ajlm-1578	119	17	of	of	ADP
ajlm-1578	119	18	potential	potential	ADJ
ajlm-1578	119	19	involvement	involvement	NOUN
ajlm-1578	119	20	and	and	CCONJ
ajlm-1578	119	21	the	the	DET
ajlm-1578	119	22	costs	cost	NOUN
ajlm-1578	119	23	involved	involve	VERB
ajlm-1578	119	24	in	in	ADP
ajlm-1578	119	25	routine	routine	ADJ
ajlm-1578	119	26	radiological	radiological	ADJ
ajlm-1578	119	27	screening	screening	NOUN
ajlm-1578	119	28	and	and	CCONJ
ajlm-1578	119	29	endoscopies	endoscopy	NOUN
ajlm-1578	119	30	.	.	PUNCT
ajlm-1578	120	1	realistically	realistically	ADV
ajlm-1578	120	2	in	in	ADP
ajlm-1578	120	3	our	our	PRON
ajlm-1578	120	4	setting	setting	NOUN
ajlm-1578	120	5	,	,	PUNCT
ajlm-1578	120	6	the	the	DET
ajlm-1578	120	7	clinical	clinical	ADJ
ajlm-1578	120	8	history	history	NOUN
ajlm-1578	120	9	and	and	CCONJ
ajlm-1578	120	10	findings	finding	NOUN
ajlm-1578	120	11	are	be	AUX
ajlm-1578	120	12	used	use	VERB
ajlm-1578	120	13	as	as	ADP
ajlm-1578	120	14	a	a	DET
ajlm-1578	120	15	screening	screening	NOUN
ajlm-1578	120	16	tool	tool	NOUN
ajlm-1578	120	17	to	to	PART
ajlm-1578	120	18	identify	identify	VERB
ajlm-1578	120	19	patients	patient	NOUN
ajlm-1578	120	20	that	that	PRON
ajlm-1578	120	21	require	require	VERB
ajlm-1578	120	22	further	further	ADJ
ajlm-1578	120	23	work	work	NOUN
ajlm-1578	120	24	-	-	PUNCT
ajlm-1578	120	25	up	up	NOUN
ajlm-1578	120	26	for	for	ADP
ajlm-1578	120	27	second	second	ADJ
ajlm-1578	120	28	malignancies	malignancy	NOUN
ajlm-1578	120	29	.	.	PUNCT
ajlm-1578	121	1	at	at	ADP
ajlm-1578	121	2	present	present	ADJ
ajlm-1578	121	3	,	,	PUNCT
ajlm-1578	121	4	the	the	DET
ajlm-1578	121	5	most	most	ADV
ajlm-1578	121	6	effective	effective	ADJ
ajlm-1578	121	7	management	management	NOUN
ajlm-1578	121	8	of	of	ADP
ajlm-1578	121	9	bc	bc	PROPN
ajlm-1578	121	10	-	-	PUNCT
ajlm-1578	121	11	cml	cml	PROPN
ajlm-1578	121	12	is	be	AUX
ajlm-1578	121	13	its	its	PRON
ajlm-1578	121	14	prevention	prevention	NOUN
ajlm-1578	121	15	.	.	PUNCT
ajlm-1578	122	1	this	this	PRON
ajlm-1578	122	2	is	be	AUX
ajlm-1578	122	3	through	through	ADP
ajlm-1578	122	4	the	the	DET
ajlm-1578	122	5	achievement	achievement	NOUN
ajlm-1578	122	6	of	of	ADP
ajlm-1578	122	7	rapid	rapid	ADJ
ajlm-1578	122	8	and	and	CCONJ
ajlm-1578	122	9	deeper	deep	ADJ
ajlm-1578	122	10	molecular	molecular	ADJ
ajlm-1578	122	11	responses	response	NOUN
ajlm-1578	122	12	in	in	ADP
ajlm-1578	122	13	chronic	chronic	ADJ
ajlm-1578	122	14	and	and	CCONJ
ajlm-1578	122	15	accelerated	accelerate	VERB
ajlm-1578	122	16	disease	disease	NOUN
ajlm-1578	122	17	,	,	PUNCT
ajlm-1578	122	18	identification	identification	NOUN
ajlm-1578	122	19	of	of	ADP
ajlm-1578	122	20	high	high	ADJ
ajlm-1578	122	21	-	-	PUNCT
ajlm-1578	122	22	risk	risk	NOUN
ajlm-1578	122	23	individuals	individual	NOUN
ajlm-1578	122	24	with	with	ADP
ajlm-1578	122	25	close	close	ADJ
ajlm-1578	122	26	monitoring	monitoring	NOUN
ajlm-1578	122	27	(	(	PUNCT
ajlm-1578	122	28	laboratory	laboratory	NOUN
ajlm-1578	122	29	,	,	PUNCT
ajlm-1578	122	30	clinical	clinical	ADJ
ajlm-1578	122	31	)	)	PUNCT
ajlm-1578	122	32	and	and	CCONJ
ajlm-1578	122	33	timeous	timeous	ADJ
ajlm-1578	122	34	therapy	therapy	NOUN
ajlm-1578	122	35	changes	change	NOUN
ajlm-1578	122	36	in	in	ADP
ajlm-1578	122	37	non	non	NOUN
ajlm-1578	122	38	-	-	NOUN
ajlm-1578	122	39	responders	responder	NOUN
ajlm-1578	122	40	.	.	PUNCT
ajlm-1578	123	1	more	more	ADJ
ajlm-1578	123	2	advocay	advocay	NOUN
ajlm-1578	123	3	for	for	ADP
ajlm-1578	123	4	new	new	ADJ
ajlm-1578	123	5	and	and	CCONJ
ajlm-1578	123	6	novel	novel	ADJ
ajlm-1578	123	7	treatment	treatment	NOUN
ajlm-1578	123	8	approaches	approach	NOUN
ajlm-1578	123	9	in	in	ADP
ajlm-1578	123	10	our	our	PRON
ajlm-1578	123	11	setting	setting	NOUN
ajlm-1578	123	12	is	be	AUX
ajlm-1578	123	13	necessary	necessary	ADJ
ajlm-1578	123	14	.	.	PUNCT
ajlm-1578	124	1	limitations	limitation	NOUN
ajlm-1578	124	2	the	the	DET
ajlm-1578	124	3	limitations	limitation	NOUN
ajlm-1578	124	4	in	in	ADP
ajlm-1578	124	5	this	this	DET
ajlm-1578	124	6	study	study	NOUN
ajlm-1578	124	7	include	include	VERB
ajlm-1578	124	8	the	the	DET
ajlm-1578	124	9	paucity	paucity	NOUN
ajlm-1578	124	10	of	of	ADP
ajlm-1578	124	11	clinical	clinical	ADJ
ajlm-1578	124	12	information	information	NOUN
ajlm-1578	124	13	and	and	CCONJ
ajlm-1578	124	14	reliable	reliable	ADJ
ajlm-1578	124	15	outcome	outcome	NOUN
ajlm-1578	124	16	data	datum	NOUN
ajlm-1578	124	17	as	as	ADP
ajlm-1578	124	18	a	a	DET
ajlm-1578	124	19	result	result	NOUN
ajlm-1578	124	20	of	of	ADP
ajlm-1578	124	21	the	the	DET
ajlm-1578	124	22	retrospective	retrospective	ADJ
ajlm-1578	124	23	design	design	NOUN
ajlm-1578	124	24	.	.	PUNCT
ajlm-1578	125	1	cases	case	NOUN
ajlm-1578	125	2	without	without	ADP
ajlm-1578	125	3	flow	flow	NOUN
ajlm-1578	125	4	cytometry	cytometry	NOUN
ajlm-1578	125	5	,	,	PUNCT
ajlm-1578	125	6	especially	especially	ADV
ajlm-1578	125	7	isolated	isolate	VERB
ajlm-1578	125	8	extramedullary	extramedullary	ADJ
ajlm-1578	125	9	transformation	transformation	NOUN
ajlm-1578	125	10	,	,	PUNCT
ajlm-1578	125	11	were	be	AUX
ajlm-1578	125	12	missed	miss	VERB
ajlm-1578	125	13	.	.	PUNCT
ajlm-1578	126	1	furthermore	furthermore	ADV
ajlm-1578	126	2	,	,	PUNCT
ajlm-1578	126	3	molecular	molecular	ADJ
ajlm-1578	126	4	information	information	NOUN
ajlm-1578	126	5	,	,	PUNCT
ajlm-1578	126	6	namely	namely	ADV
ajlm-1578	126	7	ccy	ccy	NOUN
ajlm-1578	126	8	or	or	CCONJ
ajlm-1578	126	9	responses	response	NOUN
ajlm-1578	126	10	by	by	ADP
ajlm-1578	126	11	quantitative	quantitative	ADJ
ajlm-1578	126	12	reverse	reverse	ADJ
ajlm-1578	126	13	transcriptase	transcriptase	NOUN
ajlm-1578	126	14	-	-	PUNCT
ajlm-1578	126	15	polymerase	polymerase	NOUN
ajlm-1578	126	16	chain	chain	NOUN
ajlm-1578	126	17	reaction	reaction	NOUN
ajlm-1578	126	18	,	,	PUNCT
ajlm-1578	126	19	was	be	AUX
ajlm-1578	126	20	not	not	PART
ajlm-1578	126	21	available	available	ADJ
ajlm-1578	126	22	for	for	ADP
ajlm-1578	126	23	a	a	DET
ajlm-1578	126	24	notable	notable	ADJ
ajlm-1578	126	25	proportion	proportion	NOUN
ajlm-1578	126	26	of	of	ADP
ajlm-1578	126	27	the	the	DET
ajlm-1578	126	28	patients	patient	NOUN
ajlm-1578	126	29	,	,	PUNCT
ajlm-1578	126	30	preventing	prevent	VERB
ajlm-1578	126	31	an	an	DET
ajlm-1578	126	32	accurate	accurate	ADJ
ajlm-1578	126	33	picture	picture	NOUN
ajlm-1578	126	34	of	of	ADP
ajlm-1578	126	35	the	the	DET
ajlm-1578	126	36	molecular	molecular	ADJ
ajlm-1578	126	37	landscape	landscape	NOUN
ajlm-1578	126	38	of	of	ADP
ajlm-1578	126	39	bc	bc	PROPN
ajlm-1578	126	40	-	-	PUNCT
ajlm-1578	126	41	cml	cml	PROPN
ajlm-1578	126	42	.	.	PUNCT
ajlm-1578	127	1	lastly	lastly	ADV
ajlm-1578	127	2	,	,	PUNCT
ajlm-1578	127	3	given	give	VERB
ajlm-1578	127	4	the	the	DET
ajlm-1578	127	5	rarity	rarity	NOUN
ajlm-1578	127	6	of	of	ADP
ajlm-1578	127	7	this	this	DET
ajlm-1578	127	8	entity	entity	NOUN
ajlm-1578	127	9	,	,	PUNCT
ajlm-1578	127	10	factors	factor	NOUN
ajlm-1578	127	11	which	which	PRON
ajlm-1578	127	12	affect	affect	VERB
ajlm-1578	127	13	outcomes	outcome	NOUN
ajlm-1578	127	14	are	be	AUX
ajlm-1578	127	15	difficult	difficult	ADJ
ajlm-1578	127	16	to	to	PART
ajlm-1578	127	17	determine	determine	VERB
ajlm-1578	127	18	.	.	PUNCT
ajlm-1578	128	1	conclusion	conclusion	NOUN
ajlm-1578	128	2	a	a	DET
ajlm-1578	128	3	laboratory	laboratory	NOUN
ajlm-1578	128	4	-	-	PUNCT
ajlm-1578	128	5	based	base	VERB
ajlm-1578	128	6	retrospective	retrospective	ADJ
ajlm-1578	128	7	study	study	NOUN
ajlm-1578	128	8	of	of	ADP
ajlm-1578	128	9	bc	bc	PROPN
ajlm-1578	128	10	-	-	PUNCT
ajlm-1578	128	11	cml	cml	PROPN
ajlm-1578	128	12	was	be	AUX
ajlm-1578	128	13	performed	perform	VERB
ajlm-1578	128	14	in	in	ADP
ajlm-1578	128	15	a	a	DET
ajlm-1578	128	16	public	public	ADJ
ajlm-1578	128	17	health	health	NOUN
ajlm-1578	128	18	sector	sector	NOUN
ajlm-1578	128	19	setting	set	VERB
ajlm-1578	128	20	in	in	ADP
ajlm-1578	128	21	south	south	PROPN
ajlm-1578	128	22	africa	africa	PROPN
ajlm-1578	128	23	.	.	PUNCT
ajlm-1578	129	1	the	the	DET
ajlm-1578	129	2	results	result	NOUN
ajlm-1578	129	3	showed	show	VERB
ajlm-1578	129	4	that	that	SCONJ
ajlm-1578	129	5	bc	bc	PROPN
ajlm-1578	129	6	-	-	PUNCT
ajlm-1578	129	7	cml	cml	PROPN
ajlm-1578	129	8	occurs	occur	VERB
ajlm-1578	129	9	at	at	ADP
ajlm-1578	129	10	a	a	DET
ajlm-1578	129	11	younger	young	ADJ
ajlm-1578	129	12	age	age	NOUN
ajlm-1578	129	13	in	in	ADP
ajlm-1578	129	14	adults	adult	NOUN
ajlm-1578	129	15	as	as	SCONJ
ajlm-1578	129	16	compared	compare	VERB
ajlm-1578	129	17	with	with	ADP
ajlm-1578	129	18	international	international	ADJ
ajlm-1578	129	19	studies	study	NOUN
ajlm-1578	129	20	.	.	PUNCT
ajlm-1578	130	1	this	this	PRON
ajlm-1578	130	2	corresponds	correspond	VERB
ajlm-1578	130	3	to	to	ADP
ajlm-1578	130	4	the	the	DET
ajlm-1578	130	5	younger	young	ADJ
ajlm-1578	130	6	age	age	NOUN
ajlm-1578	130	7	of	of	ADP
ajlm-1578	130	8	chronic	chronic	ADJ
ajlm-1578	130	9	phase	phase	NOUN
ajlm-1578	130	10	cml	cml	PROPN
ajlm-1578	130	11	seen	see	VERB
ajlm-1578	130	12	in	in	ADP
ajlm-1578	130	13	our	our	PRON
ajlm-1578	130	14	setting	setting	NOUN
ajlm-1578	130	15	,	,	PUNCT
ajlm-1578	130	16	a	a	DET
ajlm-1578	130	17	finding	finding	NOUN
ajlm-1578	130	18	which	which	PRON
ajlm-1578	130	19	may	may	AUX
ajlm-1578	130	20	reflect	reflect	VERB
ajlm-1578	130	21	the	the	DET
ajlm-1578	130	22	country	country	NOUN
ajlm-1578	130	23	demographics	demographic	NOUN
ajlm-1578	130	24	,	,	PUNCT
ajlm-1578	130	25	different	different	ADJ
ajlm-1578	130	26	environmental	environmental	ADJ
ajlm-1578	130	27	exposures	exposure	NOUN
ajlm-1578	130	28	or	or	CCONJ
ajlm-1578	130	29	genetic	genetic	ADJ
ajlm-1578	130	30	predispositions	predisposition	NOUN
ajlm-1578	130	31	.	.	PUNCT
ajlm-1578	131	1	disease	disease	NOUN
ajlm-1578	131	2	characteristics	characteristic	NOUN
ajlm-1578	131	3	were	be	AUX
ajlm-1578	131	4	similar	similar	ADJ
ajlm-1578	131	5	when	when	SCONJ
ajlm-1578	131	6	compared	compare	VERB
ajlm-1578	131	7	with	with	ADP
ajlm-1578	131	8	other	other	ADJ
ajlm-1578	131	9	reports	report	NOUN
ajlm-1578	131	10	of	of	ADP
ajlm-1578	131	11	bc	bc	PROPN
ajlm-1578	131	12	-	-	PUNCT
ajlm-1578	131	13	cml	cml	PROPN
ajlm-1578	131	14	,	,	PUNCT
ajlm-1578	131	15	supporting	support	VERB
ajlm-1578	131	16	the	the	DET
ajlm-1578	131	17	use	use	NOUN
ajlm-1578	131	18	of	of	ADP
ajlm-1578	131	19	international	international	ADJ
ajlm-1578	131	20	treatment	treatment	NOUN
ajlm-1578	131	21	protocols	protocol	NOUN
ajlm-1578	131	22	and	and	CCONJ
ajlm-1578	131	23	guidelines	guideline	NOUN
ajlm-1578	131	24	.	.	PUNCT
ajlm-1578	132	1	there	there	PRON
ajlm-1578	132	2	was	be	VERB
ajlm-1578	132	3	a	a	DET
ajlm-1578	132	4	dismal	dismal	ADJ
ajlm-1578	132	5	overall	overall	ADJ
ajlm-1578	132	6	survival	survival	NOUN
ajlm-1578	132	7	of	of	ADP
ajlm-1578	132	8	7	7	NUM
ajlm-1578	132	9	months	month	NOUN
ajlm-1578	132	10	,	,	PUNCT
ajlm-1578	132	11	with	with	ADP
ajlm-1578	132	12	sepsis	sepsis	NOUN
ajlm-1578	132	13	and	and	CCONJ
ajlm-1578	132	14	relapsed	relapse	VERB
ajlm-1578	132	15	refractory	refractory	NOUN
ajlm-1578	132	16	disease	disease	NOUN
ajlm-1578	132	17	being	be	AUX
ajlm-1578	132	18	the	the	DET
ajlm-1578	132	19	major	major	ADJ
ajlm-1578	132	20	contributors	contributor	NOUN
ajlm-1578	132	21	,	,	PUNCT
ajlm-1578	132	22	highlighting	highlight	VERB
ajlm-1578	132	23	the	the	DET
ajlm-1578	132	24	need	need	NOUN
ajlm-1578	132	25	to	to	PART
ajlm-1578	132	26	advocate	advocate	VERB
ajlm-1578	132	27	for	for	ADP
ajlm-1578	132	28	new	new	ADJ
ajlm-1578	132	29	and	and	CCONJ
ajlm-1578	132	30	novel	novel	ADJ
ajlm-1578	132	31	therapies	therapy	NOUN
ajlm-1578	132	32	.	.	PUNCT
ajlm-1578	133	1	acknowledgements	acknowledgement	NOUN
ajlm-1578	133	2	we	we	PRON
ajlm-1578	133	3	would	would	AUX
ajlm-1578	133	4	like	like	VERB
ajlm-1578	133	5	to	to	PART
ajlm-1578	133	6	acknowledge	acknowledge	VERB
ajlm-1578	133	7	all	all	DET
ajlm-1578	133	8	the	the	DET
ajlm-1578	133	9	staff	staff	NOUN
ajlm-1578	133	10	members	member	NOUN
ajlm-1578	133	11	of	of	ADP
ajlm-1578	133	12	the	the	DET
ajlm-1578	133	13	following	follow	VERB
ajlm-1578	133	14	units	unit	NOUN
ajlm-1578	133	15	for	for	ADP
ajlm-1578	133	16	their	their	PRON
ajlm-1578	133	17	invaluable	invaluable	ADJ
ajlm-1578	133	18	contributions	contribution	NOUN
ajlm-1578	133	19	towards	towards	ADP
ajlm-1578	133	20	leukaemia	leukaemia	NOUN
ajlm-1578	133	21	diagnosis	diagnosis	NOUN
ajlm-1578	133	22	and	and	CCONJ
ajlm-1578	133	23	management	management	NOUN
ajlm-1578	133	24	in	in	ADP
ajlm-1578	133	25	johannesburg	johannesburg	PROPN
ajlm-1578	133	26	:	:	PUNCT
ajlm-1578	133	27	the	the	DET
ajlm-1578	133	28	flow	flow	NOUN
ajlm-1578	133	29	cytometry	cytometry	PROPN
ajlm-1578	133	30	laboratory	laboratory	NOUN
ajlm-1578	133	31	at	at	ADP
ajlm-1578	133	32	the	the	DET
ajlm-1578	133	33	cmjah	cmjah	NOUN
ajlm-1578	133	34	,	,	PUNCT
ajlm-1578	133	35	the	the	DET
ajlm-1578	133	36	somatic	somatic	ADJ
ajlm-1578	133	37	cell	cell	NOUN
ajlm-1578	133	38	genetics	genetic	NOUN
ajlm-1578	133	39	unit	unit	NOUN
ajlm-1578	133	40	at	at	ADP
ajlm-1578	133	41	the	the	DET
ajlm-1578	133	42	cmjah	cmjah	NOUN
ajlm-1578	133	43	,	,	PUNCT
ajlm-1578	133	44	the	the	DET
ajlm-1578	133	45	morphology	morphology	NOUN
ajlm-1578	133	46	units	unit	NOUN
ajlm-1578	133	47	of	of	ADP
ajlm-1578	133	48	the	the	DET
ajlm-1578	133	49	cmjah	cmjah	NOUN
ajlm-1578	133	50	,	,	PUNCT
ajlm-1578	133	51	the	the	DET
ajlm-1578	133	52	chbah	chbah	NOUN
ajlm-1578	133	53	and	and	CCONJ
ajlm-1578	133	54	helen	helen	PROPN
ajlm-1578	133	55	joseph	joseph	PROPN
ajlm-1578	133	56	hospital	hospital	PROPN
ajlm-1578	133	57	,	,	PUNCT
ajlm-1578	133	58	the	the	DET
ajlm-1578	133	59	medical	medical	ADJ
ajlm-1578	133	60	oncology	oncology	NOUN
ajlm-1578	133	61	unit	unit	NOUN
ajlm-1578	133	62	at	at	ADP
ajlm-1578	133	63	the	the	DET
ajlm-1578	133	64	cmjah	cmjah	NOUN
ajlm-1578	133	65	,	,	PUNCT
ajlm-1578	133	66	the	the	DET
ajlm-1578	133	67	paediatric	paediatric	ADJ
ajlm-1578	133	68	oncology	oncology	NOUN
ajlm-1578	133	69	units	unit	NOUN
ajlm-1578	133	70	at	at	ADP
ajlm-1578	133	71	the	the	DET
ajlm-1578	133	72	cmjah	cmjah	NOUN
ajlm-1578	133	73	and	and	CCONJ
ajlm-1578	133	74	chbah	chbah	NOUN
ajlm-1578	133	75	,	,	PUNCT
ajlm-1578	133	76	and	and	CCONJ
ajlm-1578	133	77	the	the	DET
ajlm-1578	133	78	clinical	clinical	ADJ
ajlm-1578	133	79	haematology	haematology	NOUN
ajlm-1578	133	80	unit	unit	NOUN
ajlm-1578	133	81	at	at	ADP
ajlm-1578	133	82	the	the	DET
ajlm-1578	133	83	chbah	chbah	NOUN
ajlm-1578	133	84	.	.	PUNCT
ajlm-1578	134	1	competing	compete	VERB
ajlm-1578	134	2	interests	interest	NOUN
ajlm-1578	134	3	the	the	DET
ajlm-1578	134	4	authors	author	NOUN
ajlm-1578	134	5	declare	declare	VERB
ajlm-1578	134	6	that	that	SCONJ
ajlm-1578	134	7	they	they	PRON
ajlm-1578	134	8	have	have	VERB
ajlm-1578	134	9	no	no	DET
ajlm-1578	134	10	financial	financial	ADJ
ajlm-1578	134	11	or	or	CCONJ
ajlm-1578	134	12	personal	personal	ADJ
ajlm-1578	134	13	relationships	relationship	NOUN
ajlm-1578	134	14	that	that	PRON
ajlm-1578	134	15	may	may	AUX
ajlm-1578	134	16	have	have	AUX
ajlm-1578	134	17	inappropriately	inappropriately	ADV
ajlm-1578	134	18	influenced	influence	VERB
ajlm-1578	134	19	them	they	PRON
ajlm-1578	134	20	in	in	ADP
ajlm-1578	134	21	writing	write	VERB
ajlm-1578	134	22	this	this	DET
ajlm-1578	134	23	article	article	NOUN
ajlm-1578	134	24	.	.	PUNCT
ajlm-1578	135	1	authors	author	NOUN
ajlm-1578	135	2	’	’	PART
ajlm-1578	135	3	contributions	contribution	NOUN
ajlm-1578	135	4	k.e.h	k.e.h	PROPN
ajlm-1578	135	5	.	.	PUNCT
ajlm-1578	135	6	,	,	PUNCT
ajlm-1578	135	7	n.b	n.b	PROPN
ajlm-1578	135	8	.	.	PROPN
ajlm-1578	135	9	and	and	CCONJ
ajlm-1578	135	10	j.v	j.v	PROPN
ajlm-1578	135	11	.	.	PROPN
ajlm-1578	135	12	were	be	AUX
ajlm-1578	135	13	involved	involve	VERB
ajlm-1578	135	14	in	in	ADP
ajlm-1578	135	15	the	the	DET
ajlm-1578	135	16	conceptualisation	conceptualisation	NOUN
ajlm-1578	135	17	and	and	CCONJ
ajlm-1578	135	18	methodology	methodology	NOUN
ajlm-1578	135	19	,	,	PUNCT
ajlm-1578	135	20	k.e.h	k.e.h	NOUN
ajlm-1578	135	21	.	.	PUNCT
ajlm-1578	136	1	and	and	CCONJ
ajlm-1578	136	2	j.v	j.v	PROPN
ajlm-1578	136	3	.	.	PUNCT
ajlm-1578	137	1	in	in	ADP
ajlm-1578	137	2	data	data	PROPN
ajlm-1578	137	3	collection	collection	NOUN
ajlm-1578	137	4	,	,	PUNCT
ajlm-1578	137	5	k.e.h	k.e.h	NOUN
ajlm-1578	137	6	.	.	PUNCT
ajlm-1578	138	1	in	in	ADP
ajlm-1578	138	2	data	data	NOUN
ajlm-1578	138	3	analysis	analysis	NOUN
ajlm-1578	138	4	and	and	CCONJ
ajlm-1578	138	5	drafting	draft	VERB
ajlm-1578	138	6	the	the	DET
ajlm-1578	138	7	initial	initial	ADJ
ajlm-1578	138	8	manuscript	manuscript	NOUN
ajlm-1578	138	9	,	,	PUNCT
ajlm-1578	138	10	n.b	n.b	PROPN
ajlm-1578	138	11	.	.	PROPN
ajlm-1578	138	12	and	and	CCONJ
ajlm-1578	138	13	j.v	j.v	PROPN
ajlm-1578	138	14	.	.	PUNCT
ajlm-1578	139	1	in	in	ADP
ajlm-1578	139	2	editing	edit	VERB
ajlm-1578	139	3	and	and	CCONJ
ajlm-1578	139	4	all	all	DET
ajlm-1578	139	5	authors	author	NOUN
ajlm-1578	139	6	discussed	discuss	VERB
ajlm-1578	139	7	the	the	DET
ajlm-1578	139	8	results	result	NOUN
ajlm-1578	139	9	and	and	CCONJ
ajlm-1578	139	10	contributed	contribute	VERB
ajlm-1578	139	11	to	to	ADP
ajlm-1578	139	12	the	the	DET
ajlm-1578	139	13	final	final	ADJ
ajlm-1578	139	14	manuscript	manuscript	NOUN
ajlm-1578	139	15	.	.	PUNCT
ajlm-1578	140	1	sources	source	NOUN
ajlm-1578	140	2	of	of	ADP
ajlm-1578	140	3	support	support	NOUN
ajlm-1578	140	4	this	this	DET
ajlm-1578	140	5	research	research	NOUN
ajlm-1578	140	6	did	do	AUX
ajlm-1578	140	7	not	not	PART
ajlm-1578	140	8	receive	receive	VERB
ajlm-1578	140	9	any	any	DET
ajlm-1578	140	10	specific	specific	ADJ
ajlm-1578	140	11	grant	grant	NOUN
ajlm-1578	140	12	from	from	ADP
ajlm-1578	140	13	funding	fund	VERB
ajlm-1578	140	14	agencies	agency	NOUN
ajlm-1578	140	15	in	in	ADP
ajlm-1578	140	16	the	the	DET
ajlm-1578	140	17	public	public	ADJ
ajlm-1578	140	18	,	,	PUNCT
ajlm-1578	140	19	commercial	commercial	ADJ
ajlm-1578	140	20	,	,	PUNCT
ajlm-1578	140	21	or	or	CCONJ
ajlm-1578	140	22	not	not	PART
ajlm-1578	140	23	-	-	PUNCT
ajlm-1578	140	24	for	for	ADP
ajlm-1578	140	25	-	-	PUNCT
ajlm-1578	140	26	profit	profit	NOUN
ajlm-1578	140	27	sectors	sector	NOUN
ajlm-1578	140	28	.	.	PUNCT
ajlm-1578	141	1	data	datum	NOUN
ajlm-1578	141	2	availability	availability	NOUN
ajlm-1578	141	3	the	the	DET
ajlm-1578	141	4	authors	author	NOUN
ajlm-1578	141	5	confirm	confirm	VERB
ajlm-1578	141	6	that	that	SCONJ
ajlm-1578	141	7	the	the	DET
ajlm-1578	141	8	data	datum	NOUN
ajlm-1578	141	9	supporting	support	VERB
ajlm-1578	141	10	the	the	DET
ajlm-1578	141	11	findings	finding	NOUN
ajlm-1578	141	12	of	of	ADP
ajlm-1578	141	13	this	this	DET
ajlm-1578	141	14	study	study	NOUN
ajlm-1578	141	15	are	be	AUX
ajlm-1578	141	16	available	available	ADJ
ajlm-1578	141	17	within	within	ADP
ajlm-1578	141	18	the	the	DET
ajlm-1578	141	19	article	article	NOUN
ajlm-1578	141	20	.	.	PUNCT
ajlm-1578	142	1	disclaimer	disclaimer	VERB
ajlm-1578	142	2	the	the	DET
ajlm-1578	142	3	views	view	NOUN
ajlm-1578	142	4	and	and	CCONJ
ajlm-1578	142	5	opinions	opinion	NOUN
ajlm-1578	142	6	expressed	express	VERB
ajlm-1578	142	7	in	in	ADP
ajlm-1578	142	8	this	this	DET
ajlm-1578	142	9	article	article	NOUN
ajlm-1578	142	10	are	be	AUX
ajlm-1578	142	11	those	those	PRON
ajlm-1578	142	12	of	of	ADP
ajlm-1578	142	13	the	the	DET
ajlm-1578	142	14	authors	author	NOUN
ajlm-1578	142	15	and	and	CCONJ
ajlm-1578	142	16	do	do	AUX
ajlm-1578	142	17	not	not	PART
ajlm-1578	142	18	necessarily	necessarily	ADV
ajlm-1578	142	19	reflect	reflect	VERB
ajlm-1578	142	20	the	the	DET
ajlm-1578	142	21	official	official	ADJ
ajlm-1578	142	22	policy	policy	NOUN
ajlm-1578	142	23	or	or	CCONJ
ajlm-1578	142	24	position	position	NOUN
ajlm-1578	142	25	of	of	ADP
ajlm-1578	142	26	any	any	DET
ajlm-1578	142	27	affiliated	affiliated	ADJ
ajlm-1578	142	28	agency	agency	NOUN
ajlm-1578	142	29	of	of	ADP
ajlm-1578	142	30	the	the	DET
ajlm-1578	142	31	authors	author	NOUN
ajlm-1578	142	32	.	.	PUNCT
ajlm-1578	143	1	references	reference	NOUN
ajlm-1578	143	2	fialkow	fialkow	VERB
ajlm-1578	143	3	pj	pj	PROPN
ajlm-1578	143	4	,	,	PUNCT
ajlm-1578	143	5	jacobson	jacobson	PROPN
ajlm-1578	143	6	rj	rj	PROPN
ajlm-1578	143	7	,	,	PUNCT
ajlm-1578	143	8	papayannopoulou	papayannopoulou	ADJ
ajlm-1578	143	9	t.	t.	PROPN
ajlm-1578	143	10	chronic	chronic	ADJ
ajlm-1578	143	11	myelocytic	myelocytic	ADJ
ajlm-1578	143	12	leukemia	leukemia	NOUN
ajlm-1578	143	13	:	:	PUNCT
ajlm-1578	143	14	clonal	clonal	ADJ
ajlm-1578	143	15	origin	origin	NOUN
ajlm-1578	143	16	in	in	ADP
ajlm-1578	143	17	a	a	DET
ajlm-1578	143	18	stem	stem	NOUN
ajlm-1578	143	19	cell	cell	NOUN
ajlm-1578	143	20	common	common	ADJ
ajlm-1578	143	21	to	to	ADP
ajlm-1578	143	22	the	the	DET
ajlm-1578	143	23	granulocyte	granulocyte	NOUN
ajlm-1578	143	24	,	,	PUNCT
ajlm-1578	143	25	erythrocyte	erythrocyte	NOUN
ajlm-1578	143	26	,	,	PUNCT
ajlm-1578	143	27	platelet	platelet	NOUN
ajlm-1578	143	28	and	and	CCONJ
ajlm-1578	143	29	monocyte	monocyte	ADJ
ajlm-1578	143	30	/	/	SYM
ajlm-1578	143	31	macrophage	macrophage	NOUN
ajlm-1578	143	32	.	.	PUNCT
ajlm-1578	144	1	am	be	AUX
ajlm-1578	144	2	j	j	PROPN
ajlm-1578	144	3	med	med	PROPN
ajlm-1578	144	4	.	.	PUNCT
ajlm-1578	145	1	1977;63(1):125–130	1977;63(1):125–130	NUM
ajlm-1578	145	2	.	.	PUNCT
ajlm-1578	145	3	https://doi.org/10.1016/0002-9343(77)90124-3	https://doi.org/10.1016/0002-9343(77)90124-3	PROPN
ajlm-1578	145	4	clein	clein	PROPN
ajlm-1578	145	5	gp	gp	NOUN
ajlm-1578	145	6	,	,	PUNCT
ajlm-1578	145	7	flemans	flemans	PROPN
ajlm-1578	145	8	rj	rj	PROPN
ajlm-1578	145	9	.	.	PUNCT
ajlm-1578	145	10	involvement	involvement	NOUN
ajlm-1578	145	11	of	of	ADP
ajlm-1578	145	12	the	the	DET
ajlm-1578	145	13	erythroid	erythroid	PROPN
ajlm-1578	145	14	series	series	PROPN
ajlm-1578	145	15	in	in	ADP
ajlm-1578	145	16	blastic	blastic	ADJ
ajlm-1578	145	17	crisis	crisis	NOUN
ajlm-1578	145	18	of	of	ADP
ajlm-1578	145	19	chronic	chronic	ADJ
ajlm-1578	145	20	myeloid	myeloid	NOUN
ajlm-1578	145	21	leukaemia	leukaemia	NOUN
ajlm-1578	145	22	.	.	PUNCT
ajlm-1578	146	1	further	further	ADJ
ajlm-1578	146	2	evidence	evidence	NOUN
ajlm-1578	146	3	for	for	ADP
ajlm-1578	146	4	the	the	DET
ajlm-1578	146	5	presence	presence	NOUN
ajlm-1578	146	6	of	of	ADP
ajlm-1578	146	7	philadelphia	philadelphia	PROPN
ajlm-1578	146	8	chromosome	chromosome	NOUN
ajlm-1578	146	9	in	in	ADP
ajlm-1578	146	10	erythroblasts	erythroblast	NOUN
ajlm-1578	146	11	.	.	PUNCT
ajlm-1578	147	1	br	br	PROPN
ajlm-1578	147	2	j	j	PROPN
ajlm-1578	147	3	haematol	haematol	NOUN
ajlm-1578	147	4	.	.	PUNCT
ajlm-1578	148	1	1966;12(6):754–758	1966;12(6):754–758	X
ajlm-1578	148	2	.	.	PUNCT
ajlm-1578	149	1	https://doi.org/10.1111/j.1365-2141.1966.tb00162.x	https://doi.org/10.1111/j.1365-2141.1966.tb00162.x	PROPN
ajlm-1578	149	2	rastrick	rastrick	PROPN
ajlm-1578	149	3	jm	jm	PROPN
ajlm-1578	149	4	,	,	PUNCT
ajlm-1578	149	5	fitzgerald	fitzgerald	PROPN
ajlm-1578	149	6	ph	ph	PROPN
ajlm-1578	149	7	,	,	PUNCT
ajlm-1578	149	8	gunz	gunz	PROPN
ajlm-1578	149	9	fw	fw	PROPN
ajlm-1578	149	10	.	.	PUNCT
ajlm-1578	150	1	direct	direct	ADJ
ajlm-1578	150	2	evidence	evidence	NOUN
ajlm-1578	150	3	for	for	ADP
ajlm-1578	150	4	presence	presence	NOUN
ajlm-1578	150	5	of	of	ADP
ajlm-1578	150	6	ph-1	ph-1	NOUN
ajlm-1578	150	7	chromosome	chromosome	NOUN
ajlm-1578	150	8	in	in	ADP
ajlm-1578	150	9	erythroid	erythroid	ADJ
ajlm-1578	150	10	cells	cell	NOUN
ajlm-1578	150	11	.	.	PUNCT
ajlm-1578	151	1	br	br	PROPN
ajlm-1578	151	2	med	med	PROPN
ajlm-1578	151	3	j.	j.	PROPN
ajlm-1578	151	4	1968;1(5584):96–98	1968;1(5584):96–98	PROPN
ajlm-1578	151	5	.	.	PUNCT
ajlm-1578	152	1	https://doi.org/10.1136/bmj.1.5584.96	https://doi.org/10.1136/bmj.1.5584.96	PROPN
ajlm-1578	152	2	nowell	nowell	PROPN
ajlm-1578	152	3	pc	pc	NOUN
ajlm-1578	152	4	.	.	PUNCT
ajlm-1578	153	1	the	the	DET
ajlm-1578	153	2	minute	minute	NOUN
ajlm-1578	153	3	chromosome	chromosome	NOUN
ajlm-1578	153	4	(	(	PUNCT
ajlm-1578	153	5	phl	phl	NOUN
ajlm-1578	153	6	)	)	PUNCT
ajlm-1578	153	7	in	in	ADP
ajlm-1578	153	8	chronic	chronic	ADJ
ajlm-1578	153	9	granulocytic	granulocytic	ADJ
ajlm-1578	153	10	leukemia	leukemia	NOUN
ajlm-1578	153	11	.	.	PUNCT
ajlm-1578	154	1	blut	blut	PROPN
ajlm-1578	154	2	.	.	PUNCT
ajlm-1578	155	1	1962;8:65–66	1962;8:65–66	X
ajlm-1578	155	2	.	.	PUNCT
ajlm-1578	156	1	https://doi.org/10.1007/bf01630378	https://doi.org/10.1007/bf01630378	PRON
ajlm-1578	156	2	rowley	rowley	VERB
ajlm-1578	156	3	jd	jd	PROPN
ajlm-1578	156	4	.	.	PROPN
ajlm-1578	156	5	letter	letter	PROPN
ajlm-1578	156	6	:	:	PUNCT
ajlm-1578	156	7	a	a	DET
ajlm-1578	156	8	new	new	ADJ
ajlm-1578	156	9	consistent	consistent	ADJ
ajlm-1578	156	10	chromosomal	chromosomal	ADJ
ajlm-1578	156	11	abnormality	abnormality	NOUN
ajlm-1578	156	12	in	in	ADP
ajlm-1578	156	13	chronic	chronic	ADJ
ajlm-1578	156	14	myelogenous	myelogenous	ADJ
ajlm-1578	156	15	leukaemia	leukaemia	NOUN
ajlm-1578	156	16	identified	identify	VERB
ajlm-1578	156	17	by	by	ADP
ajlm-1578	156	18	quinacrine	quinacrine	ADJ
ajlm-1578	156	19	fluorescence	fluorescence	NOUN
ajlm-1578	156	20	and	and	CCONJ
ajlm-1578	156	21	giemsa	giemsa	NOUN
ajlm-1578	156	22	staining	staining	NOUN
ajlm-1578	156	23	.	.	PUNCT
ajlm-1578	157	1	nature	nature	NOUN
ajlm-1578	157	2	.	.	PUNCT
ajlm-1578	158	1	1973;243(5405):290–293	1973;243(5405):290–293	X
ajlm-1578	158	2	.	.	PUNCT
ajlm-1578	159	1	https://doi.org/10.1038/243290a0	https://doi.org/10.1038/243290a0	PROPN
ajlm-1578	159	2	wang	wang	PROPN
ajlm-1578	159	3	es	es	PROPN
ajlm-1578	159	4	.	.	PUNCT
ajlm-1578	159	5	treating	treat	VERB
ajlm-1578	159	6	acute	acute	ADJ
ajlm-1578	159	7	myeloid	myeloid	NOUN
ajlm-1578	159	8	leukemia	leukemia	NOUN
ajlm-1578	159	9	in	in	ADP
ajlm-1578	159	10	older	old	ADJ
ajlm-1578	159	11	adults	adult	NOUN
ajlm-1578	159	12	.	.	PUNCT
ajlm-1578	160	1	hematology	hematology	NOUN
ajlm-1578	160	2	am	be	AUX
ajlm-1578	160	3	soc	soc	NOUN
ajlm-1578	160	4	hematol	hematol	NOUN
ajlm-1578	160	5	educ	educ	PROPN
ajlm-1578	160	6	program	program	NOUN
ajlm-1578	160	7	.	.	PUNCT
ajlm-1578	161	1	2014;2014(1):14–20	2014;2014(1):14–20	NUM
ajlm-1578	161	2	.	.	PUNCT
ajlm-1578	162	1	https://doi.org/10.1182/asheducation-2014.1.14	https://doi.org/10.1182/asheducation-2014.1.14	PRON
ajlm-1578	162	2	schoch	schoch	PROPN
ajlm-1578	162	3	c	c	PROPN
ajlm-1578	162	4	,	,	PUNCT
ajlm-1578	162	5	schnittger	schnittger	NOUN
ajlm-1578	162	6	s	s	NOUN
ajlm-1578	162	7	,	,	PUNCT
ajlm-1578	162	8	bursch	bursch	PROPN
ajlm-1578	162	9	s	s	PROPN
ajlm-1578	162	10	,	,	PUNCT
ajlm-1578	162	11	et	et	PROPN
ajlm-1578	162	12	al	al	PROPN
ajlm-1578	162	13	.	.	PROPN
ajlm-1578	162	14	comparison	comparison	NOUN
ajlm-1578	162	15	of	of	ADP
ajlm-1578	162	16	chromosome	chromosome	NOUN
ajlm-1578	162	17	banding	banding	NOUN
ajlm-1578	162	18	analysis	analysis	NOUN
ajlm-1578	162	19	,	,	PUNCT
ajlm-1578	162	20	interphaseand	interphaseand	ADJ
ajlm-1578	162	21	hypermetaphase	hypermetaphase	NOUN
ajlm-1578	162	22	-	-	PUNCT
ajlm-1578	162	23	fish	fish	NOUN
ajlm-1578	162	24	,	,	PUNCT
ajlm-1578	162	25	qualitative	qualitative	ADJ
ajlm-1578	162	26	and	and	CCONJ
ajlm-1578	162	27	quantitative	quantitative	ADJ
ajlm-1578	162	28	pcr	pcr	NOUN
ajlm-1578	162	29	for	for	ADP
ajlm-1578	162	30	diagnosis	diagnosis	NOUN
ajlm-1578	162	31	and	and	CCONJ
ajlm-1578	162	32	for	for	ADP
ajlm-1578	162	33	follow	follow	NOUN
ajlm-1578	162	34	-	-	PUNCT
ajlm-1578	162	35	up	up	NOUN
ajlm-1578	162	36	in	in	ADP
ajlm-1578	162	37	chronic	chronic	ADJ
ajlm-1578	162	38	myeloid	myeloid	NOUN
ajlm-1578	162	39	leukemia	leukemia	NOUN
ajlm-1578	162	40	:	:	PUNCT
ajlm-1578	162	41	a	a	DET
ajlm-1578	162	42	study	study	NOUN
ajlm-1578	162	43	on	on	ADP
ajlm-1578	162	44	350	350	NUM
ajlm-1578	162	45	cases	case	NOUN
ajlm-1578	162	46	.	.	PUNCT
ajlm-1578	163	1	leukemia	leukemia	NOUN
ajlm-1578	163	2	.	.	PUNCT
ajlm-1578	164	1	2002;16(1):53–59	2002;16(1):53–59	X
ajlm-1578	164	2	.	.	PUNCT
ajlm-1578	164	3	https://doi.org/10.1038/sj.leu.2402329	https://doi.org/10.1038/sj.leu.2402329	PROPN
ajlm-1578	165	1	mcgahon	mcgahon	PROPN
ajlm-1578	165	2	a	a	DET
ajlm-1578	165	3	,	,	PUNCT
ajlm-1578	165	4	bissonnette	bissonnette	NOUN
ajlm-1578	165	5	r	r	NOUN
ajlm-1578	165	6	,	,	PUNCT
ajlm-1578	165	7	schmitt	schmitt	PROPN
ajlm-1578	165	8	m	m	PROPN
ajlm-1578	165	9	,	,	PUNCT
ajlm-1578	165	10	et	et	PROPN
ajlm-1578	165	11	al	al	PROPN
ajlm-1578	165	12	.	.	PUNCT
ajlm-1578	165	13	bcr	bcr	PROPN
ajlm-1578	165	14	-	-	PROPN
ajlm-1578	165	15	abl	abl	PROPN
ajlm-1578	165	16	maintains	maintain	VERB
ajlm-1578	165	17	resistance	resistance	NOUN
ajlm-1578	165	18	of	of	ADP
ajlm-1578	165	19	chronic	chronic	ADJ
ajlm-1578	165	20	myelogenous	myelogenous	ADJ
ajlm-1578	165	21	leukemia	leukemia	NOUN
ajlm-1578	165	22	cells	cell	NOUN
ajlm-1578	165	23	to	to	ADP
ajlm-1578	165	24	apoptotic	apoptotic	ADJ
ajlm-1578	165	25	cell	cell	NOUN
ajlm-1578	165	26	death	death	NOUN
ajlm-1578	165	27	.	.	PUNCT
ajlm-1578	166	1	blood	blood	NOUN
ajlm-1578	166	2	.	.	PUNCT
ajlm-1578	167	1	1994;83(5):1179–1187	1994;83(5):1179–1187	NUM
ajlm-1578	167	2	.	.	PUNCT
ajlm-1578	168	1	https://doi.org/10.1182/blood.v83.5.1179.1179	https://doi.org/10.1182/blood.v83.5.1179.1179	PROPN
ajlm-1578	168	2	gordon	gordon	PROPN
ajlm-1578	168	3	my	my	PRON
ajlm-1578	168	4	,	,	PUNCT
ajlm-1578	168	5	dowding	dowding	PROPN
ajlm-1578	168	6	cr	cr	PROPN
ajlm-1578	168	7	,	,	PUNCT
ajlm-1578	168	8	riley	riley	PROPN
ajlm-1578	168	9	gp	gp	PROPN
ajlm-1578	168	10	,	,	PUNCT
ajlm-1578	168	11	goldman	goldman	PROPN
ajlm-1578	168	12	jm	jm	PROPN
ajlm-1578	168	13	,	,	PUNCT
ajlm-1578	168	14	greaves	greave	VERB
ajlm-1578	168	15	mf	mf	X
ajlm-1578	168	16	.	.	PROPN
ajlm-1578	168	17	altered	alter	VERB
ajlm-1578	168	18	adhesive	adhesive	ADJ
ajlm-1578	168	19	interactions	interaction	NOUN
ajlm-1578	168	20	with	with	ADP
ajlm-1578	168	21	marrow	marrow	NOUN
ajlm-1578	168	22	stroma	stroma	NOUN
ajlm-1578	168	23	of	of	ADP
ajlm-1578	168	24	haematopoietic	haematopoietic	ADJ
ajlm-1578	168	25	progenitor	progenitor	NOUN
ajlm-1578	168	26	cells	cell	NOUN
ajlm-1578	168	27	in	in	ADP
ajlm-1578	168	28	chronic	chronic	ADJ
ajlm-1578	168	29	myeloid	myeloid	NOUN
ajlm-1578	168	30	leukaemia	leukaemia	NOUN
ajlm-1578	168	31	.	.	PUNCT
ajlm-1578	169	1	nature	nature	NOUN
ajlm-1578	169	2	.	.	PUNCT
ajlm-1578	170	1	1987;328(6128):342–344	1987;328(6128):342–344	X
ajlm-1578	170	2	.	.	PUNCT
ajlm-1578	171	1	https://doi.org/10.1038/328342a0	https://doi.org/10.1038/328342a0	PROPN
ajlm-1578	171	2	strife	strife	NOUN
ajlm-1578	171	3	a	a	PRON
ajlm-1578	171	4	,	,	PUNCT
ajlm-1578	171	5	clarkson	clarkson	PROPN
ajlm-1578	171	6	b.	b.	PROPN
ajlm-1578	171	7	biology	biology	NOUN
ajlm-1578	171	8	of	of	ADP
ajlm-1578	171	9	chronic	chronic	ADJ
ajlm-1578	171	10	myelogenous	myelogenous	ADJ
ajlm-1578	171	11	leukemia	leukemia	NOUN
ajlm-1578	171	12	:	:	PUNCT
ajlm-1578	171	13	is	be	AUX
ajlm-1578	171	14	discordant	discordant	ADJ
ajlm-1578	171	15	maturation	maturation	NOUN
ajlm-1578	171	16	the	the	DET
ajlm-1578	171	17	primary	primary	ADJ
ajlm-1578	171	18	defect	defect	NOUN
ajlm-1578	171	19	?	?	PUNCT
ajlm-1578	172	1	semin	semin	PROPN
ajlm-1578	172	2	hematol	hematol	PROPN
ajlm-1578	172	3	.	.	PUNCT
ajlm-1578	173	1	1988;25(1):1–19	1988;25(1):1–19	X
ajlm-1578	173	2	.	.	PUNCT
ajlm-1578	173	3	faderl	faderl	PROPN
ajlm-1578	173	4	s	s	PROPN
ajlm-1578	173	5	,	,	PUNCT
ajlm-1578	173	6	talpaz	talpaz	PROPN
ajlm-1578	173	7	m	m	PROPN
ajlm-1578	173	8	,	,	PUNCT
ajlm-1578	173	9	estrov	estrov	PROPN
ajlm-1578	173	10	z	z	PROPN
ajlm-1578	173	11	,	,	PUNCT
ajlm-1578	173	12	kantarjian	kantarjian	ADJ
ajlm-1578	173	13	hm	hm	INTJ
ajlm-1578	173	14	.	.	PUNCT
ajlm-1578	173	15	chronic	chronic	ADJ
ajlm-1578	173	16	myelogenous	myelogenous	ADJ
ajlm-1578	173	17	leukemia	leukemia	NOUN
ajlm-1578	173	18	:	:	PUNCT
ajlm-1578	173	19	biology	biology	NOUN
ajlm-1578	173	20	and	and	CCONJ
ajlm-1578	173	21	therapy	therapy	NOUN
ajlm-1578	173	22	.	.	PUNCT
ajlm-1578	174	1	ann	ann	PROPN
ajlm-1578	174	2	intern	intern	PROPN
ajlm-1578	174	3	med	me	VERB
ajlm-1578	174	4	.	.	PUNCT
ajlm-1578	175	1	1999;131(3):207–219	1999;131(3):207–219	NUM
ajlm-1578	175	2	.	.	PUNCT
ajlm-1578	175	3	https://doi.org/10.7326/0003-4819-131-3-199908030-00008	https://doi.org/10.7326/0003-4819-131-3-199908030-00008	PROPN
ajlm-1578	175	4	arber	arber	PROPN
ajlm-1578	175	5	da	da	PROPN
ajlm-1578	175	6	,	,	PUNCT
ajlm-1578	175	7	orazi	orazi	X
ajlm-1578	175	8	a	a	PRON
ajlm-1578	175	9	,	,	PUNCT
ajlm-1578	175	10	hasserjian	hasserjian	ADJ
ajlm-1578	175	11	r	r	NOUN
ajlm-1578	175	12	,	,	PUNCT
ajlm-1578	175	13	et	et	PROPN
ajlm-1578	175	14	al	al	PROPN
ajlm-1578	175	15	.	.	PUNCT
ajlm-1578	176	1	the	the	DET
ajlm-1578	176	2	2016	2016	NUM
ajlm-1578	176	3	revision	revision	NOUN
ajlm-1578	176	4	to	to	ADP
ajlm-1578	176	5	the	the	DET
ajlm-1578	176	6	world	world	PROPN
ajlm-1578	176	7	health	health	PROPN
ajlm-1578	176	8	organization	organization	PROPN
ajlm-1578	176	9	classification	classification	NOUN
ajlm-1578	176	10	of	of	ADP
ajlm-1578	176	11	myeloid	myeloid	ADJ
ajlm-1578	176	12	neoplasms	neoplasm	NOUN
ajlm-1578	176	13	and	and	CCONJ
ajlm-1578	176	14	acute	acute	ADJ
ajlm-1578	176	15	leukemia	leukemia	NOUN
ajlm-1578	176	16	.	.	PUNCT
ajlm-1578	177	1	blood	blood	NOUN
ajlm-1578	177	2	.	.	PUNCT
ajlm-1578	178	1	2016;127(20):2391–2405	2016;127(20):2391–2405	NUM
ajlm-1578	178	2	.	.	PUNCT
ajlm-1578	178	3	https://doi.org/10.1182/blood-2016-03-643544	https://doi.org/10.1182/blood-2016-03-643544	PROPN
ajlm-1578	178	4	döhner	döhner	PROPN
ajlm-1578	178	5	h	h	NOUN
ajlm-1578	178	6	,	,	PUNCT
ajlm-1578	178	7	estey	estey	PROPN
ajlm-1578	178	8	e	e	NOUN
ajlm-1578	178	9	,	,	PUNCT
ajlm-1578	178	10	grimwade	grimwade	ADJ
ajlm-1578	178	11	d	d	PROPN
ajlm-1578	178	12	,	,	PUNCT
ajlm-1578	178	13	et	et	PROPN
ajlm-1578	178	14	al	al	PROPN
ajlm-1578	178	15	.	.	PUNCT
ajlm-1578	178	16	diagnosis	diagnosis	NOUN
ajlm-1578	178	17	and	and	CCONJ
ajlm-1578	178	18	management	management	NOUN
ajlm-1578	178	19	of	of	ADP
ajlm-1578	178	20	aml	aml	NOUN
ajlm-1578	178	21	in	in	ADP
ajlm-1578	178	22	adults	adult	NOUN
ajlm-1578	178	23	:	:	PUNCT
ajlm-1578	178	24	2017	2017	NUM
ajlm-1578	178	25	eln	eln	NOUN
ajlm-1578	178	26	recommendations	recommendation	NOUN
ajlm-1578	178	27	from	from	ADP
ajlm-1578	178	28	an	an	DET
ajlm-1578	178	29	international	international	ADJ
ajlm-1578	178	30	expert	expert	NOUN
ajlm-1578	178	31	panel	panel	NOUN
ajlm-1578	178	32	.	.	PUNCT
ajlm-1578	179	1	blood	blood	NOUN
ajlm-1578	179	2	.	.	PUNCT
ajlm-1578	180	1	2017;129(4):424–447	2017;129(4):424–447	NUM
ajlm-1578	180	2	.	.	PUNCT
ajlm-1578	180	3	https://doi.org/10.1182/blood-2016-08-733196	https://doi.org/10.1182/blood-2016-08-733196	PROPN
ajlm-1578	180	4	sokal	sokal	PROPN
ajlm-1578	180	5	je	je	PROPN
ajlm-1578	180	6	,	,	PUNCT
ajlm-1578	180	7	baccarani	baccarani	PROPN
ajlm-1578	180	8	m	m	PROPN
ajlm-1578	180	9	,	,	PUNCT
ajlm-1578	180	10	russo	russo	PROPN
ajlm-1578	180	11	d	d	PROPN
ajlm-1578	180	12	,	,	PUNCT
ajlm-1578	180	13	tura	tura	PROPN
ajlm-1578	180	14	s.	s.	PROPN
ajlm-1578	180	15	staging	staging	NOUN
ajlm-1578	180	16	and	and	CCONJ
ajlm-1578	180	17	prognosis	prognosis	NOUN
ajlm-1578	180	18	in	in	ADP
ajlm-1578	180	19	chronic	chronic	ADJ
ajlm-1578	180	20	myelogenous	myelogenous	ADJ
ajlm-1578	180	21	leukemia	leukemia	NOUN
ajlm-1578	180	22	.	.	PUNCT
ajlm-1578	181	1	semin	semin	PROPN
ajlm-1578	181	2	hematol	hematol	PROPN
ajlm-1578	181	3	.	.	PUNCT
ajlm-1578	182	1	1988;25(1):49–61	1988;25(1):49–61	X
ajlm-1578	182	2	.	.	X
ajlm-1578	182	3	ley	ley	PROPN
ajlm-1578	182	4	tj	tj	PROPN
ajlm-1578	182	5	,	,	PUNCT
ajlm-1578	182	6	mardis	mardis	PROPN
ajlm-1578	182	7	er	er	INTJ
ajlm-1578	182	8	,	,	PUNCT
ajlm-1578	182	9	ding	ding	NOUN
ajlm-1578	182	10	l	l	NOUN
ajlm-1578	182	11	,	,	PUNCT
ajlm-1578	182	12	et	et	PROPN
ajlm-1578	182	13	al	al	PROPN
ajlm-1578	182	14	.	.	PROPN
ajlm-1578	183	1	dna	dna	PROPN
ajlm-1578	183	2	sequencing	sequence	VERB
ajlm-1578	183	3	of	of	ADP
ajlm-1578	183	4	a	a	DET
ajlm-1578	183	5	cytogenetically	cytogenetically	NOUN
ajlm-1578	183	6	normal	normal	ADJ
ajlm-1578	183	7	acute	acute	NOUN
ajlm-1578	183	8	myeloid	myeloid	NOUN
ajlm-1578	183	9	leukaemia	leukaemia	NOUN
ajlm-1578	183	10	genome	genome	NOUN
ajlm-1578	183	11	.	.	PUNCT
ajlm-1578	184	1	nature	nature	NOUN
ajlm-1578	184	2	.	.	PUNCT
ajlm-1578	185	1	2008;456(7218):66–72	2008;456(7218):66–72	NOUN
ajlm-1578	185	2	.	.	PUNCT
ajlm-1578	186	1	https://doi.org/10.1038/nature07485	https://doi.org/10.1038/nature07485	NOUN
ajlm-1578	186	2	deininger	deininger	NOUN
ajlm-1578	186	3	m	m	PROPN
ajlm-1578	186	4	,	,	PUNCT
ajlm-1578	186	5	o’brien	o’brien	PROPN
ajlm-1578	186	6	sg	sg	ADP
ajlm-1578	186	7	,	,	PUNCT
ajlm-1578	186	8	guilhot	guilhot	ADJ
ajlm-1578	186	9	fo	fo	PROPN
ajlm-1578	186	10	,	,	PUNCT
ajlm-1578	186	11	et	et	PROPN
ajlm-1578	186	12	al	al	PROPN
ajlm-1578	186	13	.	.	PUNCT
ajlm-1578	187	1	international	international	ADJ
ajlm-1578	187	2	randomized	randomized	ADJ
ajlm-1578	187	3	study	study	NOUN
ajlm-1578	187	4	of	of	ADP
ajlm-1578	187	5	interferon	interferon	NOUN
ajlm-1578	187	6	vs	vs	ADP
ajlm-1578	187	7	sti571	sti571	PROPN
ajlm-1578	187	8	(	(	PUNCT
ajlm-1578	187	9	iris	iris	NOUN
ajlm-1578	187	10	)	)	PUNCT
ajlm-1578	187	11	8	8	NUM
ajlm-1578	187	12	-	-	PUNCT
ajlm-1578	187	13	year	year	NOUN
ajlm-1578	187	14	follow	follow	NOUN
ajlm-1578	187	15	up	up	ADV
ajlm-1578	187	16	:	:	PUNCT
ajlm-1578	187	17	sustained	sustained	ADJ
ajlm-1578	187	18	survival	survival	NOUN
ajlm-1578	187	19	and	and	CCONJ
ajlm-1578	187	20	low	low	ADJ
ajlm-1578	187	21	risk	risk	NOUN
ajlm-1578	187	22	for	for	ADP
ajlm-1578	187	23	progression	progression	NOUN
ajlm-1578	187	24	or	or	CCONJ
ajlm-1578	187	25	events	event	NOUN
ajlm-1578	187	26	in	in	ADP
ajlm-1578	187	27	patients	patient	NOUN
ajlm-1578	187	28	with	with	ADP
ajlm-1578	187	29	newly	newly	ADV
ajlm-1578	187	30	diagnosed	diagnose	VERB
ajlm-1578	187	31	chronic	chronic	ADJ
ajlm-1578	187	32	myeloid	myeloid	NOUN
ajlm-1578	187	33	leukemia	leukemia	NOUN
ajlm-1578	187	34	in	in	ADP
ajlm-1578	187	35	chronic	chronic	ADJ
ajlm-1578	187	36	phase	phase	NOUN
ajlm-1578	187	37	(	(	PUNCT
ajlm-1578	187	38	cml	cml	PROPN
ajlm-1578	187	39	-	-	PUNCT
ajlm-1578	187	40	cp	cp	NOUN
ajlm-1578	187	41	)	)	PUNCT
ajlm-1578	187	42	treated	treat	VERB
ajlm-1578	187	43	with	with	ADP
ajlm-1578	187	44	imatinib	imatinib	NOUN
ajlm-1578	187	45	.	.	PUNCT
ajlm-1578	188	1	blood	blood	NOUN
ajlm-1578	188	2	.	.	PUNCT
ajlm-1578	189	1	2009;114(22):1126	2009;114(22):1126	X
ajlm-1578	189	2	.	.	PUNCT
ajlm-1578	189	3	https://doi.org/10.1182/blood.v114.22.1126.1126	https://doi.org/10.1182/blood.v114.22.1126.1126	PROPN
ajlm-1578	189	4	sasaki	sasaki	PROPN
ajlm-1578	189	5	k	k	PROPN
ajlm-1578	189	6	,	,	PUNCT
ajlm-1578	189	7	strom	strom	PROPN
ajlm-1578	189	8	ss	ss	PROPN
ajlm-1578	189	9	,	,	PUNCT
ajlm-1578	189	10	o’brien	o’brien	PROPN
ajlm-1578	189	11	s	s	PART
ajlm-1578	189	12	,	,	PUNCT
ajlm-1578	189	13	et	et	PROPN
ajlm-1578	189	14	al	al	PROPN
ajlm-1578	189	15	.	.	PROPN
ajlm-1578	189	16	relative	relative	ADJ
ajlm-1578	189	17	survival	survival	NOUN
ajlm-1578	189	18	in	in	ADP
ajlm-1578	189	19	patients	patient	NOUN
ajlm-1578	189	20	with	with	ADP
ajlm-1578	189	21	chronic	chronic	ADJ
ajlm-1578	189	22	-	-	PUNCT
ajlm-1578	189	23	phase	phase	NOUN
ajlm-1578	189	24	chronic	chronic	ADJ
ajlm-1578	189	25	myeloid	myeloid	NOUN
ajlm-1578	189	26	leukaemia	leukaemia	NOUN
ajlm-1578	189	27	in	in	ADP
ajlm-1578	189	28	the	the	DET
ajlm-1578	189	29	tyrosine	tyrosine	NOUN
ajlm-1578	189	30	-	-	PUNCT
ajlm-1578	189	31	kinase	kinase	PROPN
ajlm-1578	189	32	inhibitor	inhibitor	PROPN
ajlm-1578	189	33	era	era	NOUN
ajlm-1578	189	34	:	:	PUNCT
ajlm-1578	189	35	analysis	analysis	NOUN
ajlm-1578	189	36	of	of	ADP
ajlm-1578	189	37	patient	patient	ADJ
ajlm-1578	189	38	data	datum	NOUN
ajlm-1578	189	39	from	from	ADP
ajlm-1578	189	40	six	six	NUM
ajlm-1578	189	41	prospective	prospective	ADJ
ajlm-1578	189	42	clinical	clinical	ADJ
ajlm-1578	189	43	trials	trial	NOUN
ajlm-1578	189	44	.	.	PUNCT
ajlm-1578	190	1	lancet	lancet	PROPN
ajlm-1578	190	2	haematol	haematol	PROPN
ajlm-1578	190	3	.	.	PUNCT
ajlm-1578	191	1	2015;2(5):e186	2015;2(5):e186	PROPN
ajlm-1578	191	2	–	–	PUNCT
ajlm-1578	191	3	e193	e193	PROPN
ajlm-1578	191	4	.	.	PUNCT
ajlm-1578	192	1	https://doi.org/10.1016/s2352-3026(15)00048-4	https://doi.org/10.1016/s2352-3026(15)00048-4	PROPN
ajlm-1578	192	2	baccarani	baccarani	PROPN
ajlm-1578	192	3	m	m	PROPN
ajlm-1578	192	4	,	,	PUNCT
ajlm-1578	192	5	deininger	deininger	PROPN
ajlm-1578	192	6	mw	mw	PROPN
ajlm-1578	192	7	,	,	PUNCT
ajlm-1578	192	8	rosti	rosti	NOUN
ajlm-1578	192	9	g	g	NOUN
ajlm-1578	192	10	,	,	PUNCT
ajlm-1578	192	11	et	et	PROPN
ajlm-1578	192	12	al	al	PROPN
ajlm-1578	192	13	.	.	PROPN
ajlm-1578	192	14	european	european	PROPN
ajlm-1578	192	15	leukemianet	leukemianet	PROPN
ajlm-1578	192	16	recommendations	recommendation	NOUN
ajlm-1578	192	17	for	for	ADP
ajlm-1578	192	18	the	the	DET
ajlm-1578	192	19	management	management	NOUN
ajlm-1578	192	20	of	of	ADP
ajlm-1578	192	21	chronic	chronic	ADJ
ajlm-1578	192	22	myeloid	myeloid	NOUN
ajlm-1578	192	23	leukemia	leukemia	NOUN
ajlm-1578	192	24	:	:	PUNCT
ajlm-1578	192	25	2013	2013	NUM
ajlm-1578	192	26	.	.	PUNCT
ajlm-1578	193	1	blood	blood	NOUN
ajlm-1578	193	2	.	.	PUNCT
ajlm-1578	194	1	2013;122(6):872–884	2013;122(6):872–884	NUM
ajlm-1578	194	2	.	.	PUNCT
ajlm-1578	194	3	https://doi.org/10.1182/blood-2013-05-501569	https://doi.org/10.1182/blood-2013-05-501569	PROPN
ajlm-1578	194	4	jain	jain	PROPN
ajlm-1578	194	5	p	p	X
ajlm-1578	194	6	,	,	PUNCT
ajlm-1578	194	7	kantarjian	kantarjian	ADJ
ajlm-1578	194	8	hm	hm	INTJ
ajlm-1578	194	9	,	,	PUNCT
ajlm-1578	194	10	ghorab	ghorab	VERB
ajlm-1578	194	11	a	a	PRON
ajlm-1578	194	12	,	,	PUNCT
ajlm-1578	194	13	et	et	PROPN
ajlm-1578	194	14	al	al	PROPN
ajlm-1578	194	15	.	.	PUNCT
ajlm-1578	195	1	prognostic	prognostic	ADJ
ajlm-1578	195	2	factors	factor	NOUN
ajlm-1578	195	3	and	and	CCONJ
ajlm-1578	195	4	survival	survival	NOUN
ajlm-1578	195	5	outcomes	outcome	NOUN
ajlm-1578	195	6	in	in	ADP
ajlm-1578	195	7	patients	patient	NOUN
ajlm-1578	195	8	with	with	ADP
ajlm-1578	195	9	chronic	chronic	ADJ
ajlm-1578	195	10	myeloid	myeloid	NOUN
ajlm-1578	195	11	leukemia	leukemia	NOUN
ajlm-1578	195	12	in	in	ADP
ajlm-1578	195	13	blast	blast	NOUN
ajlm-1578	195	14	phase	phase	NOUN
ajlm-1578	195	15	in	in	ADP
ajlm-1578	195	16	the	the	DET
ajlm-1578	195	17	tyrosine	tyrosine	NOUN
ajlm-1578	195	18	kinase	kinase	PROPN
ajlm-1578	195	19	inhibitor	inhibitor	PROPN
ajlm-1578	195	20	era	era	NOUN
ajlm-1578	195	21	:	:	PUNCT
ajlm-1578	195	22	cohort	cohort	NOUN
ajlm-1578	195	23	study	study	NOUN
ajlm-1578	195	24	of	of	ADP
ajlm-1578	195	25	477	477	NUM
ajlm-1578	195	26	patients	patient	NOUN
ajlm-1578	195	27	.	.	PUNCT
ajlm-1578	196	1	cancer	cancer	NOUN
ajlm-1578	196	2	.	.	PUNCT
ajlm-1578	197	1	2017;123(22):4391–4402	2017;123(22):4391–4402	NUM
ajlm-1578	197	2	.	.	PUNCT
ajlm-1578	198	1	https://doi.org/10.1002/cncr.30864	https://doi.org/10.1002/cncr.30864	PROPN
ajlm-1578	198	2	patel	patel	PROPN
ajlm-1578	198	3	m	m	PROPN
ajlm-1578	198	4	,	,	PUNCT
ajlm-1578	198	5	philip	philip	PROPN
ajlm-1578	198	6	v	v	PROPN
ajlm-1578	198	7	,	,	PUNCT
ajlm-1578	198	8	fazel	fazel	PROPN
ajlm-1578	198	9	f	f	NOUN
ajlm-1578	198	10	,	,	PUNCT
ajlm-1578	198	11	lakha	lakha	PROPN
ajlm-1578	198	12	a	a	NOUN
ajlm-1578	198	13	,	,	PUNCT
ajlm-1578	198	14	vorog	vorog	NOUN
ajlm-1578	198	15	a	a	DET
ajlm-1578	198	16	,	,	PUNCT
ajlm-1578	198	17	ali	ali	PROPN
ajlm-1578	198	18	n	n	PROPN
ajlm-1578	198	19	,	,	PUNCT
ajlm-1578	198	20	et	et	PROPN
ajlm-1578	198	21	al	al	PROPN
ajlm-1578	198	22	.	.	PUNCT
ajlm-1578	199	1	human	human	ADJ
ajlm-1578	199	2	immunodeficiency	immunodeficiency	NOUN
ajlm-1578	199	3	virus	virus	NOUN
ajlm-1578	199	4	infection	infection	NOUN
ajlm-1578	199	5	and	and	CCONJ
ajlm-1578	199	6	chronic	chronic	ADJ
ajlm-1578	199	7	myeloid	myeloid	NOUN
ajlm-1578	199	8	leukemia	leukemia	NOUN
ajlm-1578	199	9	.	.	PUNCT
ajlm-1578	200	1	leuk	leuk	PROPN
ajlm-1578	200	2	res	re	NOUN
ajlm-1578	200	3	.	.	PUNCT
ajlm-1578	201	1	2012;36(11):1334–8	2012;36(11):1334–8	NUM
ajlm-1578	201	2	.	.	PUNCT
ajlm-1578	201	3	https://doi.10.1016	https://doi.10.1016	PROPN
ajlm-1578	201	4	/	/	SYM
ajlm-1578	201	5	j.leukres.2012.07.012	j.leukres.2012.07.012	PROPN
ajlm-1578	201	6	.	.	PROPN
ajlm-1578	202	1	oliver	oliver	PROPN
ajlm-1578	202	2	s	s	PROPN
ajlm-1578	202	3	,	,	PUNCT
ajlm-1578	202	4	samy	samy	PROPN
ajlm-1578	202	5	f	f	PROPN
ajlm-1578	202	6	,	,	PUNCT
ajlm-1578	202	7	lawton	lawton	PROPN
ajlm-1578	202	8	s	s	PROPN
ajlm-1578	202	9	,	,	PUNCT
ajlm-1578	202	10	et	et	PROPN
ajlm-1578	202	11	al	al	PROPN
ajlm-1578	202	12	.	.	PUNCT
ajlm-1578	203	1	national	national	PROPN
ajlm-1578	203	2	cancer	cancer	PROPN
ajlm-1578	203	3	intelligence	intelligence	NOUN
ajlm-1578	203	4	network	network	NOUN
ajlm-1578	203	5	trends	trend	NOUN
ajlm-1578	203	6	in	in	ADP
ajlm-1578	203	7	incidence	incidence	NOUN
ajlm-1578	203	8	and	and	CCONJ
ajlm-1578	203	9	outcome	outcome	VERB
ajlm-1578	203	10	for	for	ADP
ajlm-1578	203	11	haematological	haematological	ADJ
ajlm-1578	203	12	cancers	cancer	NOUN
ajlm-1578	203	13	in	in	ADP
ajlm-1578	203	14	england	england	PROPN
ajlm-1578	203	15	:	:	PUNCT
ajlm-1578	203	16	2001–2010	2001–2010	NUM
ajlm-1578	203	17	public	public	ADJ
ajlm-1578	203	18	health	health	PROPN
ajlm-1578	203	19	england	england	PROPN
ajlm-1578	203	20	,	,	PUNCT
ajlm-1578	203	21	wellington	wellington	PROPN
ajlm-1578	203	22	house	house	PROPN
ajlm-1578	203	23	,	,	PUNCT
ajlm-1578	203	24	133	133	NUM
ajlm-1578	203	25	-	-	SYM
ajlm-1578	203	26	155	155	NUM
ajlm-1578	203	27	waterloo	waterloo	PROPN
ajlm-1578	203	28	road	road	PROPN
ajlm-1578	203	29	london	london	PROPN
ajlm-1578	203	30	se1	se1	PROPN
ajlm-1578	203	31	8ug	8ug	PROPN
ajlm-1578	203	32	:	:	PUNCT
ajlm-1578	203	33	phe	phe	NOUN
ajlm-1578	203	34	publications	publication	NOUN
ajlm-1578	203	35	gateway	gateway	NOUN
ajlm-1578	203	36	number	number	NOUN
ajlm-1578	203	37	;	;	PUNCT
ajlm-1578	203	38	november	november	PROPN
ajlm-1578	203	39	2014	2014	NUM
ajlm-1578	203	40	.	.	PUNCT
ajlm-1578	204	1	khalidi	khalidi	PROPN
ajlm-1578	204	2	hs	hs	PROPN
ajlm-1578	204	3	,	,	PUNCT
ajlm-1578	204	4	brynes	bryne	VERB
ajlm-1578	204	5	rk	rk	PROPN
ajlm-1578	204	6	,	,	PUNCT
ajlm-1578	204	7	medeiros	medeiros	PROPN
ajlm-1578	204	8	lj	lj	PROPN
ajlm-1578	204	9	,	,	PUNCT
ajlm-1578	204	10	et	et	PROPN
ajlm-1578	204	11	al	al	PROPN
ajlm-1578	204	12	.	.	PUNCT
ajlm-1578	205	1	the	the	DET
ajlm-1578	205	2	immunophenotype	immunophenotype	NOUN
ajlm-1578	205	3	of	of	ADP
ajlm-1578	205	4	blast	blast	NOUN
ajlm-1578	205	5	transformation	transformation	NOUN
ajlm-1578	205	6	of	of	ADP
ajlm-1578	205	7	chronic	chronic	ADJ
ajlm-1578	205	8	myelogenous	myelogenous	ADJ
ajlm-1578	205	9	leukemia	leukemia	NOUN
ajlm-1578	205	10	:	:	PUNCT
ajlm-1578	205	11	a	a	DET
ajlm-1578	205	12	high	high	ADJ
ajlm-1578	205	13	frequency	frequency	NOUN
ajlm-1578	205	14	of	of	ADP
ajlm-1578	205	15	mixed	mixed	ADJ
ajlm-1578	205	16	lineage	lineage	NOUN
ajlm-1578	205	17	phenotype	phenotype	NOUN
ajlm-1578	205	18	in	in	ADP
ajlm-1578	205	19	‘	'	PUNCT
ajlm-1578	205	20	lymphoid	lymphoid	ADJ
ajlm-1578	205	21	’	'	PUNCT
ajlm-1578	205	22	blasts	blast	NOUN
ajlm-1578	205	23	and	and	CCONJ
ajlm-1578	205	24	a	a	DET
ajlm-1578	205	25	comparison	comparison	NOUN
ajlm-1578	205	26	of	of	ADP
ajlm-1578	205	27	morphologic	morphologic	ADJ
ajlm-1578	205	28	,	,	PUNCT
ajlm-1578	205	29	immunophenotypic	immunophenotypic	ADJ
ajlm-1578	205	30	,	,	PUNCT
ajlm-1578	205	31	and	and	CCONJ
ajlm-1578	205	32	molecular	molecular	ADJ
ajlm-1578	205	33	findings	finding	NOUN
ajlm-1578	205	34	.	.	PUNCT
ajlm-1578	206	1	mod	mod	PROPN
ajlm-1578	206	2	pathol	pathol	PROPN
ajlm-1578	206	3	.	.	PUNCT
ajlm-1578	207	1	1998;11(12):1211–1221	1998;11(12):1211–1221	X
ajlm-1578	207	2	.	.	PUNCT
ajlm-1578	208	1	https://doi.org/10.1093/ajcp/109.2.211	https://doi.org/10.1093/ajcp/109.2.211	PROPN
ajlm-1578	208	2	höglund	höglund	PROPN
ajlm-1578	208	3	m	m	PROPN
ajlm-1578	208	4	,	,	PUNCT
ajlm-1578	208	5	sandin	sandin	VERB
ajlm-1578	208	6	f	f	X
ajlm-1578	208	7	,	,	PUNCT
ajlm-1578	208	8	hellström	hellström	PROPN
ajlm-1578	208	9	k	k	PROPN
ajlm-1578	208	10	,	,	PUNCT
ajlm-1578	208	11	et	et	PROPN
ajlm-1578	208	12	al	al	PROPN
ajlm-1578	208	13	.	.	PUNCT
ajlm-1578	209	1	tyrosine	tyrosine	PROPN
ajlm-1578	209	2	kinase	kinase	PROPN
ajlm-1578	209	3	inhibitor	inhibitor	NOUN
ajlm-1578	209	4	usage	usage	NOUN
ajlm-1578	209	5	,	,	PUNCT
ajlm-1578	209	6	treatment	treatment	NOUN
ajlm-1578	209	7	outcome	outcome	NOUN
ajlm-1578	209	8	,	,	PUNCT
ajlm-1578	209	9	and	and	CCONJ
ajlm-1578	209	10	prognostic	prognostic	ADJ
ajlm-1578	209	11	scores	score	NOUN
ajlm-1578	209	12	in	in	ADP
ajlm-1578	209	13	cml	cml	PROPN
ajlm-1578	209	14	:	:	PUNCT
ajlm-1578	209	15	report	report	NOUN
ajlm-1578	209	16	from	from	ADP
ajlm-1578	209	17	the	the	DET
ajlm-1578	209	18	population	population	NOUN
ajlm-1578	209	19	-	-	PUNCT
ajlm-1578	209	20	based	base	VERB
ajlm-1578	209	21	swedish	swedish	PROPN
ajlm-1578	209	22	cml	cml	PROPN
ajlm-1578	209	23	registry	registry	PROPN
ajlm-1578	209	24	.	.	PUNCT
ajlm-1578	210	1	blood	blood	NOUN
ajlm-1578	210	2	.	.	PUNCT
ajlm-1578	211	1	2013;122(7):1284–1292	2013;122(7):1284–1292	NUM
ajlm-1578	211	2	.	.	PUNCT
ajlm-1578	211	3	https://doi.org/10.1182/blood-2013-04-495598	https://doi.org/10.1182/blood-2013-04-495598	NUM
ajlm-1578	211	4	lópez	lópez	NOUN
ajlm-1578	211	5	-	-	PUNCT
ajlm-1578	211	6	karpovitch	karpovitch	NOUN
ajlm-1578	211	7	x	x	PROPN
ajlm-1578	211	8	,	,	PUNCT
ajlm-1578	211	9	cárdenas	cárdenas	PROPN
ajlm-1578	211	10	r	r	PROPN
ajlm-1578	211	11	,	,	PUNCT
ajlm-1578	211	12	piedras	piedras	PROPN
ajlm-1578	211	13	j.	j.	PROPN
ajlm-1578	211	14	immunophenotypic	immunophenotypic	PROPN
ajlm-1578	211	15	characteristics	characteristic	NOUN
ajlm-1578	211	16	of	of	ADP
ajlm-1578	211	17	the	the	DET
ajlm-1578	211	18	blast	blast	NOUN
ajlm-1578	211	19	crisis	crisis	NOUN
ajlm-1578	211	20	in	in	ADP
ajlm-1578	211	21	chronic	chronic	ADJ
ajlm-1578	211	22	myeloid	myeloid	NOUN
ajlm-1578	211	23	leukemia	leukemia	NOUN
ajlm-1578	211	24	.	.	PUNCT
ajlm-1578	212	1	rev	rev	AUX
ajlm-1578	212	2	invest	invest	VERB
ajlm-1578	212	3	clin	clin	PROPN
ajlm-1578	212	4	.	.	PUNCT
ajlm-1578	213	1	1997;49(1):31–36	1997;49(1):31–36	NUM
ajlm-1578	213	2	.	.	PUNCT
ajlm-1578	213	3	yen	yen	PROPN
ajlm-1578	213	4	cc	cc	PROPN
ajlm-1578	213	5	,	,	PUNCT
ajlm-1578	213	6	liu	liu	PROPN
ajlm-1578	213	7	jh	jh	PROPN
ajlm-1578	213	8	,	,	PUNCT
ajlm-1578	213	9	wang	wang	PROPN
ajlm-1578	213	10	ws	ws	PROPN
ajlm-1578	213	11	,	,	PUNCT
ajlm-1578	213	12	et	et	PROPN
ajlm-1578	213	13	al	al	PROPN
ajlm-1578	213	14	.	.	PROPN
ajlm-1578	213	15	immunophenotypic	immunophenotypic	ADJ
ajlm-1578	213	16	and	and	CCONJ
ajlm-1578	213	17	genotypic	genotypic	ADJ
ajlm-1578	213	18	characteristics	characteristic	NOUN
ajlm-1578	213	19	of	of	ADP
ajlm-1578	213	20	chronic	chronic	ADJ
ajlm-1578	213	21	myelogenous	myelogenous	ADJ
ajlm-1578	213	22	leukemia	leukemia	NOUN
ajlm-1578	213	23	in	in	ADP
ajlm-1578	213	24	blast	blast	NOUN
ajlm-1578	213	25	crisis	crisis	NOUN
ajlm-1578	213	26	.	.	PUNCT
ajlm-1578	214	1	zhonghua	zhonghua	PROPN
ajlm-1578	214	2	yi	yi	PROPN
ajlm-1578	214	3	xue	xue	PROPN
ajlm-1578	214	4	za	za	PROPN
ajlm-1578	214	5	zhi	zhi	PROPN
ajlm-1578	214	6	(	(	PUNCT
ajlm-1578	214	7	taipei	taipei	PROPN
ajlm-1578	214	8	)	)	PUNCT
ajlm-1578	214	9	.	.	PUNCT
ajlm-1578	215	1	2000;63(11):785–791	2000;63(11):785–791	NUM
ajlm-1578	215	2	.	.	PUNCT
ajlm-1578	216	1	verma	verma	PROPN
ajlm-1578	216	2	d	d	PROPN
ajlm-1578	216	3	,	,	PUNCT
ajlm-1578	216	4	kantarjian	kantarjian	ADJ
ajlm-1578	216	5	hm	hm	PROPN
ajlm-1578	216	6	,	,	PUNCT
ajlm-1578	216	7	jones	jones	PROPN
ajlm-1578	216	8	d	d	PROPN
ajlm-1578	216	9	,	,	PUNCT
ajlm-1578	216	10	et	et	PROPN
ajlm-1578	216	11	al	al	PROPN
ajlm-1578	216	12	.	.	PROPN
ajlm-1578	216	13	chronic	chronic	ADJ
ajlm-1578	216	14	myeloid	myeloid	PROPN
ajlm-1578	216	15	leukemia	leukemia	NOUN
ajlm-1578	216	16	(	(	PUNCT
ajlm-1578	216	17	cml	cml	PROPN
ajlm-1578	216	18	)	)	PUNCT
ajlm-1578	216	19	with	with	ADP
ajlm-1578	216	20	p190	p190	PROPN
ajlm-1578	216	21	bcr	bcr	PROPN
ajlm-1578	216	22	-	-	PUNCT
ajlm-1578	216	23	abl	abl	NOUN
ajlm-1578	216	24	:	:	PUNCT
ajlm-1578	216	25	analysis	analysis	NOUN
ajlm-1578	216	26	of	of	ADP
ajlm-1578	216	27	characteristics	characteristic	NOUN
ajlm-1578	216	28	,	,	PUNCT
ajlm-1578	216	29	outcomes	outcome	NOUN
ajlm-1578	216	30	,	,	PUNCT
ajlm-1578	216	31	and	and	CCONJ
ajlm-1578	216	32	prognostic	prognostic	ADJ
ajlm-1578	216	33	significance	significance	NOUN
ajlm-1578	216	34	.	.	PUNCT
ajlm-1578	217	1	blood	blood	NOUN
ajlm-1578	217	2	.	.	PUNCT
ajlm-1578	218	1	2009;114(11):2232–2235	2009;114(11):2232–2235	X
ajlm-1578	218	2	.	.	NOUN
ajlm-1578	218	3	https://doi.org/10.1182/blood-2009-02-204693	https://doi.org/10.1182/blood-2009-02-204693	PROPN
ajlm-1578	218	4	van	van	PROPN
ajlm-1578	218	5	rhee	rhee	PROPN
ajlm-1578	218	6	f	f	PROPN
ajlm-1578	218	7	,	,	PUNCT
ajlm-1578	218	8	hochhaus	hochhaus	PROPN
ajlm-1578	218	9	a	a	NOUN
ajlm-1578	218	10	,	,	PUNCT
ajlm-1578	218	11	lin	lin	PROPN
ajlm-1578	218	12	f	f	PROPN
ajlm-1578	218	13	,	,	PUNCT
ajlm-1578	218	14	et	et	PROPN
ajlm-1578	218	15	al	al	PROPN
ajlm-1578	218	16	.	.	PUNCT
ajlm-1578	219	1	p190	p190	ADJ
ajlm-1578	219	2	bcr	bcr	PROPN
ajlm-1578	219	3	-	-	PUNCT
ajlm-1578	219	4	abl	abl	PROPN
ajlm-1578	219	5	mrna	mrna	PROPN
ajlm-1578	219	6	is	be	AUX
ajlm-1578	219	7	expressed	express	VERB
ajlm-1578	219	8	at	at	ADP
ajlm-1578	219	9	low	low	ADJ
ajlm-1578	219	10	levels	level	NOUN
ajlm-1578	219	11	in	in	ADP
ajlm-1578	219	12	p210	p210	ADJ
ajlm-1578	219	13	-	-	ADJ
ajlm-1578	219	14	positive	positive	ADJ
ajlm-1578	219	15	chronic	chronic	ADJ
ajlm-1578	219	16	myeloid	myeloid	NOUN
ajlm-1578	219	17	and	and	CCONJ
ajlm-1578	219	18	acute	acute	ADJ
ajlm-1578	219	19	lymphoblastic	lymphoblastic	ADJ
ajlm-1578	219	20	leukemias	leukemia	NOUN
ajlm-1578	219	21	.	.	PUNCT
ajlm-1578	220	1	blood	blood	NOUN
ajlm-1578	220	2	.	.	PUNCT
ajlm-1578	221	1	1996;87(12):5213–5217	1996;87(12):5213–5217	NUM
ajlm-1578	221	2	.	.	PUNCT
ajlm-1578	222	1	https://doi.org/10.1182/blood.v87.12.5213.bloodjournal87125213	https://doi.org/10.1182/blood.v87.12.5213.bloodjournal87125213	PROPN
ajlm-1578	222	2	issa	issa	PROPN
ajlm-1578	222	3	gc	gc	PROPN
ajlm-1578	222	4	,	,	PUNCT
ajlm-1578	222	5	kantarjian	kantarjian	PROPN
ajlm-1578	222	6	hm	hm	PROPN
ajlm-1578	222	7	,	,	PUNCT
ajlm-1578	222	8	gonzalez	gonzalez	PROPN
ajlm-1578	222	9	gn	gn	PROPN
ajlm-1578	222	10	,	,	PUNCT
ajlm-1578	222	11	et	et	PROPN
ajlm-1578	222	12	al	al	PROPN
ajlm-1578	222	13	.	.	PROPN
ajlm-1578	222	14	clonal	clonal	ADJ
ajlm-1578	222	15	chromosomal	chromosomal	ADJ
ajlm-1578	222	16	abnormalities	abnormality	NOUN
ajlm-1578	222	17	appearing	appear	VERB
ajlm-1578	222	18	in	in	ADP
ajlm-1578	222	19	philadelphia	philadelphia	PROPN
ajlm-1578	222	20	chromosome	chromosome	NOUN
ajlm-1578	222	21	-	-	PUNCT
ajlm-1578	222	22	negative	negative	ADJ
ajlm-1578	222	23	metaphases	metaphase	NOUN
ajlm-1578	222	24	during	during	ADP
ajlm-1578	222	25	cml	cml	PROPN
ajlm-1578	222	26	treatment	treatment	NOUN
ajlm-1578	222	27	.	.	PUNCT
ajlm-1578	223	1	blood	blood	NOUN
ajlm-1578	223	2	.	.	PUNCT
ajlm-1578	224	1	2017;130(19):2084–2091	2017;130(19):2084–2091	NUM
ajlm-1578	224	2	.	.	PUNCT
ajlm-1578	224	3	https://doi.org/10.1182/blood-2017-07-792143	https://doi.org/10.1182/blood-2017-07-792143	NOUN
ajlm-1578	224	4	hehlmann	hehlmann	PROPN
ajlm-1578	224	5	r	r	NOUN
ajlm-1578	224	6	,	,	PUNCT
ajlm-1578	224	7	voskanyan	voskanyan	VERB
ajlm-1578	224	8	a	a	PRON
ajlm-1578	224	9	,	,	PUNCT
ajlm-1578	224	10	lauseker	lauseker	NOUN
ajlm-1578	224	11	m	m	PROPN
ajlm-1578	224	12	,	,	PUNCT
ajlm-1578	224	13	et	et	PROPN
ajlm-1578	224	14	al	al	PROPN
ajlm-1578	224	15	.	.	PROPN
ajlm-1578	225	1	high	high	ADJ
ajlm-1578	225	2	-	-	PUNCT
ajlm-1578	225	3	risk	risk	NOUN
ajlm-1578	225	4	additional	additional	ADJ
ajlm-1578	225	5	chromosomal	chromosomal	ADJ
ajlm-1578	225	6	abnormalities	abnormality	NOUN
ajlm-1578	225	7	at	at	ADP
ajlm-1578	225	8	low	low	ADJ
ajlm-1578	225	9	blast	blast	NOUN
ajlm-1578	225	10	counts	count	VERB
ajlm-1578	225	11	herald	herald	PROPN
ajlm-1578	225	12	death	death	NOUN
ajlm-1578	225	13	by	by	ADP
ajlm-1578	225	14	cml	cml	PROPN
ajlm-1578	225	15	.	.	PUNCT
ajlm-1578	225	16	leukemia	leukemia	NOUN
ajlm-1578	225	17	.	.	PUNCT
ajlm-1578	226	1	2020;34(8):2074–2086	2020;34(8):2074–2086	NUM
ajlm-1578	226	2	.	.	PUNCT
ajlm-1578	227	1	https://doi.org/10.1038/s41375-020-0826-9	https://doi.org/10.1038/s41375-020-0826-9	NOUN
ajlm-1578	227	2	cervantes	cervante	VERB
ajlm-1578	227	3	f	f	PROPN
ajlm-1578	227	4	,	,	PUNCT
ajlm-1578	227	5	rozman	rozman	PROPN
ajlm-1578	227	6	m	m	PROPN
ajlm-1578	227	7	,	,	PUNCT
ajlm-1578	227	8	rosell	rosell	PROPN
ajlm-1578	227	9	j	j	PROPN
ajlm-1578	227	10	,	,	PUNCT
ajlm-1578	227	11	et	et	PROPN
ajlm-1578	227	12	al	al	PROPN
ajlm-1578	227	13	.	.	PUNCT
ajlm-1578	228	1	a	a	DET
ajlm-1578	228	2	study	study	NOUN
ajlm-1578	228	3	of	of	ADP
ajlm-1578	228	4	prognostic	prognostic	ADJ
ajlm-1578	228	5	factors	factor	NOUN
ajlm-1578	228	6	in	in	ADP
ajlm-1578	228	7	blast	blast	NOUN
ajlm-1578	228	8	crisis	crisis	NOUN
ajlm-1578	228	9	of	of	ADP
ajlm-1578	228	10	philadelphia	philadelphia	PROPN
ajlm-1578	228	11	chromosome	chromosome	NOUN
ajlm-1578	228	12	-	-	PUNCT
ajlm-1578	228	13	positive	positive	ADJ
ajlm-1578	228	14	chronic	chronic	ADJ
ajlm-1578	228	15	myelogenous	myelogenous	ADJ
ajlm-1578	228	16	leukaemia	leukaemia	NOUN
ajlm-1578	228	17	.	.	PUNCT
ajlm-1578	229	1	br	br	X
ajlm-1578	229	2	j	j	PROPN
ajlm-1578	229	3	haematol	haematol	NOUN
ajlm-1578	229	4	.	.	PUNCT
ajlm-1578	230	1	1990;76(1):27–32	1990;76(1):27–32	X
ajlm-1578	230	2	.	.	PUNCT
ajlm-1578	231	1	https://doi.org/10.1111/j.1365-2141.1990.tb07832.x	https://doi.org/10.1111/j.1365-2141.1990.tb07832.x	PROPN
ajlm-1578	231	2	takahashi	takahashi	PROPN
ajlm-1578	231	3	k	k	PROPN
ajlm-1578	231	4	,	,	PUNCT
ajlm-1578	231	5	kantarjian	kantarjian	PROPN
ajlm-1578	231	6	hm	hm	PROPN
ajlm-1578	231	7	,	,	PUNCT
ajlm-1578	231	8	yang	yang	PROPN
ajlm-1578	231	9	y	y	PROPN
ajlm-1578	231	10	,	,	PUNCT
ajlm-1578	231	11	et	et	PROPN
ajlm-1578	231	12	al	al	PROPN
ajlm-1578	231	13	.	.	PUNCT
ajlm-1578	232	1	a	a	DET
ajlm-1578	232	2	propensity	propensity	NOUN
ajlm-1578	232	3	score	score	NOUN
ajlm-1578	232	4	matching	match	VERB
ajlm-1578	232	5	analysis	analysis	NOUN
ajlm-1578	232	6	of	of	ADP
ajlm-1578	232	7	dasatinib	dasatinib	NOUN
ajlm-1578	232	8	and	and	CCONJ
ajlm-1578	232	9	nilotinib	nilotinib	NOUN
ajlm-1578	232	10	as	as	ADP
ajlm-1578	232	11	a	a	DET
ajlm-1578	232	12	frontline	frontline	NOUN
ajlm-1578	232	13	therapy	therapy	NOUN
ajlm-1578	232	14	for	for	ADP
ajlm-1578	232	15	patients	patient	NOUN
ajlm-1578	232	16	with	with	ADP
ajlm-1578	232	17	chronic	chronic	ADJ
ajlm-1578	232	18	myeloid	myeloid	NOUN
ajlm-1578	232	19	leukemia	leukemia	NOUN
ajlm-1578	232	20	in	in	ADP
ajlm-1578	232	21	chronic	chronic	ADJ
ajlm-1578	232	22	phase	phase	NOUN
ajlm-1578	232	23	.	.	PUNCT
ajlm-1578	233	1	cancer	cancer	NOUN
ajlm-1578	233	2	.	.	PUNCT
ajlm-1578	234	1	2016;122(21):3336–3343	2016;122(21):3336–3343	NUM
ajlm-1578	234	2	.	.	PROPN
ajlm-1578	234	3	https://doi.org/10.1002/cncr.30197	https://doi.org/10.1002/cncr.30197	PROPN
ajlm-1578	234	4	sasaki	sasaki	PROPN
ajlm-1578	234	5	k	k	PROPN
ajlm-1578	234	6	,	,	PUNCT
ajlm-1578	234	7	lahoti	lahoti	PROPN
ajlm-1578	234	8	a	a	DET
ajlm-1578	234	9	,	,	PUNCT
ajlm-1578	234	10	jabbour	jabbour	NOUN
ajlm-1578	234	11	e	e	NOUN
ajlm-1578	234	12	,	,	PUNCT
ajlm-1578	234	13	et	et	PROPN
ajlm-1578	234	14	al	al	PROPN
ajlm-1578	234	15	.	.	PROPN
ajlm-1578	235	1	clinical	clinical	ADJ
ajlm-1578	235	2	safety	safety	NOUN
ajlm-1578	235	3	and	and	CCONJ
ajlm-1578	235	4	efficacy	efficacy	NOUN
ajlm-1578	235	5	of	of	ADP
ajlm-1578	235	6	nilotinib	nilotinib	NOUN
ajlm-1578	235	7	or	or	CCONJ
ajlm-1578	235	8	dasatinib	dasatinib	NOUN
ajlm-1578	235	9	in	in	ADP
ajlm-1578	235	10	patients	patient	NOUN
ajlm-1578	235	11	with	with	ADP
ajlm-1578	235	12	newly	newly	ADV
ajlm-1578	235	13	diagnosed	diagnose	VERB
ajlm-1578	235	14	chronic	chronic	ADJ
ajlm-1578	235	15	-	-	PUNCT
ajlm-1578	235	16	phase	phase	NOUN
ajlm-1578	235	17	chronic	chronic	ADJ
ajlm-1578	235	18	myelogenous	myelogenous	ADJ
ajlm-1578	235	19	leukemia	leukemia	NOUN
ajlm-1578	235	20	and	and	CCONJ
ajlm-1578	235	21	pre	pre	ADJ
ajlm-1578	235	22	-	-	ADJ
ajlm-1578	235	23	existing	existing	ADJ
ajlm-1578	235	24	liver	liver	NOUN
ajlm-1578	235	25	and/or	and/or	CCONJ
ajlm-1578	235	26	renal	renal	ADJ
ajlm-1578	235	27	dysfunction	dysfunction	NOUN
ajlm-1578	235	28	.	.	PUNCT
ajlm-1578	236	1	clin	clin	PROPN
ajlm-1578	236	2	lymphoma	lymphoma	PROPN
ajlm-1578	236	3	myeloma	myeloma	PROPN
ajlm-1578	236	4	leuk	leuk	PROPN
ajlm-1578	236	5	.	.	PUNCT
ajlm-1578	237	1	2016;16(3):152–162	2016;16(3):152–162	X
ajlm-1578	237	2	.	.	PUNCT
ajlm-1578	238	1	https://doi.org/10.1016/j.clml.2015.12.003	https://doi.org/10.1016/j.clml.2015.12.003	ADJ
ajlm-1578	238	2	hochhaus	hochhaus	NOUN
ajlm-1578	238	3	a	a	NOUN
ajlm-1578	238	4	,	,	PUNCT
ajlm-1578	238	5	saussele	saussele	NOUN
ajlm-1578	238	6	s	s	PART
ajlm-1578	238	7	,	,	PUNCT
ajlm-1578	238	8	rosti	rosti	NOUN
ajlm-1578	238	9	g	g	NOUN
ajlm-1578	238	10	,	,	PUNCT
ajlm-1578	238	11	et	et	PROPN
ajlm-1578	238	12	al	al	PROPN
ajlm-1578	238	13	.	.	PROPN
ajlm-1578	238	14	chronic	chronic	ADJ
ajlm-1578	238	15	myeloid	myeloid	NOUN
ajlm-1578	238	16	leukaemia	leukaemia	NOUN
ajlm-1578	238	17	:	:	PUNCT
ajlm-1578	238	18	esmo	esmo	VERB
ajlm-1578	238	19	clinical	clinical	ADJ
ajlm-1578	238	20	practice	practice	NOUN
ajlm-1578	238	21	guidelines	guideline	NOUN
ajlm-1578	238	22	for	for	ADP
ajlm-1578	238	23	diagnosis	diagnosis	NOUN
ajlm-1578	238	24	,	,	PUNCT
ajlm-1578	238	25	treatment	treatment	NOUN
ajlm-1578	238	26	and	and	CCONJ
ajlm-1578	238	27	follow	follow	NOUN
ajlm-1578	238	28	-	-	PUNCT
ajlm-1578	238	29	up	up	NOUN
ajlm-1578	238	30	.	.	PUNCT
ajlm-1578	239	1	ann	ann	PROPN
ajlm-1578	239	2	oncol	oncol	PROPN
ajlm-1578	239	3	.	.	PUNCT
ajlm-1578	240	1	2017;28(suppl_4):iv41	2017;28(suppl_4):iv41	NUM
ajlm-1578	240	2	–	–	PUNCT
ajlm-1578	240	3	iv51	iv51	PROPN
ajlm-1578	240	4	.	.	PUNCT
ajlm-1578	240	5	https://doi.org/10.1093/annonc/mdx219	https://doi.org/10.1093/annonc/mdx219	PROPN
ajlm-1578	240	6	radich	radich	VERB
ajlm-1578	240	7	jp	jp	PROPN
ajlm-1578	240	8	,	,	PUNCT
ajlm-1578	240	9	deininger	deininger	PROPN
ajlm-1578	240	10	m	m	PROPN
ajlm-1578	240	11	,	,	PUNCT
ajlm-1578	240	12	abboud	abboud	PROPN
ajlm-1578	240	13	cn	cn	PROPN
ajlm-1578	240	14	,	,	PUNCT
ajlm-1578	240	15	et	et	PROPN
ajlm-1578	240	16	al	al	PROPN
ajlm-1578	240	17	.	.	PROPN
ajlm-1578	240	18	chronic	chronic	ADJ
ajlm-1578	240	19	myeloid	myeloid	NOUN
ajlm-1578	240	20	leukemia	leukemia	NOUN
ajlm-1578	240	21	,	,	PUNCT
ajlm-1578	240	22	version	version	NOUN
ajlm-1578	240	23	1.2019	1.2019	NUM
ajlm-1578	240	24	,	,	PUNCT
ajlm-1578	240	25	nccn	nccn	ADJ
ajlm-1578	240	26	clinical	clinical	ADJ
ajlm-1578	240	27	practice	practice	NOUN
ajlm-1578	240	28	guidelines	guideline	NOUN
ajlm-1578	240	29	in	in	ADP
ajlm-1578	240	30	oncology	oncology	NOUN
ajlm-1578	240	31	.	.	PUNCT
ajlm-1578	241	1	j	j	PROPN
ajlm-1578	241	2	natl	natl	PROPN
ajlm-1578	241	3	compr	compr	PROPN
ajlm-1578	241	4	canc	canc	PROPN
ajlm-1578	241	5	netw	netw	PROPN
ajlm-1578	241	6	.	.	PUNCT
ajlm-1578	242	1	2018;16(9):1108–1135	2018;16(9):1108–1135	NOUN
ajlm-1578	242	2	.	.	PUNCT
ajlm-1578	243	1	https://doi.org/10.6004/jnccn.2018.0071	https://doi.org/10.6004/jnccn.2018.0071	PROPN
ajlm-1578	243	2	rea	rea	VERB
ajlm-1578	244	1	d	d	NOUN
ajlm-1578	244	2	,	,	PUNCT
ajlm-1578	244	3	ame	ame	PROPN
ajlm-1578	244	4	s	s	PROPN
ajlm-1578	244	5	,	,	PUNCT
ajlm-1578	244	6	berger	berger	PROPN
ajlm-1578	244	7	m	m	PROPN
ajlm-1578	244	8	,	,	PUNCT
ajlm-1578	244	9	et	et	PROPN
ajlm-1578	244	10	al	al	PROPN
ajlm-1578	244	11	.	.	PUNCT
ajlm-1578	245	1	discontinuation	discontinuation	NOUN
ajlm-1578	245	2	of	of	ADP
ajlm-1578	245	3	tyrosine	tyrosine	NOUN
ajlm-1578	245	4	kinase	kinase	PROPN
ajlm-1578	245	5	inhibitors	inhibitor	NOUN
ajlm-1578	245	6	in	in	ADP
ajlm-1578	245	7	chronic	chronic	ADJ
ajlm-1578	245	8	myeloid	myeloid	NOUN
ajlm-1578	245	9	leukemia	leukemia	NOUN
ajlm-1578	245	10	:	:	PUNCT
ajlm-1578	245	11	recommendations	recommendation	NOUN
ajlm-1578	245	12	for	for	ADP
ajlm-1578	245	13	clinical	clinical	ADJ
ajlm-1578	245	14	practice	practice	NOUN
ajlm-1578	245	15	from	from	ADP
ajlm-1578	245	16	the	the	DET
ajlm-1578	245	17	french	french	ADJ
ajlm-1578	245	18	chronic	chronic	ADJ
ajlm-1578	245	19	myeloid	myeloid	NOUN
ajlm-1578	245	20	leukemia	leukemia	PROPN
ajlm-1578	245	21	study	study	NOUN
ajlm-1578	245	22	group	group	NOUN
ajlm-1578	245	23	.	.	PUNCT
ajlm-1578	246	1	cancer	cancer	NOUN
ajlm-1578	246	2	.	.	PUNCT
ajlm-1578	247	1	2018;124(14):2956–2963	2018;124(14):2956–2963	NUM
ajlm-1578	247	2	.	.	PUNCT
ajlm-1578	248	1	https://doi.org/10.1002/cncr.31411	https://doi.org/10.1002/cncr.31411	NOUN
ajlm-1578	248	2	hughes	hughes	PROPN
ajlm-1578	248	3	tp	tp	PROPN
ajlm-1578	248	4	,	,	PUNCT
ajlm-1578	248	5	ross	ross	PROPN
ajlm-1578	248	6	dm	dm	PROPN
ajlm-1578	248	7	.	.	PUNCT
ajlm-1578	249	1	moving	move	VERB
ajlm-1578	249	2	treatment	treatment	NOUN
ajlm-1578	249	3	-	-	PUNCT
ajlm-1578	249	4	free	free	ADJ
ajlm-1578	249	5	remission	remission	NOUN
ajlm-1578	249	6	into	into	ADP
ajlm-1578	249	7	mainstream	mainstream	ADJ
ajlm-1578	249	8	clinical	clinical	ADJ
ajlm-1578	249	9	practice	practice	NOUN
ajlm-1578	249	10	in	in	ADP
ajlm-1578	249	11	cml	cml	PROPN
ajlm-1578	249	12	.	.	PUNCT
ajlm-1578	249	13	blood	blood	NOUN
ajlm-1578	249	14	.	.	PUNCT
ajlm-1578	250	1	2016;128(1):17–23	2016;128(1):17–23	X
ajlm-1578	250	2	.	.	PUNCT
ajlm-1578	250	3	https://doi.org/10.1182/blood-2016-01-694265	https://doi.org/10.1182/blood-2016-01-694265	NUM
ajlm-1578	250	4	hehlmann	hehlmann	PROPN
ajlm-1578	250	5	r.	r.	PROPN
ajlm-1578	250	6	how	how	SCONJ
ajlm-1578	250	7	i	i	PRON
ajlm-1578	250	8	treat	treat	VERB
ajlm-1578	250	9	cml	cml	PROPN
ajlm-1578	250	10	blast	blast	NOUN
ajlm-1578	250	11	crisis	crisis	NOUN
ajlm-1578	250	12	.	.	PUNCT
ajlm-1578	251	1	blood	blood	NOUN
ajlm-1578	251	2	.	.	PUNCT
ajlm-1578	252	1	2012;120(4):737–747	2012;120(4):737–747	X
ajlm-1578	252	2	.	.	PUNCT
ajlm-1578	252	3	https://doi.org/10.1182/blood-2012-03-380147	https://doi.org/10.1182/blood-2012-03-380147	NUM
ajlm-1578	252	4	palandri	palandri	PROPN
ajlm-1578	252	5	f	f	PROPN
ajlm-1578	252	6	,	,	PUNCT
ajlm-1578	252	7	castagnetti	castagnetti	NOUN
ajlm-1578	252	8	f	f	PROPN
ajlm-1578	252	9	,	,	PUNCT
ajlm-1578	252	10	testoni	testoni	NOUN
ajlm-1578	252	11	n	n	CCONJ
ajlm-1578	252	12	,	,	PUNCT
ajlm-1578	252	13	et	et	PROPN
ajlm-1578	252	14	al	al	PROPN
ajlm-1578	252	15	.	.	PROPN
ajlm-1578	252	16	chronic	chronic	ADJ
ajlm-1578	252	17	myeloid	myeloid	NOUN
ajlm-1578	252	18	leukemia	leukemia	NOUN
ajlm-1578	252	19	in	in	ADP
ajlm-1578	252	20	blast	blast	NOUN
ajlm-1578	252	21	crisis	crisis	NOUN
ajlm-1578	252	22	treated	treat	VERB
ajlm-1578	252	23	with	with	ADP
ajlm-1578	252	24	imatinib	imatinib	NOUN
ajlm-1578	252	25	600	600	NUM
ajlm-1578	252	26	mg	mg	NUM
ajlm-1578	252	27	:	:	PUNCT
ajlm-1578	252	28	outcome	outcome	NOUN
ajlm-1578	252	29	of	of	ADP
ajlm-1578	252	30	the	the	DET
ajlm-1578	252	31	patients	patient	NOUN
ajlm-1578	252	32	alive	alive	ADJ
ajlm-1578	252	33	after	after	ADP
ajlm-1578	252	34	a	a	DET
ajlm-1578	252	35	6	6	NUM
ajlm-1578	252	36	-	-	PUNCT
ajlm-1578	252	37	year	year	NOUN
ajlm-1578	252	38	follow	follow	NOUN
ajlm-1578	252	39	-	-	PUNCT
ajlm-1578	252	40	up	up	NOUN
ajlm-1578	252	41	.	.	PUNCT
ajlm-1578	253	1	haematologica	haematologica	PROPN
ajlm-1578	253	2	.	.	PUNCT
ajlm-1578	254	1	2008;93(12):1792–1796	2008;93(12):1792–1796	X
ajlm-1578	254	2	.	.	PUNCT
ajlm-1578	255	1	https://doi.org/10.3324/haematol.13068	https://doi.org/10.3324/haematol.13068	VERB
ajlm-1578	255	2	kantarjian	kantarjian	PROPN
ajlm-1578	255	3	hm	hm	PROPN
ajlm-1578	255	4	,	,	PUNCT
ajlm-1578	255	5	cortes	corte	VERB
ajlm-1578	255	6	j	j	PROPN
ajlm-1578	255	7	,	,	PUNCT
ajlm-1578	255	8	o’brien	o’brien	PROPN
ajlm-1578	255	9	s	s	PART
ajlm-1578	255	10	,	,	PUNCT
ajlm-1578	255	11	et	et	PROPN
ajlm-1578	255	12	al	al	PROPN
ajlm-1578	255	13	.	.	PUNCT
ajlm-1578	256	1	imatinib	imatinib	PROPN
ajlm-1578	256	2	mesylate	mesylate	NOUN
ajlm-1578	256	3	(	(	PUNCT
ajlm-1578	256	4	sti571	sti571	NOUN
ajlm-1578	256	5	)	)	PUNCT
ajlm-1578	256	6	therapy	therapy	NOUN
ajlm-1578	256	7	for	for	ADP
ajlm-1578	256	8	philadelphia	philadelphia	PROPN
ajlm-1578	256	9	chromosome	chromosome	NOUN
ajlm-1578	256	10	-	-	PUNCT
ajlm-1578	256	11	positive	positive	ADJ
ajlm-1578	256	12	chronic	chronic	ADJ
ajlm-1578	256	13	myelogenous	myelogenous	ADJ
ajlm-1578	256	14	leukemia	leukemia	NOUN
ajlm-1578	256	15	in	in	ADP
ajlm-1578	256	16	blast	blast	NOUN
ajlm-1578	256	17	phase	phase	NOUN
ajlm-1578	256	18	.	.	PUNCT
ajlm-1578	257	1	blood	blood	NOUN
ajlm-1578	257	2	.	.	PUNCT
ajlm-1578	258	1	2002;99(10):3547–3553	2002;99(10):3547–3553	X
ajlm-1578	258	2	.	.	X
ajlm-1578	258	3	https://doi.org/10.1182/blood.v99.10.3547	https://doi.org/10.1182/blood.v99.10.3547	PROPN
ajlm-1578	258	4	saglio	saglio	PROPN
ajlm-1578	258	5	g	g	PROPN
ajlm-1578	258	6	,	,	PUNCT
ajlm-1578	258	7	hochhaus	hochhaus	NOUN
ajlm-1578	258	8	a	a	NOUN
ajlm-1578	258	9	,	,	PUNCT
ajlm-1578	258	10	goh	goh	PROPN
ajlm-1578	258	11	yt	yt	PROPN
ajlm-1578	258	12	,	,	PUNCT
ajlm-1578	259	1	et	et	PROPN
ajlm-1578	259	2	al	al	PROPN
ajlm-1578	259	3	.	.	PROPN
ajlm-1578	259	4	dasatinib	dasatinib	NOUN
ajlm-1578	259	5	in	in	ADP
ajlm-1578	259	6	imatinib	imatinib	NOUN
ajlm-1578	259	7	-	-	PUNCT
ajlm-1578	259	8	resistant	resistant	ADJ
ajlm-1578	259	9	or	or	CCONJ
ajlm-1578	259	10	imatinib	imatinib	NOUN
ajlm-1578	259	11	-	-	PUNCT
ajlm-1578	259	12	intolerant	intolerant	ADJ
ajlm-1578	259	13	chronic	chronic	ADJ
ajlm-1578	259	14	myeloid	myeloid	NOUN
ajlm-1578	259	15	leukemia	leukemia	NOUN
ajlm-1578	259	16	in	in	ADP
ajlm-1578	259	17	blast	blast	NOUN
ajlm-1578	259	18	phase	phase	NOUN
ajlm-1578	259	19	after	after	ADP
ajlm-1578	259	20	2	2	NUM
ajlm-1578	259	21	years	year	NOUN
ajlm-1578	259	22	of	of	ADP
ajlm-1578	259	23	follow	follow	NOUN
ajlm-1578	259	24	-	-	PUNCT
ajlm-1578	259	25	up	up	NOUN
ajlm-1578	259	26	in	in	ADP
ajlm-1578	259	27	a	a	DET
ajlm-1578	259	28	phase	phase	NOUN
ajlm-1578	259	29	3	3	NUM
ajlm-1578	259	30	study	study	NOUN
ajlm-1578	259	31	:	:	PUNCT
ajlm-1578	259	32	efficacy	efficacy	NOUN
ajlm-1578	259	33	and	and	CCONJ
ajlm-1578	259	34	tolerability	tolerability	NOUN
ajlm-1578	259	35	of	of	ADP
ajlm-1578	259	36	140	140	NUM
ajlm-1578	259	37	milligrams	milligram	NOUN
ajlm-1578	259	38	once	once	ADV
ajlm-1578	259	39	daily	daily	ADJ
ajlm-1578	259	40	and	and	CCONJ
ajlm-1578	259	41	70	70	NUM
ajlm-1578	259	42	milligrams	milligram	NOUN
ajlm-1578	259	43	twice	twice	ADV
ajlm-1578	259	44	daily	daily	ADV
ajlm-1578	259	45	.	.	PUNCT
ajlm-1578	260	1	cancer	cancer	NOUN
ajlm-1578	260	2	.	.	PUNCT
ajlm-1578	261	1	2010;116(16):3852–3861	2010;116(16):3852–3861	NUM
ajlm-1578	261	2	.	.	PUNCT
ajlm-1578	262	1	https://doi.org/10.1002/cncr.25123	https://doi.org/10.1002/cncr.25123	VERB
ajlm-1578	262	2	giles	giles	PROPN
ajlm-1578	262	3	fj	fj	PROPN
ajlm-1578	262	4	,	,	PUNCT
ajlm-1578	262	5	le	le	X
ajlm-1578	262	6	coutre	coutre	PROPN
ajlm-1578	262	7	pd	pd	PROPN
ajlm-1578	262	8	,	,	PUNCT
ajlm-1578	262	9	pinilla	pinilla	NOUN
ajlm-1578	262	10	-	-	PUNCT
ajlm-1578	262	11	ibarz	ibarz	PROPN
ajlm-1578	262	12	j	j	PROPN
ajlm-1578	262	13	,	,	PUNCT
ajlm-1578	262	14	et	et	PROPN
ajlm-1578	262	15	al	al	PROPN
ajlm-1578	262	16	.	.	PROPN
ajlm-1578	262	17	nilotinib	nilotinib	NOUN
ajlm-1578	262	18	in	in	ADP
ajlm-1578	262	19	imatinib	imatinib	NOUN
ajlm-1578	262	20	-	-	PUNCT
ajlm-1578	262	21	resistant	resistant	ADJ
ajlm-1578	262	22	or	or	CCONJ
ajlm-1578	262	23	imatinib	imatinib	NOUN
ajlm-1578	262	24	-	-	PUNCT
ajlm-1578	262	25	intolerant	intolerant	ADJ
ajlm-1578	262	26	patients	patient	NOUN
ajlm-1578	262	27	with	with	ADP
ajlm-1578	262	28	chronic	chronic	ADJ
ajlm-1578	262	29	myeloid	myeloid	NOUN
ajlm-1578	262	30	leukemia	leukemia	NOUN
ajlm-1578	262	31	in	in	ADP
ajlm-1578	262	32	chronic	chronic	ADJ
ajlm-1578	262	33	phase	phase	NOUN
ajlm-1578	262	34	:	:	PUNCT
ajlm-1578	262	35	48	48	NUM
ajlm-1578	262	36	-	-	PUNCT
ajlm-1578	262	37	month	month	NOUN
ajlm-1578	262	38	follow	follow	NOUN
ajlm-1578	262	39	-	-	PUNCT
ajlm-1578	262	40	up	up	ADP
ajlm-1578	262	41	results	result	NOUN
ajlm-1578	262	42	of	of	ADP
ajlm-1578	262	43	a	a	DET
ajlm-1578	262	44	phase	phase	NOUN
ajlm-1578	262	45	ii	ii	NOUN
ajlm-1578	262	46	study	study	NOUN
ajlm-1578	262	47	.	.	PUNCT
ajlm-1578	263	1	leukemia	leukemia	NOUN
ajlm-1578	263	2	.	.	PUNCT
ajlm-1578	264	1	2013;27(1):107–112	2013;27(1):107–112	X
ajlm-1578	264	2	.	.	PUNCT
ajlm-1578	265	1	https://doi.org/10.1038/leu.2012.181	https://doi.org/10.1038/leu.2012.181	PROPN
ajlm-1578	265	2	saussele	saussele	NOUN
ajlm-1578	265	3	s	s	PROPN
ajlm-1578	265	4	,	,	PUNCT
ajlm-1578	265	5	lauseker	lauseker	NOUN
ajlm-1578	265	6	m	m	PROPN
ajlm-1578	265	7	,	,	PUNCT
ajlm-1578	265	8	gratwohl	gratwohl	VERB
ajlm-1578	265	9	a	a	PRON
ajlm-1578	265	10	,	,	PUNCT
ajlm-1578	265	11	et	et	PROPN
ajlm-1578	265	12	al	al	PROPN
ajlm-1578	265	13	.	.	PROPN
ajlm-1578	266	1	allogeneic	allogeneic	ADJ
ajlm-1578	266	2	hematopoietic	hematopoietic	ADJ
ajlm-1578	266	3	stem	stem	NOUN
ajlm-1578	266	4	cell	cell	NOUN
ajlm-1578	266	5	transplantation	transplantation	NOUN
ajlm-1578	266	6	(	(	PUNCT
ajlm-1578	266	7	allo	allo	PROPN
ajlm-1578	266	8	sct	sct	PROPN
ajlm-1578	266	9	)	)	PUNCT
ajlm-1578	266	10	for	for	ADP
ajlm-1578	266	11	chronic	chronic	ADJ
ajlm-1578	266	12	myeloid	myeloid	NOUN
ajlm-1578	266	13	leukemia	leukemia	NOUN
ajlm-1578	266	14	in	in	ADP
ajlm-1578	266	15	the	the	DET
ajlm-1578	266	16	imatinib	imatinib	ADJ
ajlm-1578	266	17	era	era	NOUN
ajlm-1578	266	18	:	:	PUNCT
ajlm-1578	266	19	evaluation	evaluation	NOUN
ajlm-1578	266	20	of	of	ADP
ajlm-1578	266	21	its	its	PRON
ajlm-1578	266	22	impact	impact	NOUN
ajlm-1578	266	23	within	within	ADP
ajlm-1578	266	24	a	a	DET
ajlm-1578	266	25	subgroup	subgroup	NOUN
ajlm-1578	266	26	of	of	ADP
ajlm-1578	266	27	the	the	DET
ajlm-1578	266	28	randomized	randomized	ADJ
ajlm-1578	266	29	german	german	NOUN
ajlm-1578	266	30	cml	cml	PROPN
ajlm-1578	266	31	study	study	PROPN
ajlm-1578	266	32	iv	iv	PROPN
ajlm-1578	266	33	.	.	PUNCT
ajlm-1578	266	34	blood	blood	NOUN
ajlm-1578	266	35	.	.	PUNCT
ajlm-1578	267	1	2010;115(10):1880–1885	2010;115(10):1880–1885	NUM
ajlm-1578	267	2	.	.	PUNCT
ajlm-1578	267	3	doi.10.1182	doi.10.1182	NOUN
ajlm-1578	267	4	/	/	SYM
ajlm-1578	267	5	blood-2009	blood-2009	NOUN
ajlm-1578	267	6	-	-	PUNCT
ajlm-1578	267	7	08	08	NUM
ajlm-1578	267	8	-	-	PUNCT
ajlm-1578	267	9	237115	237115	NUM
ajlm-1578	267	10	cortes	corte	VERB
ajlm-1578	267	11	j	j	PROPN
ajlm-1578	267	12	,	,	PUNCT
ajlm-1578	267	13	kim	kim	PROPN
ajlm-1578	267	14	dw	dw	PROPN
ajlm-1578	267	15	,	,	PUNCT
ajlm-1578	267	16	raffoux	raffoux	NOUN
ajlm-1578	267	17	e	e	NOUN
ajlm-1578	267	18	,	,	PUNCT
ajlm-1578	267	19	et	et	PROPN
ajlm-1578	267	20	al	al	PROPN
ajlm-1578	267	21	.	.	PROPN
ajlm-1578	267	22	efficacy	efficacy	NOUN
ajlm-1578	267	23	and	and	CCONJ
ajlm-1578	267	24	safety	safety	NOUN
ajlm-1578	267	25	of	of	ADP
ajlm-1578	267	26	dasatinib	dasatinib	NOUN
ajlm-1578	267	27	in	in	ADP
ajlm-1578	267	28	imatinib	imatinib	NOUN
ajlm-1578	267	29	-	-	PUNCT
ajlm-1578	267	30	resistant	resistant	ADJ
ajlm-1578	267	31	or	or	CCONJ
ajlm-1578	267	32	-intolerant	-intolerant	ADJ
ajlm-1578	267	33	patients	patient	NOUN
ajlm-1578	267	34	with	with	ADP
ajlm-1578	267	35	chronic	chronic	ADJ
ajlm-1578	267	36	myeloid	myeloid	NOUN
ajlm-1578	267	37	leukemia	leukemia	NOUN
ajlm-1578	267	38	in	in	ADP
ajlm-1578	267	39	blast	blast	NOUN
ajlm-1578	267	40	phase	phase	NOUN
ajlm-1578	267	41	.	.	PUNCT
ajlm-1578	268	1	leukemia	leukemia	NOUN
ajlm-1578	268	2	.	.	PUNCT
ajlm-1578	269	1	2008;22(12):2176–2183	2008;22(12):2176–2183	X
ajlm-1578	269	2	.	.	PUNCT
ajlm-1578	270	1	https://doi.org/10.1038/leu.2008.221	https://doi.org/10.1038/leu.2008.221	PROPN
ajlm-1578	270	2	morita	morita	PROPN
ajlm-1578	270	3	k	k	PROPN
ajlm-1578	270	4	,	,	PUNCT
ajlm-1578	270	5	kantarjian	kantarjian	ADJ
ajlm-1578	270	6	hm	hm	INTJ
ajlm-1578	270	7	,	,	PUNCT
ajlm-1578	270	8	sasaki	sasaki	PROPN
ajlm-1578	270	9	k	k	PROPN
ajlm-1578	270	10	,	,	PUNCT
ajlm-1578	270	11	et	et	PROPN
ajlm-1578	270	12	al	al	PROPN
ajlm-1578	270	13	.	.	PROPN
ajlm-1578	270	14	outcome	outcome	NOUN
ajlm-1578	270	15	of	of	ADP
ajlm-1578	270	16	patients	patient	NOUN
ajlm-1578	270	17	with	with	ADP
ajlm-1578	270	18	chronic	chronic	ADJ
ajlm-1578	270	19	myeloid	myeloid	NOUN
ajlm-1578	270	20	leukemia	leukemia	NOUN
ajlm-1578	270	21	in	in	ADP
ajlm-1578	270	22	lymphoid	lymphoid	ADJ
ajlm-1578	270	23	blastic	blastic	ADJ
ajlm-1578	270	24	phase	phase	NOUN
ajlm-1578	270	25	and	and	CCONJ
ajlm-1578	270	26	philadelphia	philadelphia	PROPN
ajlm-1578	270	27	chromosome	chromosome	NOUN
ajlm-1578	270	28	-	-	PUNCT
ajlm-1578	270	29	positive	positive	ADJ
ajlm-1578	270	30	acute	acute	NOUN
ajlm-1578	270	31	lymphoblastic	lymphoblastic	ADJ
ajlm-1578	270	32	leukemia	leukemia	NOUN
ajlm-1578	270	33	treated	treat	VERB
ajlm-1578	270	34	with	with	ADP
ajlm-1578	270	35	hyper	hyper	NOUN
ajlm-1578	270	36	-	-	NOUN
ajlm-1578	270	37	cvad	cvad	NOUN
ajlm-1578	270	38	and	and	CCONJ
ajlm-1578	270	39	dasatinib	dasatinib	NOUN
ajlm-1578	270	40	.	.	PUNCT
ajlm-1578	271	1	cancer	cancer	NOUN
ajlm-1578	271	2	.	.	PUNCT
ajlm-1578	272	1	2021;127(15):2641–2647	2021;127(15):2641–2647	NUM
ajlm-1578	272	2	.	.	PUNCT
ajlm-1578	272	3	https://doi.org/10.1002/cncr.33539	https://doi.org/10.1002/cncr.33539	PROPN
ajlm-1578	272	4	maiti	maiti	PROPN
ajlm-1578	272	5	a	a	PRON
ajlm-1578	272	6	,	,	PUNCT
ajlm-1578	272	7	franquiz	franquiz	PROPN
ajlm-1578	272	8	mj	mj	PROPN
ajlm-1578	272	9	,	,	PUNCT
ajlm-1578	272	10	ravandi	ravandi	NOUN
ajlm-1578	272	11	f	f	NOUN
ajlm-1578	272	12	,	,	PUNCT
ajlm-1578	272	13	et	et	PROPN
ajlm-1578	272	14	al	al	PROPN
ajlm-1578	272	15	.	.	PROPN
ajlm-1578	272	16	venetoclax	venetoclax	PROPN
ajlm-1578	272	17	and	and	CCONJ
ajlm-1578	272	18	bcr	bcr	PROPN
ajlm-1578	272	19	-	-	ADJ
ajlm-1578	272	20	abl	abl	PROPN
ajlm-1578	272	21	tyrosine	tyrosine	PROPN
ajlm-1578	272	22	kinase	kinase	PROPN
ajlm-1578	272	23	inhibitor	inhibitor	PROPN
ajlm-1578	272	24	combinations	combination	NOUN
ajlm-1578	272	25	:	:	PUNCT
ajlm-1578	272	26	outcome	outcome	VERB
ajlm-1578	272	27	in	in	ADP
ajlm-1578	272	28	patients	patient	NOUN
ajlm-1578	272	29	with	with	ADP
ajlm-1578	272	30	philadelphia	philadelphia	PROPN
ajlm-1578	272	31	chromosome	chromosome	NOUN
ajlm-1578	272	32	-	-	PUNCT
ajlm-1578	272	33	positive	positive	ADJ
ajlm-1578	272	34	advanced	advanced	ADJ
ajlm-1578	272	35	myeloid	myeloid	ADJ
ajlm-1578	272	36	leukemias	leukemias	X
ajlm-1578	272	37	.	.	PUNCT
ajlm-1578	273	1	acta	acta	PROPN
ajlm-1578	273	2	haematol	haematol	PROPN
ajlm-1578	273	3	.	.	PUNCT
ajlm-1578	274	1	2020;143(6):567–573	2020;143(6):567–573	NUM
ajlm-1578	274	2	.	.	PUNCT
ajlm-1578	274	3	https://doi.org/10.1159/000506346	https://doi.org/10.1159/000506346	PROPN
ajlm-1578	274	4	sasaki	sasaki	PROPN
ajlm-1578	274	5	k	k	PROPN
ajlm-1578	274	6	,	,	PUNCT
ajlm-1578	274	7	kantarjian	kantarjian	ADJ
ajlm-1578	274	8	hm	hm	INTJ
ajlm-1578	274	9	,	,	PUNCT
ajlm-1578	274	10	o’brien	o’brien	PROPN
ajlm-1578	274	11	s	s	PART
ajlm-1578	274	12	,	,	PUNCT
ajlm-1578	274	13	et	et	PROPN
ajlm-1578	274	14	al	al	PROPN
ajlm-1578	274	15	.	.	PROPN
ajlm-1578	274	16	incidence	incidence	NOUN
ajlm-1578	274	17	of	of	ADP
ajlm-1578	274	18	second	second	ADJ
ajlm-1578	274	19	malignancies	malignancy	NOUN
ajlm-1578	274	20	in	in	ADP
ajlm-1578	274	21	patients	patient	NOUN
ajlm-1578	274	22	with	with	ADP
ajlm-1578	274	23	chronic	chronic	ADJ
ajlm-1578	274	24	myeloid	myeloid	NOUN
ajlm-1578	274	25	leukemia	leukemia	NOUN
ajlm-1578	274	26	in	in	ADP
ajlm-1578	274	27	the	the	DET
ajlm-1578	274	28	era	era	NOUN
ajlm-1578	274	29	of	of	ADP
ajlm-1578	274	30	tyrosine	tyrosine	NOUN
ajlm-1578	274	31	kinase	kinase	PROPN
ajlm-1578	274	32	inhibitors	inhibitor	NOUN
ajlm-1578	274	33	.	.	PUNCT
ajlm-1578	275	1	int	int	NOUN
ajlm-1578	275	2	j	j	PROPN
ajlm-1578	275	3	hematol	hematol	NOUN
ajlm-1578	275	4	.	.	PUNCT
ajlm-1578	276	1	2019;109(5):545–552	2019;109(5):545–552	NUM
ajlm-1578	276	2	.	.	PROPN
ajlm-1578	276	3	https://doi.org/10.1007/s12185-019-02620-2	https://doi.org/10.1007/s12185-019-02620-2	PROPN
ajlm-1578	276	4	jain	jain	PROPN
ajlm-1578	276	5	p	p	X
ajlm-1578	276	6	,	,	PUNCT
ajlm-1578	276	7	kantarjian	kantarjian	ADJ
ajlm-1578	276	8	h	h	NOUN
ajlm-1578	276	9	,	,	PUNCT
ajlm-1578	276	10	boddu	boddu	ADP
ajlm-1578	276	11	pc	pc	NOUN
ajlm-1578	276	12	,	,	PUNCT
ajlm-1578	276	13	et	et	PROPN
ajlm-1578	276	14	al	al	PROPN
ajlm-1578	276	15	.	.	PUNCT
ajlm-1578	277	1	analysis	analysis	NOUN
ajlm-1578	277	2	of	of	ADP
ajlm-1578	277	3	cardiovascular	cardiovascular	ADJ
ajlm-1578	277	4	and	and	CCONJ
ajlm-1578	277	5	arteriothrombotic	arteriothrombotic	ADJ
ajlm-1578	277	6	adverse	adverse	ADJ
ajlm-1578	277	7	events	event	NOUN
ajlm-1578	277	8	in	in	ADP
ajlm-1578	277	9	chronic	chronic	ADJ
ajlm-1578	277	10	-	-	PUNCT
ajlm-1578	277	11	phase	phase	NOUN
ajlm-1578	277	12	cml	cml	PROPN
ajlm-1578	277	13	patients	patient	NOUN
ajlm-1578	277	14	after	after	ADP
ajlm-1578	277	15	frontline	frontline	NOUN
ajlm-1578	277	16	tkis	tkis	PROPN
ajlm-1578	277	17	.	.	PUNCT
ajlm-1578	278	1	blood	blood	PROPN
ajlm-1578	278	2	adv	adv	PROPN
ajlm-1578	278	3	.	.	PUNCT
ajlm-1578	279	1	2019;3(6):851–861	2019;3(6):851–861	NUM
ajlm-1578	279	2	.	.	PUNCT
ajlm-1578	280	1	https://doi.org/10.1182/bloodadvances.2018025874	https://doi.org/10.1182/bloodadvances.2018025874	VERB